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General Introduction
Colorectal cancer
Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of cancer 
related mortality worldwide.1, 2 The lifetime risk of developing CRC is 5% in the Netherlands, thereby 
comprising a major burden for health care. CRCs are classified into histological classification groups by the 
pathologist according to their differentiation. The majority of CRCs are the common adenocarcinomas, 
often referred to as adenocarcinomas not otherwise specified (AC).3 In 10-15% of CRC cases patients suffer 
from mucinous adenocarcinoma (MC), which is characterized by the presence of extracellular mucus, that 
comprises at least 50% of the tumor volume (Figure 1).3, 4 In only 1% of CRCs a signet-ring cell carcinoma 
(SRCC) is reported.3 The hallmark of SRCC is a tumor containing abundant mucus in more than 50% of its 
cells.4 The relatively rare occurrence of MC and SRCC makes these subtypes less studied and conclusions 
and implications have mainly been drawn from small studies. Also, the histological subtype often has not 
been addressed in clinical trials and clinical practice is generally extrapolated to all histological subtypes. 
Figure 1.  Haematoxylin and eosin stained tumor, from left to right adenocarcinoma, mucinous adenocarcinoma and 
signet-ring cell carcinoma.
Diagnostics and treatment of CRC have been subjected to continuous development over the past few 
decades. New surgical techniques have been introduced and neo-adjuvant and adjuvant therapies 
have improved disease free survival and overall survival. Also, standardized pathological assessment 
has improved reporting back to the clinic. Technological advances in imaging and introduction of 
new targeted cancer treatments initiated the era of personalized medicine. Molecular and genetic 
analyses of tumors for specific mutations that may aid in the prediction of prognosis have become one 
of the main focuses of research. This, however, resulted in overlooking the relevance of information 
that was readily available, the histological subtype.
The debate concerning the prognostic impact of the MC and SRCC subtypes has been ongoing ever 
since the introduction of the classification of CRCs according to their histological differentiation. 
Lack of numbers of patients and inaccurate registries have posed problems in determining clinical 
relevance. Nonetheless, MC and SRCC patients were considered prognostic unfavorable tumors and 
resistance to therapies was suspected.
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Tumor development and diagnosis
CRC develops when normal cell division and cell growth is distorted and becomes uncontrolled. 
Mutations in regulatory genes such as proto-oncogenes, tumor suppressor genes or genes involved 
in DNA proofreading and repair result in carcinogenesis.5 Tumors progress from local to invasive, 
eventually having the potential to spread throughout the body leading to metastatic disease. CRC 
is diagnosed after physical examination, colonoscopy and imaging such as computed tomography 
(CT) or magnetic resonance imaging (MRI). Preoperative staging and determination of tumor 
characteristics from imaging and biopsy is important, since it enables the multidisciplinary team of 
clinicians to make appropriate decisions concerning treatment.
Staging
The TNM classification system is the currently used method to classify the invasiveness of disease.4 
Depth of tumor penetration through the bowel wall (T-stage), lymph node involvement (N-stage) 
and distant metastasis (M-stage) result into a further classification of stages of disease. Stage I and II 
tumors are local tumors that are limited to the bowel wall, while stage III tumors have already spread 
to local lymph nodes. Presence of metastases leads to classification as stage IV disease, the most 
advanced stage. Preoperative and postoperative pathological staging highly influences the decision-
making process concerning the optimal treatment. 
Figure 2.  TNM classification and staging system.
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Treatment
For colorectal cancer patients, decisions regarding treatment are made in a multidisciplinary board, 
usually consisting of a surgical oncologist, a pathologist, a radiation oncologist, a medical oncologist 
and a radiologist. For each individual patient the therapeutic plan and follow-up strategy are discussed 
according to national and international guidelines.
Surgery
The main treatment for CRC is surgical removal of the tumor. For colon cancer an open or laparoscopic 
resection is performed according to principles of complete mesocolic excision. This implies that the 
tumor is removed plus a section of normal tissue on both sides of the tumor, as well as nearby 
lymph nodes that can be found in the mesentery. 
Surgical treatment of rectal cancer has changed over 
the past decades. While the initial surgery focused 
on removal of the tumor only, introduction of total 
mesorectal excision (TME), involving resection of 
the tumor together with the fatty tissue surrounding 
the rectum, has led to an impressive decline in local 
tumor recurrences and is considered standard of 
care nowadays (Figure 3).6 The main goal of TME 
surgery is to obtain a radical resection, including 
not only the tumor, but surrounding deposits as 
well, and should result in a circumferential resection 
margin (CRM) that is free of tumor. The CRM is 
defined as the shortest distance from an affected 
region to the mesorectal fascia (MRF). 
Neo-adjuvant treatment
Although chemotherapy as a neo-adjuvant treatment option is currently studied for locally advanced 
colon cancer, only rectal cancer patients are potentially eligible for additional preoperative treatment 
nowadays.7 Adequate staging of the rectal tumor is of importance for assigning patients to the right 
therapeutic regimen. The TME trial demonstrated that short-term preoperative radiotherapy with 
5x5 Gy followed by TME surgery led to a reduction of local recurrences, but did not affect overall 
survival.8-10 Nowadays, short-term radiotherapy is recommended for all T1-T3 tumors with clinical 
evidence of node positive disease. Patients who have a threatened MRF (T3-T4) and are at risk of a 
positive CRM are eligible for a different regimen of neo-adjuvant treatment. A total of 45-50 Gy is 
given to these patients in fractions of 1.8-2 Gy, usually in combination with chemotherapy for the 
full duration of radiotherapy. This treatment causes tumor regression and enables the surgeon to 
perform a radical resection. Surgery usually takes place after an eight to ten weeks interval. Patients 
demonstrating a good response can even be treated with local excision, and a wait-and-see approach 
has been proposed for patients with a pathological complete response.11, 12
Figure 3.  TME surgery, sagittal plane.
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Adjuvant treatment
In the Netherlands adjuvant systemic treatment is recommended for stage III colon cancer patients. 
Patients who receive adjuvant systemic treatment are usually treated with a combination of 
5-fluorouracil (5-FU), leucovorin and oxaliplatin.13, 14 In selected high-risk stage II patients (T4 stage, 
perforation or obstruction at presentation, less that 10 lymph nodes examined or angio-invasion) 
adjuvant chemotherapy is also recommended.15 No benefit of adjuvant chemotherapy has been 
demonstrated for rectal cancer patients.16 
Metastatic disease
Approximately 20% of all CRC patients have distant metastases upon first presentation and 30-40% of 
patients treated for potentially curable CRC relapses.3, 17-19 Tumor metastases influence survival and 
add to disease morbidity. The predominant metastatic sites of CRCs are the liver, lung and peritoneum 
but various other metastatic sites such as bone, spleen, brain and distant lymph nodes have been 
described.20-26 Localization of metastatic disease strongly influences survival.27 Patients with isolated 
liver metastases can be treated curatively with 5-year survival rates of 40%.28, 29 Unfortunately, no 
more than 20% of patients with liver metastases are amenable to potentially curative resection 
since tumor size, location, multifocality and inadequate hepatic reserve are limiting factors. A small 
proportion of patients with lung metastases undergoes resection of their metastatic lesion. When 
metastatic lesions are no longer resectable, patients progress to a palliative setting, in which cure is 
no longer aimed for, but rather elongation of survival becomes the focus of therapy. Patients then 
receive palliative chemotherapy, of which studies demonstrated less benefit in MC compared with 
AC patients (Figure 4).27, 30, 31
Figure 4.  Meta-analysis of studies on benefit from palliative chemotherapy in CRC patients.
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Outline of the thesis
This thesis discusses the clinical relevance of the mucinous and signet-ring cell subtypes within 
the spectrum of CRCs on a molecule to man to mankind-based evaluation. The distinct clinical and 
pathological appearance of MC suggests a different oncogenic development, but etiology is not well 
understood. In Chapter 1 we aim at elucidating different etiological aspects of MC, by describing 
worldwide variations in prevalence of MC and by analyzing the occurrence of MC in several patient 
subgroups. In Chapter 2 we present an extensive review of studies on the molecular background 
of MC and compare findings from colorectal MC with MCs from other organs. Findings from two 
population-based epidemiological studies form the basis of the clinical part of this thesis. Assessment 
of clinicopathological characteristics, prognostic impact and benefit from adjuvant chemotherapy 
for stage III colon cancer is described in Chapter 3 for MC and in Chapter 4 for SRCC. Findings from 
these studies are further explored in the following chapters. Treatment of rectal cancer patients has 
changed rapidly over the past two decades. Improved survival and lower recurrence rates have been 
reported, but this has not been assessed in the mucinous subtype previously. In Chapter 5 the benefits 
of modern rectal cancer treatment are analyzed for MC patients. MC is a poor prognostic factor in 
advanced-stage disease. Variations in metastatic spread are considered a possible explanation for 
this difference. Chapter 6 presents a detailed analysis of the metastatic patterns of AC, MC and SRCC 
through an autopsy study that was validated with results from the TME trial. Chapter 7 discusses the 
differences in genetic background between MC and AC, using genome-wide copy number data from 
various cohorts. Finally, Chapter 8 forms the discussion of this thesis. It reviews the advances that 
have been made regarding MC and puts results from this thesis in a broader clinical context. 
General Introduction
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INSIGHT INTO MUCINOUS COLORECTAL CARCINOMA:  
CLUES FROM ETIOLOGY
REVIEW
N. Hugen, J.J.P. van Beek, J.H.W. de Wilt and I.D. Nagtegaal
Annals of Surgical Oncology, 2014;21:2963-2970
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Abstract
The prognostic impact of mucinous carcinoma (MC) in colorectal cancer (CRC) has been the subject 
of debate ever since the introduction of the classification of tumors according to their histological 
differentiation. MC is a distinct clinical and pathological entity within the spectrum of CRC and 
accounts for approximately 10-15% of cases. Factors involved in MC development have not been 
completely understood, but clinical observations may lead to a better insight into the etiology of MC. 
In this article we provide an in-depth review of the literature regarding etiological aspects of MC. 
We show that there are worldwide differences in the prevalence of MC, with low rates in Asian 
countries and higher rates in the Western world. Moreover, MC is more commonly diagnosed in 
patients suffering from inflammatory bowel diseases or Lynch syndrome and an increased rate of MC 
is observed in patients with radiotherapy-induced CRCs. These findings are suggestive of a different 
oncogenic development.
Identification of conditions that are associated with MC generates insight into the etiological pathways 
leading to the development of this special subtype. 
Etiology of mucinous colorectal carcinoma
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1
Introduction
Worldwide, approximately 125,000 patients present with a colorectal mucinous adenocarcinoma 
(MC) annually, which is around 10% of all colorectal cancers (CRC).1 In this patient group, a higher 
rate of female patients is present. Moreover, tumors are frequently found in the proximal colon and 
are diagnosed at a higher stage compared with the more common adenocarcinoma (AC).2, 3 Also, 
the pattern of metastatic spread of MC is different.4 Conflicting results have been reported in the 
literature regarding the prognostic impact of MC, but overall survival only seems to be different in 
rectal cancer patients.2, 3 The response to systemic therapies varies between MC and the common 
adenocarcinoma (AC), and a poorer outcome has been reported for MC in metastatic disease.5-7
To fulfill the definition of MC as emphasized by the World Health Organization, more than 50% of the 
tumor should consist of extracellular mucus.8 The etiology behind the development of MC is not well 
understood. Molecular and genetic analyses revealed differences between MC and AC, suggesting 
a different oncogenic development.9, 10 This idea is enforced by the increased incidence of MC in 
specific risk groups, i.e. patients with hereditary cancer and inflammatory bowel disease. 
Identification of conditions that are associated with higher rates of MC generates insight into 
the etiological concepts leading to the development of this special subtype and may improve 
understanding of resistance to therapies. In this review we aim at providing more insight into the 
differences in worldwide prevalence of MC and analyze the occurrence of MC in several clinical 
patient subgroups. 
Geographical variations in prevalence of MC
It is generally accepted that MC is found in 10-15% of CRC cases. However, CRC incidence rates differ 
worldwide and it appears that distribution of histological subtypes also shows international variations 
(Figure 1).2, 3, 11-32 Studies from various parts of the world reported MC to occur in 1.6-25.4% of all 
CRCs. The prevalence of MC in large population-based studies ranged from 3.9% in Asia11 to 10-13.6% 
in the Western World.2, 3, 22, 23 Five-year prevalence proportions of CRC per region as estimated by 
GLOBOCAN 2012 were not linked to differences in the distribution of MC.33 Moreover, a large national 
cancer database study from the USA demonstrated that the distribution of histological subtypes was 
similar in white, African American and other races.2 This indicates that the reported differences in 
prevalence of MC appear to be influenced by other factors, such as lifestyle and dietary conditions, 
rather than by genetic variations between races. 
26
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MC in inflammatory bowel disease
Inflammatory bowel disease (IBD) is characterized by chronic relapsing inflammation of the intestines. 
Patients with long-standing IBD, such as Crohn’s disease (CD) or ulcerative colitis (UC) are at increased risk 
of developing CRC. The cumulative risk of CRC in UC was estimated to be 18% at 30 years after the onset 
of disease,34 but recent updates reported a declining risk as a result of aged cohorts.35 MCs represent a 
relatively high proportion of IBD-associated CRCs.36-46 Most studies from the nineties reported frequencies 
between 17% and 37% (Table 1),37-42 but a large study that included a recent cohort of patients (1990-
2005) reported that 17% of IBD-associated CRCs was MC, which was not considered significantly different 
from the standard population.43 The latter may be the result of improved screening and treatment of IBD 
patients. Combination of findings from the literature (n = 614) showed that MC was found in approximately 
one quarter of IBD-associated CRC patients (23.0% in CD and 21.3% in UC). 
Chronic inflammation is likely to play an important role in carcinogenesis in IBD and CRC occurs 
primarily in areas affected by inflammation, but mechanisms of carcinogenesis are not yet completely 
Figure 1.  GLOBOCAN 2012 estimated 5-year prevalence of colorectal cancer per region and geographical variations and 
weighted averages per region of MC in studies that included over 1,000 unselected colorectal cancer patients. 
* Estimated 5-year prevalence of colorectal cancer in proportions by 100,000 (GLOBOCAN 2012).
Etiology of mucinous colorectal carcinoma
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1
understood.39, 43, 47 Generation of reactive oxygen and nitrogen species by inflammatory cells during 
hypoxia causes DNA damage and increases mutation rates.48, 49 This leads to activation of oncogenes 
and inactivation of tumor suppressor genes, causing chromosomal instability. The generally accepted 
mechanism accounting for CRC development, in which a sequence of molecular alterations leads 
to progression from dysplasia to adenocarcinoma, applies to CRC in IBD as well. However, there are 
profound differences in timing and frequency of these events. Loss of APC, for example, is a common 
early event in the sporadic CRC pathway, but is less frequent and usually occurs later in the IBD-
associated CRC development.50 The mutation and loss of heterozygosity of p53, occur at an earlier 
stage in IBD-associated CRC and is already present in non-cancerous mucosal tissue, whereas p53 
mutations occur relatively late in sporadic CRC.51, 52 The high frequency of p53 mutated alleles in 
non-dysplastic mucosa in chronic colitis has been linked to oxidative stress from reactive oxygen and 
nitrogen species generated during inflammation.47 MC is associated with low p53 overexpression, 
but has a low APC mutation rate, similar as IBD-associated CRC.9, 53-55 Microsatellite instability (MSI), 
which is found in a higher frequency in MC, is also an early event in IBD mucosa, occurring even 
before dysplasia is detected.56 In vitro and animal studies demonstrated that epigenetic silencing 
of the mismatch repair (MMR) system occurs during chronic inflammation and oxidative stress in 
IBD. Paradoxically, the MMR system is less active during times of high mutational risk, increasing 
susceptibility for CRC development. This phenomenon links IBD to MSI-CRC development.57, 58 The 
disturbance in cytokine levels as seen in chronic inflammatory conditions, causes an upregulation of 
MUC2,59 that is commonly found in MC.60 Further identification of molecular changes could improve 
understanding of a possible final common pathway in IBD patients leading to MC.
Table 1.  Reports on mucinous histology among patients suffering from inflammatory bowel disease-associated colorectal 
cancer.
Study Year Study period Patients in study (n) MC (%)
Total CD UC Total CD UC
Gyde36 1980 1944-1976 9 9 - 0 0 -
Savoca37 1990 1967-1987 6 6 - 16.7 16.7 -
Sugita38 1993 1959-1988 102 - 102 28.4§ - 28.4§
Choi39 1994 1957-1991 80 28 52 17.5 22.0 15.0
Connell40 1994 1947-1992 73 - 73 37.0 - 37.0
Rubio41 1997 1951-1996 38 22 16 31.6 31.8 31.3
Mayer42 1999 1983-1995 39 8 31 25.6 62.5 16.1
Svrcek43 2007 1990-2005 57 16 41 17.3 16.7 17.5
Brackmann44 2009 1973-2005 67 6 61 10.3 - -
Higashi45 2011 1985-2009 22 - 22 38.1§ - 38.1§
Watanabe46 2011 1978-1998 121 - 121 17.4§ - 17.4§
Total 614 95 519 22.7%† 23.0%† 21.3%†
§ Includes both mucinous and signet-ring cell carcinoma
† Overall weighted percentages according to number of patients in each study
MC, mucinous adenocarcinoma; CD, Crohn’s disease; UC, ulcerative colitis
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One of the possible explanations for the worldwide differences in prevalence of MC, is the geographic 
variation of IBD. IBD is much more common in Europe, Australia and North-America, compared with 
Asia.61 Australia has incidence rates of IBD that are among the highest in the world and the prevalence 
of MC in Australia is very high as well. Japan, China and South-Korea on the contrary, have lower rates 
of IBD and are also associated with a lower prevalence of MC. In Asian countries that become more 
westernized, IBD appears to be emerging; therefore an increase in incidence of MC in the next decades 
would further support the theory that development of MC might be related to inflammation.
MC following radiotherapy
Radiotherapy is an important modality in cancer treatment, however, induction of secondary 
malignancies is unfortunately one of the unwanted late effects of radiotherapy. Radiation colitis is a 
frequent side-effect of radiotherapy and can ultimately result in CRC.62 Many cases of CRC following 
radiotherapy of the pelvis have been reported. Most reports described the occurrence of rectal 
cancer in the presence of radiation proctocolitis with latency periods ranging from 5 to 30 years. 
There seems to be an association between radiation-induced carcinoma and the presence of MC. 
Several studies noted a significant increase in MC in CRC cases following radiotherapy.63-88 In the 
largest cohort, 26% of 72 radiation-induced CRCs were MC,79 and the increase seems to be even more 
profound for rectal cancer.82 Our literature search revealed 180 cases of radiation-associated CRCs, 
of which 69 (38%) were MC (Table 2). The frequency of MC was higher in rectal cancers patients with 
52% of radiation-associated tumors being MC. In support of these results, an experimental animal 
study by Denman et al. found that colonic carcinomas induced by radiotherapy were all MC.89 
The mechanisms behind the higher frequency of MC in radiation-associated CRC are unknown, but 
it is considered possible that either radiation-induced inflammation or acquisition of DNA damage 
may facilitate mucinous differentiation. CRC usually starts off as a benign polyp, that develops into 
a carcinoma through a multistep process of genetic and molecular alterations as the result of DNA 
damage.90 In contrast, radiation-induced colorectal carcinomas may arise de novo from flat mucosa.84, 
91, 92 Ionizing radiation can cause DNA damage directly, or through the formation of reactive oxygen and 
nitrogen species.93 Genetic susceptibility, such as a deficiency in DNA repair, leading to hypersensitivity 
to the carcinogenic risk of radiation has been described.93, 94 Eventually, accumulation of multiple 
changes converts a stable genome of a normal cell into an unstable genome characteristic of a tumor. 
A high rate of mutated p53 in radiation-induced CRCs is indicative for this instability. This has been 
found in several radiation-induced MCs as well.85, 87 Interestingly, Japanese atomic bomb survivors, who 
have been exposed to radiation as well, did not show a higher frequency of MC despite an increased 
risk for CRC.95 Therapeutic radiation dosages are higher than dosages to which atomic bomb survivors 
were exposed, but it is unknown whether a dose-relation may cause differences in histological subtype. 
There was a small number of high-dose cases in the atomic bomb survivors but radiation dosages 
generally did not exceed 1 Gy, thereby not completely excluding radiation-associated DNA damage as a 
causative factor in MC development. The incidence of MC in CRC patients exposed to radiation after the 
Chernobyl or Fukushima Daiichi nuclear disasters have not been reported to date.
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Table 2.  Reports on mucinous histology among patients who developed colorectal cancer following radiotherapy 
treatment.
Study Year Reason for irradiation Rectal MC Colorectal MC
Slaughter63 1957 Cervical cancer 0/0 0/1
Smith64 1962 Cervical cancer 1/3 1/3
Black65 1965 Endometrial cancer 0/0 0/1
Pemberton66 1968 Ovarian cancer 0/0 0/1
DeCosse67 1969 Cervical cancer 0/1 0/1
Localio68 1969 Ovarian cancer 0/0 0/1
MacMahon69 1971 Cervical cancer 0/5 1/6
Castro70 1973 Cancer of cervix, uterus, ovary 8/13 14/24
Cunningham71 1973 Rectal cancer NA 0/1
Qizilbash72 1974 Cervical cancer 0/1 0/1
Burri73 1978 Cancer of cervix and uterus 0/1 2/3
Greenwald74 1978 Cervical cancer 0/1 0/1
O’Connor75 1979 Cervical and endometrial cancer 0/1 0/2
Sabio76 1979 Wilms tumor 0/0 1/1
Martins77 1980 Cervical cancer 0/2 0/2
Tan78 1981 Cervical cancer 1/2 1/2
Jao79 1987 Cancer of cervix, uterus, ovary, bladder, prostate; 
lymphoma, menorrhagia, endometriosis, low back 
pain, skin itching, sarcoma
NA 19/72
Hareyama80 1989 Cervical cancer 0/1 0/1
Levitt81 1990 Cancer of endometrium, cervix, bladder; menorrhagia 4/6 5/7
Shirouzu82 1994 Uterine cervical cancer 10/14 14/25
Kimura83 1995 Cervical cancer 2/3 2/4
Morita84 1998 Cancer of endometrium and cervix 1/2 1/2
Minami85 1998 Uterine cervical cancer 3/6 3/9
Tamai86 1999 Cervical cancer 2/2 2/3
Nakao87 2000 Cervical cancer 2/3 2/5
Yokoyama88 2004 Cancer of pelvic cavity 1/1 1/1
Total 35/68 (51.5%) 69/180 (38.3%)
MC, mucinous adenocarcinoma; NA, not available
Radiotherapy enhanced inflammation is another theory for the development of MC. Inflammation 
of irradiated tissue leads to the production of free radicals by phagocytes.96 Since free radicals 
are associated with tumor promotion,97, 98 radiation proctocolitis provides a tumor promoting 
environment, similar to that found in the prolonged inflammation in IBD. Cells try to minimize DNA 
damage from reactive oxygen species,99 but in vivo evidence suggests that this defense mechanism is 
not sufficiently initiated during the acute inflammatory response in radiation.100 Cells that are directly 
irradiated are not the only ones to exhibit a response. Non-irradiated cells adjacent to exposed cells 
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often respond, which is called the ‘bystander effect’.101, 102 It can result in cell death, mutagenesis 
and oncogenic transformation, leading to CRC eventually.103-105 Similarly to IBD, an imbalance of 
the antioxidant response in intestinal mucosa occurs during inflammation.100, 106 Resemblance in 
increased activation of mucosal cytokines such as interleukin (IL)-2, -6 and -8 in diseased and normal 
segments of colon is seen in radiation proctocolitis and IBD patients.107 Therefore, inflammation may 
be an important factor in the higher frequency of MC in radiation-associated CRC as well.
Table 3.  Reports on mucinous histology among colorectal cancer patients diagnosed with Lynch syndrome (verified 
through germ line mutation analysis and/or confirmation of MSI tumor after fulfilling clinical criteria).
Study Year Lynch patients in study (n) MC (%)
Jass108 1995 62 31.3
Young109 2001 72 22.2
Shia110 2003 24 33.3
Valle111 2007 30 40.0
Jin112 2008 8 25.0
Chiang113 2010 50 24.0
Total 246 28.5†
† Overall weighted percentage according to number of patients in each study
MC, mucinous adenocarcinoma
MC in Lynch syndrome patients
Lynch syndrome (LS), previously known as hereditary non-polyposis colorectal cancer (HNPCC), is 
an autosomal dominantly inherited cancer predisposition syndrome associated with an elevated 
risk of cancer. LS is caused by inactivating germ line mutations in genes that encode the mismatch 
repair (MMR) system. Five LS genes have been identified: MLH1, PMS2, MSH2, MSH6 and EPCAM. 
The lifetime risk of developing CRC is estimated to be 35-80% and individuals with LS have a high 
susceptibility to develop other cancers as well.114 Loss of MMR mechanisms leads to microsatellite 
instability (MSI), which is the hallmark of LS. MSI is detected in about 15% of all CRCs, 3% is caused 
by LS, the other 12% are sporadic cases.115 LS-associated CRCs have a high rate of MC compared with 
sporadic CRC, approximately 22-40% of LS-associated CRCs is MC (Table 3).108-113 It has been described 
that LS-associated MCs have a better survival compared with their non-mucinous counterparts, 
suggesting a different prognostic impact of MC in LS.17 LS-associated CRCs are associated with lower 
rates of APC and p53 mutations than sporadic CRCs and this low mutation rate of APC and p53 is 
also seen in MC patients.9, 116 This finding substantiates the concept of an alternative oncogenic 
mechanism leading to MC development, different from the classic adenoma-carcinoma sequence.
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Conclusion
Since the introduction of the classification of CRCs according to their histological differentiation, 
the debate concerning the impact of MC has been ongoing. It is widely acknowledged that MC 
constitutes a distinct clinicopathological entity within the spectrum of CRC, but factors involved in 
MC development have not been completely understood. This review described conditions in which 
high frequencies of MC have been found and analyzed the worldwide distribution of MC.
The finding of a higher prevalence of MC in various hereditary and acquired conditions associated 
with CRC is suggestive of a different oncogenic development. It seems plausible that the development 
of MC occurs through divergent mechanisms. Lifestyle and dietary conditions may explain worldwide 
variations in prevalence of MC. Also, inflammatory conditions seem to influence MC differentiation in 
CRC arising in IBD and radiotherapy-treated patients. 
The exact mechanisms causing MC differentiation in these subgroups are unknown, but genetic and 
epigenetic changes may be responsible for the development of MC. Further studies are needed to 
evaluate these factors in MC. Also, it is unknown to what extent tumors arising under inflammatory 
conditions or in LS patients show overlapping molecular alterations with sporadic CRC. CRCs in LS 
patients are associated with a better prognosis than other types of CRC and microsatellite instable 
MCs have a better prognosis than microsatellite stable MCs.117 However, further determination of 
the prognostic impact of other conditions enhancing mucinous differentiation and relevance for 
response to various therapies may help to identify patient subgroups that have a poor outcome or 
are less responsive to additional treatments such as chemotherapy or radiotherapy. 
Continuing efforts to elucidate the etiology of MC will eventually increase understanding of the 
mucinous phenotype and may improve prognostication and therapeutic options in these patients. 
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Abstract
The increasing interest of the oncology community in tumor classification and prediction of outcome 
to targeted therapies has put emphasis on an improved identification of tumor types. Colorectal 
mucinous adenocarcinoma (MC) is a subtype, that is characterized by the presence of abundant 
extracellular mucus that comprises at least 50% of the tumor volume and is found in 10-15% of 
colorectal cancer patients. MC development is poorly understood, however, the distinct clinical and 
pathological presentation of MC suggests a deviant development and molecular background. In this 
review we identify common molecular and genetic alterations in colorectal MC. MC is characterized 
by a high rate of MUC2 expression. Mutation rates in the therapeutically important RAS/RAF/MAPK 
and PI3K/AKT pathways are significantly higher in MC compared with non-mucinous adenocarcinoma 
(NMC). Furthermore, MC shows higher rates of microsatellite instability and is more frequently of the 
CpG island methylator phenotype (CIMP). 
Although the majority of MCs arise from the large intestine, this subtype also develops in other 
organs, such as the stomach, pancreas, biliary tract, ovary, breast and lung. We compared findings 
from colorectal MC with tumor characteristics of MCs from other organs. In these organs, MCs 
show different mutation rates in the RAS/RAF/MAPK and PI3K/AKT pathways as well, but a common 
mucinous pathway cannot be identified. Identification of conditions and molecular aberrations 
that are associated with MC generates insight into the aetiology of this subtype and improves 
understanding of resistance to therapies. 
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Introduction
Rapid development of individualized therapy for cancer patients has led to an increased attention 
for tumor subtypes. The search for therapeutically relevant pathways has been ongoing and 
molecular classification of cancer has become an important component in clinical decision-
making. Identification of the molecular background of tumors is one of the key challenges in cancer 
research, as it improves understanding of tumor development and may predict responsiveness to 
therapies. 
Annually, approximately 1.2 million patients develop CRC worldwide and the non-mucinous 
adenocarcinoma (NMC) forms the vast majority of these patients.1 However, in 10-15% of cases 
mucinous adenocarcinoma (MC) is diagnosed. MC is a subtype that is characterized by the presence 
of abundant extracellular mucus comprising at least 50% of the tumor volume.2 Compared with NMC, 
MC is more frequently found in the proximal colon and has a higher stage at presentation.3, 4 Moreover, 
MCs have a distinct metastatic pattern and are less responsive to palliative chemotherapy.5-8 The 
relatively rare occurrence of colorectal MC renders it a less well-studied entity and MC development 
is not well understood. Nevertheless, the distinct clinical and pathological presentation suggest a 
deviant development and molecular background.
Although the majority of MCs arises from the gastrointestinal tract, they are also found in various 
other organs. Overexpression of MUC2 is a common finding in MCs, but it does not explain the 
distinct biology of these tumors.9 Identification of conditions and molecular aberrations that are 
associated with MC may generate insight into the pathways leading to the development of this 
subtype and improves understanding of resistance to therapies. In this review we identify common 
molecular and epigenetic alterations in colorectal MC and compare findings with MCs from other 
organs.
Methods
Review of literature
The literature was searched with a Boolean search term combination until December 2013, using 
PubMed and EMBASE. Titles and abstracts were evaluated to identify relevant studies, which 
were assessed in full text. Reference lists of retrieved studies were explored for further relevant 
publications. Only studies that contained data on molecular or genetic characteristics and that 
compared MC and NMC (at least five patients per subtype) were selected. Studies that did not 
adhere to the definition of MC as reported in the guidelines of the World Health Organization 
were excluded from the analyses.2 Overlap between study populations was assessed and in case 
of overlap only the most recent data was used for analysis. Differences between categorical 
outcomes were calculated using the risk ratio (RR) and corresponding 95% confidence interval (CI). 
Heterogeneity was assessed by means of the I2 statistic. The existence of publication bias in the 
meta-analyses was assessed using funnel plots.
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The Cancer Genome Atlas Project
The Cancer Genome Atlas (TCGA) project was established to profile genomic changes in different 
cancer types. Data on 32 somatic recurrently mutated genes in CRC was published in 2012 by the 
TCGA group, and data from this study was available online.10 Data on somatic mutations that were 
involved in the RAS/RAF/MAPK and PI3K/AKT pathways was downloaded on December 22, 2013. We 
only selected samples that were designated as either MC or NMC. A total of 28 MCs and 160 NMCs 
were identified from the TCGA data set of this publication. Fisher’s exact test was used for comparing 
mutation rates between MC and NMC. Statistical analyses were two-sided and P values < 0.05 were 
considered significant.
Molecular determinants in MC
In CRC development acquisition of mutations leads to abnormal cell division and uncontrolled cell 
growth. There are several well-recognized molecular pathways in CRC development.11 Chromosomal 
instability (CIN), microsatellite instability (MSI) and hypermethylation of CpG islands are genetic 
instability pathways involved in carcinogenesis. Mutations in targets of the RAS/RAF/MAPK and PI3K/
AKT pathways are common findings in CRC. These important drivers of cancer development are of 
prognostic and predictive importance and are being explored for targeted therapies.
MUC2
Secreted gel-forming mucins are epithelial glycoproteins that play a role in physiological processes 
of the gastrointestinal tract. They are encoded by the MUC2, MUC5AC, MUC5B and MUC6 genes on 
chromosome 11p15.5.12 MUC2 is of particular interest in regard to its role in CRC as the expression 
of MUC2 is generally decreased in CRC.13 Interestingly, an increase of MUC2 has been observed in 
MCs, which also explains the mucinous appearance of these tumors.14-16 A meta-analysis by Li et al. 
demonstrated a higher rate of MUC2 positivity in MC compared with NMC (RR 2.10 95% CI 1.30-
3.40).17 Overexpression of MUC2 was one of the first molecular aberrations that distinguished MC 
from NMC and is related to the low methylation status of the promoter of the MUC2 gene in MC.18
Microsatellite instability
Loss of mismatch repair (MMR) mechanisms causes MSI, which is the hallmark of Lynch syndrome-
associated tumors. Lynch syndrome (previously known as hereditary non-polyposis colorectal cancer, 
HNPCC) is an autosomal dominantly inherited cancer predisposition syndrome, caused by germ line 
mutations in MMR genes. MC accounts for 22-40% of Lynch syndrome-associated CRCs.19 MSI is also 
found in approximately 12% of CRC patients who do not suffer from a hereditary predisposition.20 The 
prevalence of MC has been reported to be 11-77% in sporadic MSI CRC patients (weighted average of 
34%, Table 1).21-34 Studies that directly compared sporadic MSI and Lynch syndrome-associated CRCs 
found a higher rate of MC in sporadic MSI CRCs than in Lynch syndrome-associated CRCs.24, 35 A better 
survival in MC patients has been reported for tumors exhibiting MSI compared with microsatellite 
stable tumors.36-38 However, comparison of MSI rates between studies is difficult, as a wide variety of 
markers for determining MSI status is used. 
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MSI can also occur through hypermethylation of the hMLH1 promoter region, which is seen in CRCs 
that display the CpG island methylator phenotype (CIMP). CIMP is characterized by hypermethylation 
of CpG islands in the promoter region of genes involved in carcinogenesis, leading to epigenetic 
silencing.25, 39-41 Studies found 36-41% of MCs to be CIMP positive, compared with only 12-18% in 
NMC (Supplementary Figure S1).25, 33, 42-44 Tanaka et al. demonstrated that MCs more frequently have 
MSI or CIMP or BRAF mutations than NMCs (54% versus 28%) and since the various characteristics 
are correlated, this is indicative for MC arising from an alternative oncogenic pathway.39 The sequence 
of these mechanisms is not yet completely understood.
KRAS
Mutations in KRAS lead to an epidermal growth factor receptor (EGFR) independent disturbance of 
the RAS/RAF/MAPK pathway, that regulates cell proliferation and survival and is a prognostic factor 
in CRC.45, 46 Conflicting results have been reported in the literature regarding the incidence of KRAS 
mutations in MC. Rates of mutant KRAS are varying between 7-65% in MC versus 5-50% in NMC. 
Often, results were not statistically significant, possibly due to lack of power. Eighteen studies were 
included in an analysis on KRAS status in MC and NMC and KRAS mutations were found in MC more 
frequently (RR 1.27, 95% CI 1.14-1.41; Figure 1).6, 33, 47-62 
Table 1.  Reports on mucinous adenocarcinoma (MC) among patients with sporadic colorectal cancer with microsatellite 
instability (MSI).
Study Year Patients with MSI in study MC (%)
Kim21 1994 18 33.3
Bocker22 1996 11 36.4
Gafà23 2000 44 36.4
Young24 2001 42 42.9
Hawkins25 2002 43† 41.9
Shia26 2003 35† 11.4
Sarli27 2004 22 77.3
Mori28 2004 14 28.6
Chang29 2006 19† 31.6
Meng30 2007 12† 50.0
Ashktorab31 2008 6 33.3
Kim32 2010 135† 15.6
Kakar39 2012 14 50.0
Day34 2013 134† 43.3
Total 549 34.1§
† Bethesda panel was used for determination of MSI status
§ Overall weighted average according to number of patients in each study
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BRAF
Mutated BRAF is another molecular aberration that is more frequently found in MC patients. BRAF 
is the downstream effector of KRAS and is also involved in the RAS/RAF/MAPK pathway. In various 
studies mutational BRAF was found in 0-46% of MC patients, whereas 6-25% of NMC tumors 
displayed mutated BRAF (RR 2.04, 95% CI 1.67-2.51; Figure 2).6, 33, 42, 48, 50, 56-59, 63 BRAF mutations lead 
to constitutive activation of the RAS/RAF/MAPK signalling pathway.64 A hotspot for BRAF mutations 
involves replacement of a single amino acid, V600, located within the kinase domain and accounts for 
80% of BRAF mutations in CRC.65 BRAF mutations are highly correlated with CIMP, with approximately 
60-80% of CIMP tumors having BRAF mutations.39, 50, 66, 67 BRAF mutations are also frequently found in 
sporadic MSI CRC, but not in Lynch syndrome-associated CRC.66-69 
PIK3CA
Activating mutations in PIK3CA occur in approximately 13% of CRCs (Figure 3). PIK3CA encodes a catalytic 
subunit of PI3K and is a positive regulator of the PI3K/AKT pathway, which is involved in cell growth, survival, 
proliferation and motility.70 The PI3K pathway is normally inhibited by tumor suppressor gene PTEN. PIK3CA is 
more commonly mutated in MC (9-50%) than in NMC (7-12%) and a RR of 1.79 (95% CI 1.46-2.19) was found 
for MC in an analysis on mutational PIK3CA status.34, 58, 59, 71-74 Also, PIK3CA mutations occur more frequently 
in tumors that are localized in the proximal colon, as are MCs.3, 4, 34, 73 PIK3CA mutations are commonly found 
in combination with KRAS mutations and are associated with high levels of CIMP, which are both linked to 
MC.51, 72, 73 An association between PIK3CA mutation and MSI has not been demonstrated.72 In the literature 
conflicting results have been published regarding PTEN. A study by Day et al. that analyzed mutational status 
of PTEN found a higher frequency of PTEN mutations in MC (10% in MC versus 5% in NMC); however, studies 
that analyzed cytoplasmic expression of PTEN did not always find a difference between MC and NMC.34, 58, 74, 75 
Figure 1.  Relative risk for KRAS mutation in studies comparing colorectal mucinous adenocarcinoma (MC) and non-
mucinous adenocarcinoma (NMC). CI, confidence interval.
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Figure 2.  Relative risk for BRAF mutation in studies comparing colorectal mucinous adenocarcinoma (MC) and non-
mucinous adenocarcinoma (NMC). CI, confidence interval.
Figure 3.  Relative risk for PIK3CA mutation in studies comparing colorectal mucinous adenocarcinoma (MC) and non-
mucinous adenocarcinoma (NMC). CI, confidence interval.
TCGA
Besides findings from the literature, also unpublished data collected by TCGA offers possibilities to 
compare mutation rates in CRC. In 188 CRCs (28 MC and 160 NMC) the mutational status of genes involved 
in the RAS/RAF/MAPK and PI3K/AKT pathway was assessed (Figure 4). Also data on MSI was available. In 
concordance with the literature, MCs more often displayed MSI and a higher rate of BRAF and PIK3CA 
mutations was found in MC. Mutation rates for other genes were not significantly different. Inclusion of 
TCGA data into the analyses on mutational status did not significantly alter RR for BRAF (RR 2.24 95% CI 
1.84-2.72), KRAS (RR 1.26 95% CI 1.13-1.40) and PIK3CA (RR 1.82 95% CI 1.50-2.20). Mutations in ERBB2 
(which encodes HER-2), are considered uncommon in CRC and were found in only 7.1% and 6.3% of MC 
and NMC samples respectively. In conclusion, data from TCGA confirmed differences in mutation rates 
between MC and NMC of several genes that were also reported in the literature.
Mucinous colorectal pathway
Findings from the literature and TCGA suggest that MC and NMC differ on a molecular basis (Figure 5). 
An increased rate of mutations is seen in MC in the RAS/RAF/MAPK and PI3K/AKT pathways. KRAS, BRAF 
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and PIK3CA are more frequently mutated in MC compared with NMC, leading to constitutive activation 
of these pathways. No differences in expression of the cell surface receptors EGFR or HER-2, that are 
upstream of these pathways, have been reported between MC and NMC in the literature.
Although MSI, CIMP and activation of the RAS/RAF/MAPK and PI3K/AKT pathways are distinctive 
features of MC, the relationship between these characteristics and mucus production has not yet 
been elucidated. There is no data on a molecular link between MSI or CIMP and overexpression 
of MUC2. However, various in vitro studies demonstrated that both the RAS/RAF/MAPK and PI3K/
AKT pathway are involved in MUC2 upregulation in colon cancer cell lines and indicated that MUC2 
production can be inhibited by a MEK inhibitor.76-79 In another cell line, however, upregulation of 
MUC2 was considered independent of MAP kinase.80 Recently, Walsh et al. reported data on 722 CRC 
patients which supported the association between overexpression of MUC2 and activation of the 
RAS/RAF/MAPK pathway via BRAF and KRAS mutations.81 They also found that MUC2 overexpression 
was associated with a deficient MMR system and CIMP. Especially the latter is surprising, as it indicates 
an increase in protein expression in an environment in which excessive silencing of gene promoters 
is present. These findings strongly suggest that overexpression of MUC2 in MCs is related to other 
molecular aberrations, but further evaluation is needed.
Compare and contrast
Besides the colorectal variant, MC is also found in tumors originating from other organs. MC has been 
described in patients suffering from carcinoma of the esophagus, stomach, small intestine, pancreas, 
biliary tract, gall bladder, ovary, endometrium, urinary bladder, breast and lung. It is unknown 
whether MCs from different organs share common molecular characteristics. Hanski et al. previously 
demonstrated that overexpression of the MUC2 gene was found in MCs from different organs.9 The 
rare occurrence of MC in most organs is reflected by the limited number of studies regarding this 
Figure 4.  Rates of mutations and microsatellite instability (MSI) in colorectal carcinoma: 28 mucinous carcinoma (MC) 
and 160 non-mucinous carcinoma (NMC) samples from the TCGA project. MSI testing was performed for 159 NMC 
samples. * p < 0.05, ** p < 0.01.
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subtype. In this section MCs from variant organs are described, dependent on availability in the 
literature.
Mucinous gastric carcinoma
MC is one of the five main subtypes in the WHO classification system of gastric adenocarcinomas 
and comprises approximately 2-5% of all gastric cancers.28, 82-84 Since most studies use the Laurén 
classification system, which divides gastric carcinoma in an intestinal and diffuse subtype, there is 
little data on gastric MC. Identical to colorectal MC, gastric adenocarcinoma is designated mucinous if 
more than 50% of the tumor consists of extracellular mucus.2 Gastric MCs are more often diagnosed 
at a more advanced stage of disease than NMC, resulting in a poorer outcome.82, 83, 85 
Similar to colorectal MC, gastric MC is also associated with MUC2 overexpression.86, 87 Also, a higher 
rate of MSI is found in MC when compared with NMC (average of 14% versus 11%, RR 1.51 95% CI 
1.03-2.21, Supplementary Figure S2).86, 88-91 Similar to CRC, MSI has been associated with a better 
prognosis in gastric carcinoma.92, 93 HER-2 overexpression and ERBB2 gene amplification are less 
common in MC than in NMC (1% versus 6%).86, 94 A higher rate of loss of heterozygosity of 18q, which 
is associated with adverse outcome, has been reported for gastric MC compared with NMC (52% 
versus 21%).89 Expression of PTEN seems to be less altered in gastric MC, compared with NMC; Kang 
et al. found that 27% of NMCs displayed loss of PTEN whereas none of the MCs did.95 Gastric MC is 
associated with lower rates of EGFR overexpression compared with NMC (5-11% versus 26-31%).86, 94, 
96 Conversely, one small study by Liu et al. found an EGFR mutation in 2 out of 7 MCs.97 Additionally, 
this study found no KRAS mutations in MC, while 12% of NMCs had a KRAS mutation.
Mucinous non-cystic pancreas carcinoma
Mucinous non-cystic carcinoma of the pancreas is a variant of ductal adenocarcinoma and is usually 
referred to as colloid carcinoma. In pancreatic colloid carcinoma mucus accounts for more than 50% of 
the tumor.2 It is considered an uncommon subtype and arises almost exclusively from the intraductal 
papillary mucinous neoplasm (IPMN). The rare occurrence is a limiting factor on knowledge of the 
molecular background of colloid carcinoma, but Adsay et al. demonstrated a low mutational rate 
of KRAS (25%) in a small colloid carcinoma cohort, whereas KRAS is mutated in > 90% of ductal 
adenocarcinomas.98, 99 As in colorectal MC, colloid carcinoma of the pancreas is associated with a high 
expression frequency of MUC2 compared with ductal adenocarcinomas.98, 100 However, in contrast 
with colorectal MC, MSI is not a common finding in colloid carcinoma of the pancreas. Lüttges et al. 
found only one case of MSI among 12 colloid carcinomas.101
Mucinous carcinoma of the gall bladder and extrahepatic bile ducts
MCs of the gall bladder and biliary ducts contain more than 50% extracellular mucus by definition 
of the WHO classification system.2 In a population-based study on biliary tract cancers MC was 
found in 5% of cases.102 This study by Rashid et al. also found a higher rate of MSI in MCs (33%) 
from the biliary tract, compared with NMCs (2%). A recent study by Dursun et al. on 606 gall 
bladder carcinomas reported MC in 2.5% of cases.103 MUC2 expression, which is typically negative 
in NMC of the gall bladder, was positive in 86% of MCs. However, none of the MCs displayed MSI 
in this study. 
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Mucinous ovarian carcinoma
NMC of the ovary forms the majority of ovarian carcinomas and mainly consists of serous, clear cell 
and endometrioid carcinomas. MC is diagnosed in approximately 11-14% of ovarian carcinomas.104, 
105 MC is more frequently found in an early stage of disease and is associated with a better survival 
than NMC.106-108 Compared with CRC, the ovarian variant of MC is an ill-defined entity and is usually 
classified as MC when the tumor has an ‘intestinal’ or ‘cervical gland-like’ phenotype. Unlike in 
the colon, ovarian carcinoma is labeled mucinous when either intracellular or extracellular mucus 
is present, without requiring any strict quantification of the mucus component.109 Practically, this 
means that the group of ovarian MC comprises those phenotypes that are defined as both NMC and 
MC in the colon. In the literature presence of either intracellular or extracellular mucus is generally 
not mentioned nor quantified. 
In ovarian cancer KRAS is more frequently mutated in MC (10-71%), than in NMC (2-25%, 
Supplementary Figure S3).110-119 BRAF mutations are rare in ovarian carcinoma, with only 0-9% of 
MC and 0-4% of NMC showing this mutation.112, 117, 118 There seems to be no significant role for MSI 
in the mucinous differentiation, with MSI in 0-55% of MC and in 2-62% of NMC (Supplementary 
Figure S4).120-124 For PIK3CA and PTEN, literature is limited. Campbell et al. reported that 8% of NMCs 
exhibited a PIK3CA mutation, whereas none of the MCs did.125 PTEN mutations were found in up to 
10% of ovarian carcinomas, but this was not different between histological subtypes.126, 127 ERBB2 
amplification does occur in ovarian carcinoma, but no obvious differences between MC (28%) and 
NMC (19%) have been found.116 CIMP has been examined to a limited extent in ovarian carcinoma. 
The interpretation of data concerning ovarian MC is further complicated by the fact that a considerable 
part of MC consists of metastases from primary tumors originating elsewhere in the body, mainly 
from the gastrointestinal tract.128-131 Because differentiation between a primary MC and metastasis 
is difficult, it is possible that a proportion of carcinomas that are considered ovarian MC are in fact 
metastatic CRC. This might impede interpretation of the reported data, but it could also explain the 
high frequency of KRAS mutations in MC.
Mucinous lung carcinoma
Invasive mucinous adenocarcinoma (IMA) of the lung (formerly mucinous bronchioalveolar 
carcinoma) was separated from the non-mucinous subtype in the new international multidisciplinary 
classification system based on major clinical, pathological, and genetic differences between both 
subtypes.132 IMA, however, is not the pulmonary equivalent of MC from the gastrointestinal tract, 
as mucus is found intracytoplasmic in this tumor. The colloid carcinoma which is characterized by 
abundant extracellular mucus, shows more resemblance with colorectal MC. Pulmonary colloid 
carcinoma is a rare subtype (found in less than 0.5% of lung carcinomas) and is often found as a 
mixture with other NMC subtypes.133 KRAS and EGFR mutations are the two most frequently mutated 
proto-oncogenes in adenocarcinoma of the lung, whereas BRAF mutations and MSI are rare in lung 
carcinoma.134, 135 The pathogenic mechanisms behind colloid carcinoma are largely unknown, but 
MUC2 is found to be strongly expressed.133 Moreover, a study by Liu et al. found a higher rate of KRAS 
mutations and a lower rate of EGFR mutations in colloid tumors, compared with other subtypes.136 
Since EGFR tyrosine kinase inhibitors are of particular interest for lung cancer treatment, more insight 
into the molecular background of subtypes could improve targeting therapy.
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Mucinous breast carcinoma
According to the WHO classification system of breast carcinomas, MC of the breast is found in 7% of 
breast cancers and consists of clusters of tumor cells floating in pools of extracellular mucus.109 In the 
literature a pure and mixed variant of MC have been distinguished. Pure MC of the breast consists 
exclusively of MC and represents approximately 2% of all breast cancers.109 The mixed variant of MC 
shows an admixture with another component (usually infiltrating ductal carcinoma, IDC).109 Compared 
with IDC, pure MC is a less aggressive subtype that is rarely associated with lymph node metastases.137-140 
Comparison at the molecular level shows that MC is transcriptionally distinct from IDC.141, 142 MC is more 
homogenous at the genetic level and shows less genetic instability than most other types of breast 
cancer.141, 143, 144 MC of the breast is associated with higher rates of MUC2 expression than IDC.98, 145 MC 
also has a higher rate of estrogen receptor (ER) expression (73-94% versus 26-82%, Supplementary 
Figure S5) and is associated with more progesterone receptor (PR) expression (63-90% versus 47-74%, 
Supplementary Figure S6).137-140, 146-151 For MC, less HER-2 overexpression has been reported compared 
with NMC (0-14% versus 20-41%, Supplementary Figure S7).139, 140, 146, 147, 149-151 Studies that included 
small numbers of MC demonstrated that mutated PIK3CA, which is found in 16-33% of IDCs, is not a 
common finding in MC (0-13%, Supplementary Figure S8).125, 152-157 Mutations of BRAF and KRAS are 
not common in breast cancer (0-3% and 2-5%) and associations with MC have not been studied.65, 158, 
159 Unlike in colorectal MC, MSI is a rare phenomenon in MC of the breast, occurring only sporadically 
(0-3%).160-165 Studies evaluating EGFR mutations in breast cancer have not focused on MC.
Comparison with CRC
A common mucinous pathway cannot be identified for MC from different organs (Figure 5). However, 
in general limited data is available for non-colorectal MC. There are differences between MC and 
NMC in mutation rates of targets of the RAS/RAF/MAPK and PI3K/AKT pathways. Also differences 
in expression of EGFR, HER-2, ER and PR have been found in non-colorectal MCs. The association 
between these molecular characteristics and the mucinous phenotype is not well studied in non-
colorectal MC. However, in vitro studies with lung cancer cell lines showed that cell treatment with 
epidermal growth factor resulted in an increased expression of MUC2.166 Conversely, blockage of the 
PI3K/AKT pathway in gastric cancer cell lines resulted in an increase in MUC2 expression, indicating 
the need for further clarification of the regulatory mechanisms behind MUC2 expression in MCs.167
MSI is another distinctive tumor characteristic of colorectal MC, but has only been reported at a 
higher rate in MCs from the stomach and biliary tract. Since various molecular characteristics have 
been associated with either worse or improved prognosis, differences in these pathways may explain 
deviant tumor behavior of MC in different organs.
Conclusions and implications
The era of personalized medicine has led to an emerging interest in tumor subtypes and the molecular 
background of malignancies. The distinct clinicopathological presentation and the impaired response 
to systemic therapies are suggestive of a different molecular background of colorectal MC, but 
development of this subtype is not well understood. This review recapitulated alterations in several 
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therapeutically important pathways of CRC and compared findings with the literature regarding MCs 
from other organs. 
Overexpression of MUC2, leading to abundant mucus production, is a molecular key feature of MC, but 
it does not explain the distinct clinical behavior of MC. Review of the literature demonstrated that MC 
showed a higher rates of mutations in BRAF, KRAS and PIK3CA than NMC and higher rates of CIMP and MSI 
were found in MC. Funnel plots did not demonstrate publication bias (figures not shown). These findings 
suggest that mutations in the RAS/RAF/MAPK and PI3K/AKT pathways are involved in MC development. 
Figure 5.  EGFR, HER-2 and ER with 
downstream the RAS/RAF/MAPK and 
PI3K/AKT pathway. 
(A) Mutation rates of KRAS, BRAF and 
PIK3CA are different between mucinous 
carcinoma (MC) and non-mucinous 
carcinoma (AC) in colorectal cancer. 
(B). An increase or decrease in mutation 
or expression rates of components 
of the RAS/RAF/MAPK and PI3K/AKT 
pathway has been observed in MC when 
compared with AC in different tumor 
types.
A
B
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Previously, it has been reported that MC is more commonly found in tumors arising under 
inflammatory conditions and in patients with a hereditary predisposition for CRC. A higher rate of 
MC was observed in patients suffering from inflammatory bowel diseases or Lynch syndrome and 
in patients who developed CRC following radiotherapy.19 It is unknown to what extent these factors 
contribute to MC development, but they indicate that epigenetic changes may well influence MC 
development. 
From a therapeutic perspective, colorectal MC has a worse outcome than NMC when treated 
with palliative chemotherapy for advanced-stage disease.5-7 Interestingly, there is no difference in 
benefit from adjuvant chemotherapy in MC patients.4, 168 MSI tumors have been associated with less 
responsiveness to 5-FU chemotherapeutic treatment,169 but this does not explain the discrepancy 
between the adjuvant and palliative setting. In rectal cancer, resistance of MC to radiotherapy or 
chemoradiotherapy is suspected, given the poorer rate of tumor downstaging.170, 171 Also, the 
metastatic pattern is different between MC and NMC patients.8 This indicates that not only phenotype, 
but also tumor behavior is different between histological subtypes.
As the definition of MC in CRC requires that at least 50% of the tumor consists of mucus, it is not 
inconceivable that tumor heterogeneity may have influenced findings from the literature. It is 
possible that molecular aberrations have remained unnoticed due to dilution by non-mucinous 
tumor elements. However, no study has attempted to address this problem by focusing solely on 
pure MC samples in CRC. Moreover, since CRC can develop via CIN and MSI it would be interesting 
to analyze molecular aberrations stratified by these different pathways. Unfortunately, this was not 
feasible as insufficient data was available in the literature. 
This review also compared colorectal MC with MCs from other organs. The definition of MC is not 
unambiguous between different organs, as it sometimes refers to tumors containing abundant 
intracellular mucus or a combination of intra- and extracellular mucus. MC is less prevalent in other 
organs than in the colorectum, which was reflected by the limited amount of literature on molecular 
differences between subtypes in these tumors. A common mucinous pathway could not be identified, 
but between MC and NMC differences in mutation rates of components of the RAS/RAF/MAPK and 
PI3K/AKT pathways were found in most organs. Alterations in these pathways may be associated with 
MUC2 overexpression. Interestingly, the genetic instability pathway of MSI, which is a predominant 
characteristic of mucinous CRC, could not be linked to MCs in every other organ. 
Further identification of molecular aberrations may lead to the development and implementation 
of targeted therapies, but could also explain resistance of tumors to such therapies. Moreover, 
identification of the molecular background of MC may improve prognostication and could lead to a 
better prediction of response to local and systemic therapies. 
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Supplemental material
Supplementary Figure S1.  Relative risk for CpG island methylator phenotype in studies comparing colorectal mucinous 
adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC). CI, confidence interval.
Supplementary Figure S2.  Relative risk for microsatellite instability in studies comparing mucinous adenocarcinoma 
(MC) and non-mucinous adenocarcinoma (NMC) of the stomach. CI, confidence interval.
Supplementary Figure S3.  Relative risk for KRAS mutation in studies comparing mucinous adenocarcinoma (MC) and 
non-mucinous adenocarcinoma (NMC) of the ovary. CI, confidence interval.
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Supplementary Figure S4.  Relative risk for microsatellite instability in studies comparing mucinous adenocarcinoma 
(MC) and non-mucinous adenocarcinoma (NMC) of the ovary. CI, confidence interval.
Supplementary Figure S5.  Relative risk for estrogen receptor expression in studies comparing infiltrating ductal 
carcinoma (ICD) and mucinous adenocarcinoma (MC) of the breast. CI, confidence interval.
Supplementary Figure S6.  Relative risk for progesterone receptor expression in studies comparing infiltrating ductal 
carcinoma (ICD) and mucinous adenocarcinoma (MC) of the breast. CI, confidence interval.
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2Supplementary Figure S7.  Relative risk for HER-2 expression in studies comparing infiltrating ductal carcinoma (ICD) and 
mucinous adenocarcinoma (MC) of the breast. CI, confidence interval.
Supplementary Figure S8.  Relative risk for PIK3CA mutation in studies comparing infiltrating ductal carcinoma (ICD) and 
mucinous adenocarcinoma (MC) of the breast. CI, confidence interval.

TREATMENT AND BIOLOGY
Part II

Chapter 3 
PROGNOSIS AND VALUE OF ADJUVANT CHEMOTHERAPY IN 
STAGE III MUCINOUS COLORECTAL CARCINOMA
N. Hugen, R.H.A. Verhoeven, S.A. Radema, I.H.J.T. de Hingh, J.F.M. Pruijt, I.D. Nagtegaal, 
V.E.P.P. Lemmens and J.H.W. de Wilt
Annals of Oncology, 2013;24:2819-24 
66
Chapter 3
Abstract
Colorectal mucinous adenocarcinoma (MC) has been associated with impaired prognosis compared 
with non-mucinous adenocarcinoma (NMC). Response to palliative chemotherapy is poor in 
metastatic disease, but the benefit of adjuvant chemotherapeutic treatment has never been assessed 
in large patient groups. This study analyzes overall survival and efficacy of adjuvant chemotherapy in 
terms of survival in patients following radical resection for MC. 
This population-based study involved 27,251 unselected patients diagnosed with colorectal 
carcinoma between 1990 and 2010 and recorded in a prospective pathology-based registry. Kaplan-
Meier analysis and log-rank testing were used to estimate survival. Cox proportional hazard model 
was used to calculate multivariate hazard ratios for death.
MC was found in 12.3% (n = 3052) of colorectal tumors with a different distribution compared 
with NMC, with 24.4% located in the rectum and 54.3% in the proximal colon (versus 38.0% and 
30.6%, p < 0.0001). NMC was more often classified as stage I disease than MC (20.5% versus 10.9%, 
p < 0.0001). After adjustments for covariates, MC was associated with a higher risk of death only when 
located in the rectum (hazard ratio 1.22, 95% confidence interval 1.11-1.34). Multivariate regression 
analysis showed a similar survival after adjuvant chemotherapy for stage III MC and NMC patients. 
The poor prognosis for MC is only present in rectal cancer. In the adjuvant setting there is no 
difference in the efficacy of chemotherapy between MC and NMC; therefore, current adjuvant 
treatment recommendations should not take histology into account.
Prognosis and adjuvant chemotherapy in mucinous colorectal carcinoma
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Introduction
Colorectal cancer (CRC) is the third most-common cancer and the fourth most frequent cause of 
cancer-related mortality worldwide.1, 2 The majority of cases presents with adenocarcinoma not 
otherwise specified,3 but in approximately 10-15% mucinous carcinoma (MC) is reported.4, 5 At 
histological examination MC is composed of more than 50% extracellular mucus.3 MC more often 
affects younger patients,6, 7 is more frequently seen in the proximal colon6, 8 and in females6 and 
usually has a more advanced stage at presentation.7-10 The prognostic significance of MC, however, is 
considered controversial. Most studies demonstrated that patients with MC have a poorer prognosis 
compared with those with a non-mucinous histology (NMC), which is contradicted by others.4, 6, 10-19 
Especially rectal MCs have been associated with impaired overall survival (OS).6, 7 A recent systematic 
review found a small, but significantly shorter survival in MC versus NMC (hazard ratio 1.05, 95% 
confidence interval (CI) 1.02-1.08).16
Fluorouracil-based adjuvant chemotherapy has been demonstrated to be beneficial in stage III colon 
cancer.15, 20, 21 Due to the increased stage of presentation of MC, many patients with MC have an indication 
for adjuvant therapy.11, 22, 23 However, several studies demonstrated reduced responsiveness of metastatic 
MC to chemotherapy in the palliative setting, subsequently leading to a worse OS.14, 23-25 Due to relative 
resistance to systemic treatment, therapeutic benefit may be reduced in patients with MC. In the adjuvant 
setting, the only study taking tumor type into account suggests an equal benefit for MC.10
The aim of this study is to establish the role of MC in OS for CRC patients and to identify whether 
tumor type should be taken into account in decision-making concerning adjuvant chemotherapy 
following radical resection.
Patients and methods
A database containing 27,251 CRC patients diagnosed between 1990 and 2010, was extracted from 
the population-based Eindhoven Cancer Registry (ECR). Clinicopathological data were recorded by 
the registration clerks from the hospital records as routine registration for the ECR. Data on follow-
up of vital status were retrieved by linkage to the nationwide population registries network. Patients 
without a histological confirmation of the primary tumor (n = 566) were excluded from this study 
(Consort diagram in Supplementary Figure S1). Patients were also excluded if they had a previous 
malignancy within five years preceding the diagnosis of CRC (except for basal cell skin cancer or in 
situ carcinomas) (n = 1275). Tumors demonstrating a mixed histological picture or undifferentiated 
carcinoma (n = 112), and tumors that were classified as signet-ring cell carcinoma or other than 
adenocarcinoma (n = 805) were excluded. Appendiceal carcinomas were also excluded from the 
study (n = 173). Information about hereditary syndromes was not available in the database. 
The following variables were available for this study: age, sex, year of diagnosis, primary tumor 
location and histology (based upon WHO ICD-O classification), stage at presentation according to 
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the TNM classification (version dependent on year of diagnosis), surgery performed, (neo)adjuvant 
therapy, socio-economic status (SES), co-morbidity and survival time or time from diagnosis until 31 
December 2011. To compare adjuvant chemotherapy in stage III, we excluded patients who died 
within 30 days after surgery for these analyses (n = 145). As grade assignment is largely subjective 
with few or no defined criteria, and is considered inappropriate for mucinous tumors, this variable 
was not taken into account.26 Co-morbidity at diagnosis was registered according to a modified 
version of the Charlson co-morbidity index, which included among other cardiovascular disease, 
pulmonary disease or diabetes mellitus. Tumors were classified as proximal if they were found in 
the cecum, ascending colon or transverse colon up to the splenic flexure and were classified as distal 
if they were found in the descending or sigmoid colon. SES was defined by the ECR upon postal 
code, combining mean household income and mean value of the residence. Postal codes were 
divided into three SES subcategories: low, intermediate and high. Institutions, such as nursing homes, 
were assigned to a separate category. Patients received adjuvant chemotherapy in accordance with 
national therapeutic guidelines applicable at that time, which was 5-fluorouracil or capecitabine, 
with the addition of oxaliplatin (FOLFOX or CAPOX regimen) from 2005 on. In the Netherlands, neo-
adjuvant radiotherapy was standard of care for rectal cancer patients since 2000 for T2-T4 tumors 
and concomitant chemoradiotherapy was given to patients with locally advanced tumors.
Statistical analysis
The χ2 test was used to compare clinicopathological characteristics. Primary outcome was OS, which 
was defined as the interval between the date of diagnosis until the date of death of any cause or 
until the date of last follow-up. Patients who were still alive at the end of follow-up were censored. 
OS curves were generated according to the Kaplan-Meier method and equality of distributions was 
compared with the log-rank test. Multivariate analysis of OS was performed using the Cox proportional 
hazard model. Covariates were identified after study of the literature. All tests of significance were 
two tailed: differences at P values of < 0.05 were considered significant. Statistical analyses were 
performed with the statistical software package SPSS 19.0 (SPSS, Inc., Chicago, IL). 
Results
Patient characteristics
Patient and tumor characteristics are presented in Table 1. MC was found in 12.3% patients and 
females accounted for 52.4% MC versus 45.9% NMC (p < 0.0001). MC was less often located in the 
rectum (24.4% MC versus 38.0% NMC, p < 0.0001) and more frequently in the proximal colon (54.3% 
versus 30.6%, p < 0.0001). At time of diagnosis, NMCs were more often classified as stage I tumors 
(20.5% versus 10.9%, p < 0.0001).
MC as a prognostic factor 
In the rectum, there was a significant difference in OS between MC and NMC (5-year OS 41.0% versus 
51.2%, p < 0.001; Figure 1), most prominent in stage I (77.4% versus 60.9%, p = 0.001) and III (48.5% 
versus 35.6%, p < 0.0001; Supplementary Figures S2-S5). The multivariate analysis showed that rectal 
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Table 1.  Demographic and clinicopathological features of patients with colorectal carcinomas diagnosed between 1990 and 2010.
Features Mucinous
n = 3052 (12.3%)
Non-mucinous
n = 21 845 (87.7%)
    P value 
Sex < 0.0001
Female 1598 (52.4) 10 017 (45.9)
Male 1454 (47.6) 11 828 (54.1)
Age < 0.0001
Median 70 years 69 years
< 45 102 (3.3) 611 (2.8)
45-59 515 (16.9) 4171 (19.1)
60-74 1331 (43.6) 10080 (46.1)
≥ 75 1104 (36.2) 6983 (32.0)
Location < 0.0001
Proximal colon 1658 (54.3) 6685 (30.6)
Distal colon 621 (20.3) 6563 (30.0)
Rectum 744 (24.4) 8301 (38.0)
Colon, unknown 29 (1.0) 296 (1.4)
Number of co-morbidities 0.001
0 1354 (44.4) 10 438 (47.8)
1 743 (24.3) 5333 (24.4)
2 227 (7.4) 1540 (7.0)
3 28 (0.9) 151 (0.7)
Missing 606 (22.9) 4383 (20.1)
Co-morbidity
Cardiovascular disease 720 (24.3) 4878 (22.9) < 0.0001
Pulmonary disease 221 (7.5) 1754 (8.3) 0.001
Diabetes Mellitus 340 (11.5) 2234 (10.5) < 0.0001
Socio-economic status 0.012
Low 849 (28.7) 5666 (26.7)
Intermediate 1142 (38.6) 7992 (37.7)
High 804 (27.2) 6337 (29.9)
Institutionalized 160 (5.4) 1197 (5.6)
Stage < 0.0001
I 332 (10.9) 4480 (20.5)
II 1168 (38.3) 6892 (31.5)
III 861 (28.2) 5199 (23.8)
IV 625 (20.5) 4275 (19.6)
Unknown 66 (2.1) 999 (4.6)
Adjuvant chemotherapy for stage III 304 (48.8) 1630 (50.9) 0.328
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MCs were associated with a higher risk of death compared with rectal NMCs (HR 1.22, 95% CI 1.11-
1.34, p < 0.0001), while there was no difference in OS between MC and NMC located in the colon 
(Table 2).
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Adjuvant chemotherapy in stage III mucinous colon cancer patients
Stage III colon cancer patients showed higher survival in both MC and NMC groups when treated with 
chemotherapy (Figure 2). Median OS in all patients treated with chemotherapy was 133 months, 
compared with 33 months for patients who were not treated (on univariate analysis p < 0.0001). The 
multivariate Cox proportional hazard model showed that MC was not an independent prognostic 
factor in the stage III subgroup when treated with adjuvant chemotherapy (Table 3).
Figure 1.  (A) Overall survival for mucinous carcinoma (MC) and non-mucinous carcinoma (NMC) patients with colon 
cancer (p = 0.386). (B) Overall survival for MC and NMC patients with rectal cancer (p < 0.0001).
0
20
40
60
80
100 Chemo
No chemo
0 5 10 15 20 25
Nº at risk 0 5 10 15 20
Chemo 304 118 58 15 2
No chemo 333 97 42 17 4
Survival, years
Su
rv
iv
al
, %
A
0
20
40
60
80
100 Chemo
No chemo
0 5 10 15 20 25
Nº at risk 0 5 10 15 20
Chemo 1630 651 269 63 7
No chemo 1570 422 196 76 15
Survival, years
Su
rv
iv
al
, %
B
Figure 2.  (A) Overall survival for stage III colon cancer patients with mucinous carcinoma, treated with or without adjuvant 
chemotherapy (p < 0.0001). (B) Overall survival for stage III colon cancer patients with non-mucinous carcinoma, treated 
with or without adjuvant chemotherapy (p < 0.0001).
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Table 2.  Multivariate survival analysis using the Cox model concerning all rectal and colon cancer patients.
Variables Rectal cancer Colon cancer
Hazard ratio 95% Confidence 
interval
Hazard ratio 95% Confidence 
interval
Age (years)
< 45 1 1
45-59 1.13 0.94-1.36 1.25 1.06-1.47
60-74 1.68 1.40-2.01 1.69 1.44-1.98
≥ 75 3.03 2.52-3.64 2.94 2.51-3.45
Sex
Male 1 1
Female 0.94 0.89-0.99 0.91 0.87-0.95
Stage
I 1 1
II 1.81 1.66-1.97 1.47 1.37-1.58
III 2.60 2.38-2.84 2.61 2.42-2.83
IV 10.16 9.27-11.13 10.95 10.14-11.83
Socio-economic status
Low 1 1
Intermediate 0.88 0.82-0.94 0.94 0.90-0.99
High 0.81 0.75-0.87 0.90 0.85-0.95
Institutionalized 1.25 1.11-1.41 1.27 1.17-1.38
Adjuvant chemotherapy
Yes 1 1
No 1.43 1.29-1.59 1.69 1.59-1.80
Neo-adjuvant radiotherapy
Yes 1 - -
No 1.63 1.53-1.75 - -
Neo-adjuvant chemoradiotherapy
Yes 1 - -
No 1.29 1.11-1.50 - -
Number of co-morbidities
0 1 1
1 1.18 1.10-1.27 1.27 1.21-1.34
2 1.61 1.44-1.79 1.45 1.34-1.57
3 1.70 1.24-2.32 1.55 1.17-1.80
Unknown 1.10 1.03-1.18 1.19 1.13-1.25
Histology
Non-mucinous 1 1
Mucinous 1.22 1.11-1.34 0.98 0.93-1.04
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Discussion
MC is a distinct CRC, with different clinical characteristics and prognosis compared with NMC. Due to 
reduced responsiveness to chemotherapy, MC has a poor prognosis in advanced disease. We showed 
that colon cancer patients with MC seem to benefit from adjuvant chemotherapy equally to patients 
with NMC.
In the present study over 24,000 prospectively registered CRC patients were analyzed. Approximately 12% 
of our population consisted of MC, which was constant over time and is consistent with previous reports.4, 
10, 13, 14 Many well-recognized MC-associated features were confirmed in the present study.5-8, 10, 16, 24 
We found a statistically significant difference in OS between MC and NMC in stage I and III rectal 
cancer patients, consistent with the current literature.16 In contrast to previous reports, we could not 
Table 3.  Multivariate survival analysis using the Cox model concerning all stage III colon cancer patients who were treated 
with adjuvant chemotherapy.
Variables Hazard ratio 95% Confidence interval
Age (years)
< 45 1
45-59 1.16 0.78-1.74
60-74 1.55 1.05-2.30
≥ 75 2.01 1.30-3.10
Sex
Male 1
Female 0.86 0.75-1.00
Socio-economic status
Low 1
Intermediate 1.02 0.85-1.23
High 1.00 0.83-1.22
Institutionalized 1.18 0.74-1.90
Number of co-morbidities
0 1
1 1.13 0.95-1.35
2 1.25 0.89-1.74
3 1.32 0.42-4.12
Unknown 1.12 0.91-1.37
Histology
Non-mucinous 1
Mucinous 1.05 0.86-1.28
Prognosis and adjuvant chemotherapy in mucinous colorectal carcinoma
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demonstrate a difference in survival in stage IV. 14, 23, 24 Many studies described a variable prognostic 
impact of MC.4, 6, 7, 10, 12, 16-18, 24 Unfortunately, these studies are generally relatively small and prospectively 
recorded information often does not include adjuvant treatment details. Furthermore, follow-up time 
usually is too short to reveal differences between groups adequately, leading to a possible statistical 
type II error. Moreover, most of the studies were hospital-based and not population-based, which 
could have led to a selection bias. Even though we are confident that the current study depicts an 
accurate image of MC, there are limitations due to its non-randomized nature. First of all, although 
definitions of MC have been standardized, variations in interpretation may result in misclassification. 
Due to the large population size, reviewing the individual pathological diagnosis was not feasible. 
However, we compared the percentage of MC and NMC per laboratory in order to exclude a possible 
bias, and there was no significant difference (data not shown). Also, frequencies were comparable 
with data available in the literature. Secondly, because this population-based registry does not 
include information regarding the duration of adjuvant treatment or treatment drugs given during 
adjuvant chemotherapy, we were not able to account for differences in therapy during the study 
period. However, when we compared survival in 5-year time periods we found improved survival 
following adjuvant chemotherapy to be significant over time (data not shown).
In the present, large population-based study, no differences in OS were demonstrated on multivariate 
analysis between MC and NMC, except when the tumor was located in the rectum. Consistent with 
these findings, a recent National Cancer Data Base (USA) study6 showed that MC of the rectum, but 
not of the colon is associated with an increased risk of death. Reasons for this difference in OS are 
not clear, but a possible explanation might be the poorer response to radiotherapy in MCs.11, 22, 27, 28 
Other reasons could be the fact that MCs in the rectum are usually larger, more often have a positive 
circumferential margin after resection22 and might therefore have a worse outcome.12 Further studies 
are needed to evaluate these factors in rectal cancer.
The efficacy of chemotherapy in MC has mainly been studied in patients receiving palliative 
chemotherapeutic treatment.14, 23-25 In this setting, response is poorer in MC patients compared with 
NMC patients. The current study confirms that adjuvant chemotherapy for stage III carcinoma is 
associated with an improved OS. Although patients were not randomized and several biases cannot be 
accounted for, this finding is consistent with previous randomized trials regarding all CRC patients and 
current international treatment guidelines.15, 20, 21 To our knowledge this is the largest analysis in MC 
patients concerning adjuvant chemotherapy to date. Interestingly, the present analysis demonstrated 
a similar survival for NMC and MC patients who underwent adjuvant chemotherapeutic treatment 
for stage III colon cancer. A recent retrospective analysis10 with 178 MC patients also suggested a 
comparable benefit from adjuvant chemotherapy for both stage II and III MCs and NMCs after radical 
resection. Thus, MC seems clearly responsive to adjuvant chemotherapy and therefore results found 
in palliative treatment should not be extrapolated to the adjuvant setting. 
The mechanisms behind the differences in response to chemotherapy in the adjuvant and palliative 
setting remain unclear. In general, MC patients have a larger number of metastatic sites and larger 
primary tumors,23, 29 with possibly a poorer vasculature, consequently leading to a decreased delivery 
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of therapy. In advanced disease, MC patients also more often suffer from extrahepatic localizations 
of metastases,14, 23, 24 such as distant lymph node metastases12, 24 or peritoneal metastases,12, 24, 25, 29, 30 
which is associated with a poor outcome in CRC.31, 32 
Based on its histological appearance and its clinicopathological features MC may be considered 
a distinct entity with a predominant right-sided location. In consistency with recent literature we 
have shown that MC seems to have no impact on survival, except when located in the rectum. 
Despite lower response to palliative chemotherapy in MC, colon cancer patients treated with 
adjuvant chemotherapy seem to have similar benefits. Therefore, current adjuvant treatment 
recommendations should be adhered to regardless of tumor type.
Prognosis and adjuvant chemotherapy in mucinous colorectal carcinoma
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Supplemental material
Supplementary Figure S1.  Consort diagram.
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Supplementary Figure S2.  (A) Overall survival for stage I mucinous carcinoma (MC) and non-mucinous carcinoma (NMC) 
patients with colon cancer (p = 0.741). (B) Overall survival for stage I MC and NMC patients with rectal cancer (p = 0.001).
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Supplementary Figure S3.  (A) Overall survival for stage II mucinous carcinoma (MC) and non-mucinous carcinoma (NMC) 
patients with colon cancer (p = 0.512). (B) Overall survival for stage II MC and NMC patients with rectal cancer (p = 0.234).
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Supplementary Figure S4.  (A) Overall survival for stage III mucinous carcinoma (MC) and non-mucinous carcinoma 
(NMC) patients with colon cancer (p = 0.994). (B) Overall survival for stage III MC and NMC patients with rectal cancer 
(p < 0.0001).
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Supplementary Figure S5.  (A) Overall survival for stage IV mucinous carcinoma (MC) and non-mucinous carcinoma 
(NMC) patients with colon cancer (p = 0.498). (B) Overall survival for stage IV MC and NMC patients with rectal cancer 
(p = 0.066).
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Abstract
Colorectal signet-ring cell carcinoma (SRCC) has been associated with poor survival compared with 
mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant 
chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of 
SRCC and determines whether colonic SRCC patients benefit from adjuvant chemotherapy equally 
compared with MC and AC patients.
Data on 196,757 colorectal cancer (CRC) patients in the period 1989-2010 was included in this 
Dutch nationwide population-based study. Five-year relative survival estimates were calculated and 
multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) 
were performed.
SRCC was found in 1972 (1.0%) patients. SRCC patients presented more frequently with stage III or IV 
disease than AC patients (75.2% versus 43.6%, p < 0.0001) and SRCC was more frequently found in 
the proximal colon (57.7% versus 32.0%, p < 0.0001). SRCC patients had a poor 5-year relative survival 
of 30.8% (95% CI 28.1-33.6) in the colon and 19.5% (95% CI 14.7-24.8) in the rectum compared with 
56.8% (95% CI 56.4-57.1) and 58.5% (95% CI 57.9-59.1) for AC. This survival difference was found in 
stage II, but was most prominent in stage III. Compared with AC, there was no significant interaction 
between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81-1.51), suggesting a comparable 
benefit from adjuvant chemotherapy in AC and SRCC.
In conclusion, the prognostic impact of SRCC is dismal in both colon and rectal cancer patients, but 
adjuvant chemotherapy is associated with improved survival in AC, MC and SRCC patients.
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Introduction
Colorectal cancer (CRC) is one of the most-common cancers worldwide, and several histological 
subtypes have been reported.1, 2 The common adenocarcinoma (AC) accounts for the majority of 
cases and in 10-15% patients present with mucinous adenocarcinoma (MC).3-6 Signet-ring cell 
adenocarcinoma (SRCC) is a rare type of adenocarcinoma, found in approximately 1% of CRC patients 
and contains abundant intracellular mucus in more than 50% of its cells.3, 4, 7, 8 Due to the low incidence, 
SRCC has been evaluated in a limited amount of studies, with small numbers of patients. SRCC has 
been associated with a poor prognosis compared with AC.3, 7-11 However, it is unclear whether the 
prognostic impact is relevant for both colon and rectal cancer patients.
Adjuvant fluorouracil-based chemotherapy improves outcome in colon cancer patients, and is 
routinely administered to stage III patients following surgical removal of the tumor.12 The addition of 
oxaliplatin became standard of care around 2005 in the Netherlands. It is unclear whether different 
histological subtypes should influence treatment decisions, since it is often not addressed in clinical 
trials. Recently, we showed that colonic MC patients have a similar survival compared with AC patients 
and demonstrated that MC is not a prognostic factor in stage III colon cancer when treated with 
adjuvant chemotherapy.6 In the literature, there are no studies concerning outcome after adjuvant or 
palliative chemotherapy for SRCC. However, due to the aggressive behavior of SRCC it is important to 
gain insight in potential adjuvant treatment options in an effort to enhance survival in these patients.
In this population-based study we analyze clinicopathological characteristics of SRCC. Moreover, we 
establish the prognostic impact of SRCC for both colon and rectal cancer patients and determine 
whether colonic SRCC patients benefit equally from adjuvant chemotherapy following resection 
compared with MC and AC patients.
Patients and methods
Data on all CRC patients diagnosed between 1989 and 2010 in the Netherlands, were retrieved 
from the nationwide population-based Netherlands Cancer Registry (NCR). The NCR receives lists 
of newly diagnosed cancer patients on a regular basis from the pathology departments of all Dutch 
hospitals, who all participate in a nationwide network. In addition, the medical records departments 
of hospitals provide lists of diagnoses of outpatients and hospitalized cancer patients. Following 
these notifications, trained registrars of the NCR extract data on patient and tumor characteristics 
and primary treatment from the medical records. All tumors (n = 202,807) were classified according 
to the International Classification of Disease for Oncology (ICD-O). Patients were identified as 
SRCC (ICD-O morphology code: 8490), MC (ICD-O morphology codes: 8480, 8481) and AC (ICD-O 
morphology codes: 8000, 8010, 8020, 8021, 8140, 8141, 8143, 8144, 8210, 8211, 8220, 8221, 8260, 
8261, 8262, 8263). Undifferentiated tumors (n = 547) and tumors that were classified as other than 
adenocarcinoma, such as GIST and carcinoids (n = 4,759) were excluded. Appendiceal neoplasms 
were not included in this study (n = 1,795), since they are considered a unique entity. Tumor stage was 
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determined according to the TNM classification of the WHO.4 In case (parts of) the pathological stage 
(pTNM) were unknown or missing, (parts of) the clinical stage (cTNM) were used to reconstruct the 
stage. The pathological T-stage was unknown or missing in 16.9% of cases. Other available variables 
for this study included: age, gender, year of incidence, primary tumor location, surgery performed, 
(neo)adjuvant therapy and survival time. Data on follow-up of vital status was retrieved by linkage to 
the nationwide municipal population registries network. Every patient who was included in this study 
was registered in the population registries network. Information concerning the cause of death was 
not available. Since a widely accepted standard for grading is lacking and grade assignment is highly 
subjective, this variable was not taken into account.13 Tumors of the colon were classified as proximal 
if they were located in the cecum, ascending colon, or transverse colon up to the splenic flexure, 
and were classified as distal if they were found in the descending, sigmoid or rectosigmoid colon. If 
patients had two or more consecutive invasive CRCs, only the first tumor was included in the analyses. 
In the Netherlands stage III colon cancer patients are offered adjuvant chemotherapy in accordance 
with nationwide therapeutic guidelines applicable, which is 5-fluorouracil or capecitabine, with the 
addition of oxaliplatin since 2005. The study was approved by the supervisory committee of the NCR.
Statistical Analysis
The χ2 test was used to compare proportions in demographic and clinical characteristics by histological 
subtype. Primary outcome was overall survival, which was defined as the interval between the date of 
diagnosis until the date of death or until last follow-up, December 31, 2011. Patients who were alive 
at the end of follow-up were censored in the survival analyses. To compare adjuvant chemotherapy 
in stage III we excluded patients who died within 30 days after surgery for these analyses (n = 828). 
Relative survival estimates were calculated as the ratio of observed survival of the cancer patients 
and the expected survival of an age and sex matched group of the general Dutch population. The data 
for the calculation of the expected survival in the general population was obtained from Statistics 
Netherlands and consisted of the gender-specific death rates per 1-year age group per calendar 
year. Survival between different histological subtypes was compared using a multiple relative survival 
regression model, in which age, gender, tumor localization, adjuvant chemotherapy and period of 
diagnosis were included to calculate variable specific relative excess risk (RER) of death estimates. All 
tests of significance were two-tailed and differences at P values of < 0.05 were considered significant. 
Relative survival analyses were performed with SAS software (SAS system 9.2, SAS Institute, Cary, NC).
Results
Patient characteristics
A total of 196,757 patients was included in this study and most patients (85.4%) were diagnosed with 
AC (Table 1). MC accounted for 13.6% and SRCC was found in 1.0% of patients. In the group of SRCC 
patients 25.9% was younger than 60 years of age, compared with 18.7% and 19.6% in the MC and 
AC group (p < 0.0001). SRCC patients presented more frequently with stage III or IV tumors than AC 
patients (75.2% versus 43.6%, p < 0.0001) and SRCC was more commonly found in the proximal colon 
(57.7% versus 32.0%, p < 0.0001). 
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Subtype as a prognostic factor
SRCC patients had a statistically significant lower 5-year relative survival compared with MC and AC 
patients in both colon and rectal cancer patients (Figure 1). In SRCC 5-year relative survival rates were 
31% (95% CI 28.1-33.6) for colon cancer patients and 20% (95% CI 14.7-24.8) for rectal cancer patients 
compared with 57% (95% CI 56.4-57.1) and 59% (95% CI 57.9-59.1) in AC. MC and AC had a similar 
survival in colon cancer patients, but a poorer survival was found in rectal MC patients. Five-year relative 
survival rates per stage and primary tumor location are presented in Table 2 and showed a poorer 
survival in SRCC patients in stage II and most prominently in stage III in colon and rectal cancer patients. 
Adjuvant chemotherapy for stage III SRCC colon cancer patients
In SRCC 51.6% of stage III patients received adjuvant chemotherapy, compared with 51.0% and 54.0% 
in MC and AC (Table 1). Patients who were treated with adjuvant chemotherapy had a better survival 
Table 1.  Demographic and clinicopathological features of patients with colorectal carcinomas diagnosed between 1989 
and 2010.
Features AC (%)
n = 167,934
MC (%)
n = 26,851
SRCC (%)
n = 1,972
P value SRCC 
versus AC
Sex 0.121
  Female 79,493 (47.3) 14,394 (53.6) 968 (49.1)
  Male 88,441 (52.7) 12,457 (46.4) 1,004 (50.9)
Age at diagnosis < 0.0001
  Median 71 72 70
  < 45 4,462 (2.7) 890 (3.3) 151 (7.7)
  45-59 28,362 (16.9) 4,133 (15.4) 359 (18.2)
  60-74 72,107 (42.9) 10,969 (40.9) 723 (36.7)
  ≥ 75 63,003 (37.5) 10,859 (40.4) 739 (37.5)
Location < 0.0001
  Proximal colon 53,680 (32.0) 14,706 (54.8) 1,137 (57.7)
  Distal colon 64,548 (38.4) 6,987 (26.0) 424 (21.5)
  Rectum 46,605 (27.8) 4,595 (17.1) 343 (17.4)
  Colon, unknown 3,106 (1.8) 563 (2.1) 68 (3.4)
Stage < 0.0001
  I 32,988 (19.6) 3,110 (11.6) 58 (2.9)
  II 50,441 (30.0) 10,415 (38.8) 360 (18.3)
  III 40,383 (24.0) 7,513 (28.0) 763 (38.7)
  IV 32,894 (19.6) 5,284 (19.7) 720 (36.5)
  Unknown 11,228 (6.7) 529 (2.0) 71 (3.6)
Adjuvant chemo stage III
  Yes 9,952 (54.0) 1,771 (51.0) 190 (51.6) 0.372
AC, adenocarcinoma; MC; mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma
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than patients who did not receive adjuvant chemotherapy (Figure 2). In patients who received adjuvant 
chemotherapy, 5-year relative survival rates for SRCC, MC and AC were 52% (95% CI 42.9-60.5), 69% 
(95% CI 66.6-72.1) and 74% (95% CI 72.8-75.1). In patients who did not receive adjuvant chemotherapy 
5-year relative survival rates were 30% (95% CI 21.9-39.3), 52% (95% CI 47.9-54.9) and 50% (95% CI 
48.5-51.5) in SRCC, MC and AC patients respectively. Results of the multivariate relative survival analysis 
are presented in Table 3. SRCC was found a poor prognostic factor in stage III colon cancer patients 
compared with AC with an RER of 2.16 (95% CI 1.84-2.52). However, in comparison with AC, there 
was no significant interaction between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81-1.51), 
suggesting a comparable benefit from adjuvant chemotherapy in AC and SRCC. Compared with AC, MC 
and chemotherapy did show an interaction (RER 1.23, 95% CI 1.07-1.34), indicating a poorer benefit of 
adjuvant chemotherapy for MC. Eventually, this did not result in an overall poorer prognostic impact for 
MC compared with AC in stage III colon cancer patients (RER 1.04, 95% CI 0.97-1.12).
Figure 1.  Relative survival in adenocarcinoma (AC), mucinous adenocarcinoma (MC) and signet-ring cell carcinoma 
(SRCC) patients with colon cancer (A) and rectal cancer (B).
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Table 2.  Five-year relative survival with 95% confidence intervals (CI) for patients with colorectal cancer in the Netherlands 
according to tumor location, stage of disease and histology (1989-2010).
AC 95% CI MC 95% CI SRCC 95% CI
Colon
Stage I 93.7 92.9-94.5 92.9 90.3-95.3 98.4 82.4-107.6
II 77.0 76.3-77.6 78.9 77.5-80.3 67.9 59.8-75.5
III 56.8 56.0-57.5 54.4 52.8-56.0 36.4 31.9-41.1
IV 6.3 5.9-6.6 6.4 5.6-7.3 3.8 2.3-6.1
Unknown 17.8 16.7-18.9 21.3 16.1-27.3 †
All stages 56.8 56.4-57.1 57.8 56.9-58.6 30.8 28.1-33.6
Rectum
Stage I 90.0 89.0-90.9 86.9 82.9-90.7 †
II 67.1 65.9-68.3 67.7 64.2-71.2 27.4 14.6-42.7
III 54.8 53.6-56.0 45.2 42.1-48.4 25.5 17.5-34.5
IV 7.1 6.4-7.8 6.6 4.6-8.9 §
Unknown 39.0 37.0-41.1 41.8 33.4-50.4 †
All stages 58.5 57.9-59.1 53.8 51.9-55.6 19.5 14.7-24.8
† Due to small number of patients (number at risk < 10), calculation could not be performed accurately
§ No patients alive at five years after diagnosis
AC, adenocarcinoma; MC; mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma
Discussion
SRCC is an uncommon but unique histological subtype of CRC, with generally a poor prognosis 
compared with MC and AC. This population-based study demonstrated that prognosis of SRCC 
patients is impaired regardless of stage and location of the tumor. We also show that stage III colonic 
SRCC patients seem to benefit from adjuvant chemotherapy equally compared with AC in a national 
cohort study. 
Due to the low frequency, SRCC has not been well studied in CRC and reports in the literature 
are uncommon. The present study analyzed over 196,000 CRC patients who were prospectively 
registered in the NCR. Our study population consisted of 1% (n = 1972) SRCC patients, which is in 
concordance with reported numbers in the literature.3, 7, 9, 10, 14 Several clinical characteristics of SRCC, 
such as localization in the proximal part of the colon, younger age at diagnosis and more advanced 
stage at presentation were confirmed in the present study.
Previous studies suggested a poor prognosis for SRCC compared with AC.3, 7-11 In this study we 
confirmed this worse relative survival for SRCC in both colon and rectal cancer, which was most 
evident in stage III. In concordance with the literature, we demonstrated that MC was only associated 
with a worse survival when located in the rectum.3, 6 Efficacy of adjuvant chemotherapy in CRC 
patients has mainly been studied in AC and to a limited extent in MC patients. In the present study 
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Figure 2.  Relative survival in stage III colon cancer patients with adenocarcinoma (A), mucinous adenocarcinoma (B) and 
signet-ring cell carcinoma (C), treated with or without adjuvant chemotherapy.
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MC showed an interaction with adjuvant chemotherapy in stage III colon cancer patients. Previous 
studies demonstrated that MC was not a prognostic factor in colon cancer patients treated with 
adjuvant chemotherapy.6, 15 However, these studies did not define whether there was an interaction 
between MC and adjuvant chemotherapy. The current study used a different survival model and 
different variables were included in the multivariate analysis. 
Table 3.  Multivariate relative survival and interaction analysis with 95% confidence interval (CI) for stage III colon cancer 
patients following resection. 
Multivariate relative excess risk 
(RER) of death
Number (%) RER 95% CI P value
Sex
  Male 11,050 (49.6) 1
  Female 11,230 (50.4) 0.97 0.92-1.02 0.29
Age group
  < 45 676 (3.0) 0.85 0.73-0.99 0.04
  45-59 3,949 (17.7) 0.91 0.84-0.97 0.008
  60-74 9,905 (44.5) 1
  ≥ 75 7,750 (34.8) 0.91 0.85-0.97 0.006
Period of diagnosis
  1989 - 1994 1,311 (5.9) 1.26 1.13-1.40 < 0.0001
  1995 - 1999 3,675 (16.5) 1.37 1.27-1.48 < 0.0001
  2000 - 2005 7,231 (32.5) 1.17 1.10-1.25 < 0.0001
  2006 - 2010 10,063 (45.2) 1
Tumor location
  Proximal 10,691 (48.0) 1.31 1.23-1.38 < 0.0001
  Distal 11,236 (50.4) 1
  Colon NOS 353 (1.6) 1.64 1.37-1.97 < 0.0001
Adjuvant chemo
  No 10,367 (46.5) 1
  Yes 11,913 (53.5) 0.41 0.38-0.44 < 0.0001
Histology
  AC 18,439 (82.8) 1
  MC 3,473 (15.6) 1.04 0.97-1.12 0.29
  SRCC 368 (1.7) 2.16 1.84-2.52 < 0.0001
Interaction analyses
  AC and adjuvant chemo 9,952 (83.5) 1
  MC and adjuvant chemo 1,771 (14.9) 1.23 1.07-1.34 0.005
  SRCC and adjuvant chemo 190 (1.6) 1.10 0.81-1.51 0.54
AC, adenocarcinoma; MC, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma
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To our knowledge, the present study is the first that analyzed outcome after adjuvant chemotherapy 
in SRCC patients. Data presented in this large population-based study showed a longer survival in 
SRCC patients when treated with adjuvant chemotherapy. SRCC remained an independent prognostic 
marker for poor outcome in stage III colon cancer patients treated with adjuvant chemotherapy, but 
an interaction between chemotherapy and SRCC was not demonstrated. This indicates that adjuvant 
chemotherapy in SRCC patients is associated with improved survival, and that the poor outcome of 
SRCC patients is not related to a poor response to adjuvant chemotherapy. 
Since adjuvant chemotherapy in SRCC patients was associated with an improved survival, there 
must be other factors leading to differences in outcome. The more advanced stage of disease 
in which SRCCs were found may be one of the reasons for the poorer outcome. Unfortunately, 
there are no studies available that have generated insight into this difference in tumor 
progression. Another explanation for the differences in survival may be the deviant metastatic 
pattern in SRCC. SRCC patients more often develop metastatic disease, are more likely to 
develop peritoneal metastases and SRCC metastasizes via the lymphatic route more frequently, 
whereas AC metastasizes primarily to the liver.7, 10, 14, 16 Peritoneal metastases are associated with 
a poor prognosis, and survival is even worse if metastases are present in other organs.17 Often, 
these metastases cannot be treated with curative intent. Curative surgery is an option mainly 
limited to liver and lung metastases, which are the most-common metastatic sites in AC patients. 
Moreover, chemotherapy for patients with peritoneal metastases may not yield the same results 
compared with patients with hematogenous metastases and this may lead to a poor outcome in 
advanced disease in SRCC patients.18
The NCR covers nearly all cancer diagnoses in the Netherlands, thereby constituting an comprehensive 
population-based registry.19 The extensive amount of data offers the possibility to analyze relatively 
rare subtypes of cancer, such as SRCC and to study therapeutic interventions in these groups. However, 
this study has some limitations as well, because the non-randomized nature of this study could be a 
potential confounding factor. Compared with randomized controlled clinical trials that demonstrated 
efficacy of adjuvant chemotherapy, we found a much larger survival difference between patients 
who did and who did not receive adjuvant chemotherapy.20-23 Frail and elderly patients are more 
commonly ineligible for adjuvant chemotherapeutic treatment, thereby comprising a larger share in 
the patient group that did not receive chemotherapy in our study. This may have influenced outcome 
in this group, but this bias applies to all histological subgroups. Further, the NCR does not register 
detailed information concerning adjuvant treatment, therefore we were not able to account for 
differences in adjuvant therapy practice over the study period. Unfortunately, we were not able to 
analyze the benefit of adjuvant chemotherapy in high-risk stage II patients, due to the low number 
of patients who received chemotherapy in this group and because the motivation for administration 
of chemotherapy was not registered. Lastly, due to the population size, we have not been able to 
review the individual pathological diagnosis. Even though standard definitions for MC and SRCC as 
produced by the WHO are employed in the Netherlands, diagnostic heterogeneity may have led to 
misclassification. However, frequencies of subtypes were comparable with numbers reported in the 
literature.3 
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In conclusion, SRCC is considered a distinct entity based on clinical presentation and pathological 
features. In this study we have shown that the prognostic significance of SRCC is dismal with a poor 
survival in both colon and rectal cancer patients. However, we found that adjuvant chemotherapy for 
SRCC stage III colon cancer patients is associated with improved survival.
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Abstract
Mucinous carcinoma (MC) is a distinct form of rectal cancer (RC) comprising 10% of all cases, and has 
been associated with an impaired prognosis compared with non-mucinous adenocarcinoma (AC). 
The benefit of today’s modern treatment for MC patients is unknown, but a prospective randomized 
trial to answer this seems not feasible. This study provides an analysis of the modern treatment of 
rectal MC and efficacy of preoperative therapies for MC patients.
Data from three large (trial) cohorts was used. Data from the Netherlands Cancer Registry (NCR) 
was used to analyze the prognosis of RC patients over time (n = 38,035). To study the benefit of 
preoperative short-term radiotherapy patients from the TME trial (n = 1530) were selected and 
benefit from preoperative chemoradiotherapy was analyzed with data on 540 locally advanced RC 
(LARC) patients from two hospitals.
Data from the NCR confirmed that 5-year overall survival for MC was significantly worse from 1989-
1998, but no longer different from AC from 1999 onwards. MC patients had a higher rate of positive 
circumferential resection margin (CRM) than AC (TME trial 27.2% versus 16.5%, p = 0.006; LARC 
cohort 34.5% versus 9.8%, p < 0.0001) , but there was no difference in outcome between MC and AC 
patients after preoperative short-term radiotherapy or chemoradiotherapy. 
Modern treatment of RC has benefitted MC patients, leading to equal survival for MC and AC 
patients. Enhancements in the fields of imaging and quality of surgery have improved outcome and 
preoperative therapies should be recommended for both histological subtypes.
Modern treatment of mucinous rectal cancer
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Introduction
Treatment of rectal cancer (RC) patients has improved rapidly over the last decades. At the end of the 
past century total mesorectal excision (TME), which encompasses resection of the tumor together 
with the fatty tissue surrounding the rectum was introduced and significantly improved outcome.1 
Enhanced imaging by the means of MRI enabled multidisciplinary boards to make a better estimation 
of tumor invasion depth and preoperative therapies such as short-term radiotherapy and long-term 
chemoradiotherapy had a significant impact on RC treatment.2-8
Many European oncologists consider patients with a cT2 to cT4 RC eligible for preoperative 
radiotherapy and recommend to add chemotherapy for patients with locally advanced rectal cancer 
(LARC) in which the mesorectal fascia (MRF) is threatened. In North America, conversely, short-term 
radiotherapy is not commonly used for treatment of RC patients.
RC can be classified according to the histological aspect of the tumor. The majority of RCs comprises 
non-mucinous adenocarcinoma (AC). Approximately 10% of RCs is characterized by extensive 
extracellular mucus that forms more than 50% of the tumor volume.9, 10 These tumors are referred to 
as mucinous adenocarcinomas (MC) and form a distinct clinicopathological entity with an aberrant 
molecular background.11 MC is regarded as a cancer subtype with a poor prognosis when located in 
the rectum (Figure 1).9, 10, 12-17 
Figure 1.  Seven publications9, 10, 12-16 were included in a meta-analysis comparing prognostic impact in mucinous (MC) 
and non-mucinous (AC) adenocarcinoma in a timed cohort. Patients who were included were accrued from 1968 to 
2010. Five studies found a significantly worse survival in rectal MC patients. Hazard ratios (HRs) were combined 
in a meta-analysis which resulted in an overall HR of 1.23 (95% CI 1.18-1.28) for MC compared with AC in rectal 
cancer patients. Detailed information on literature search and analysis can be found in Supplementary Data S1. 
a, Multivariate HR; b, Univariate HR; CI, confidence interval.
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Several studies have reported a poor response of rectal MC to preoperative therapies, leading to a higher 
rate of resections with a positive circumferential resection margin (CRM) and a poor outcome when 
compared with rectal AC.18-22 These findings, however, are based on small and foremost timed cohorts, 
that were analyzed prior to the introduction of TME surgery, preoperative therapies and MRI scanning. 
In this study we investigate the overall survival (OS) in MC and AC patients over a long time period 
using data from a population-based cancer registry. Moreover, using data from large (trial) cohorts 
we analyze the impact for AC and MC patients of today’s modern RC treatment in which TME surgery, 
short-term radiotherapy and long-term chemoradiotherapy have become standard of care.
Patients and methods
Patient populations
For this study three independent study populations were selected to study the prognosis of RC over 
time (1) and the effects of short-term radiotherapy (2) and chemoradiotherapy (3).
1. Patients from the national cancer registry
Data on 38,035 RC patients diagnosed with AC (n = 34,459) or MC (n = 3576) between 1989 and 2006, 
were retrieved from the nationwide population-based Netherlands Cancer Registry (NCR) to study 
overall survival (OS) of RC patients over time. Tumors were classified according to the International 
Classification of Disease for Oncology (ICD-O). Patients were identified as MC (8480, 8481) and AC 
(8000, 8010, 8020, 8021, 8140, 8141, 8143, 8144, 8210, 8211, 8220, 8221, 8260, 8261, 8262, 8263). 
Follow-up of vital status was retrieved by linkage to the nationwide population registries network, 
until December 31, 2011. 
2. Patients from the TME trial
To study benefit from short-term radiotherapy, patients from the randomized multicenter TME trial were 
selected. Between January 12, 1996 and December 31, 1999, 1861 patients with clinically resectable 
RC were assigned to either preoperative radiotherapy using 5x5 Gy followed by TME or TME alone. The 
design of the trial was reported previously.23 For the present study we only included Dutch patients 
(n = 1530), who underwent a resection and did not have metastatic disease at the time of diagnosis. 
Previous research on the TME trial showed that short-term radiotherapy may lead to induction of a 
mucinous phenotype. Especially patients with a tumor containing more than 90% mucus were considered 
induced mucinous lesions when the preoperative biopsy was negative for mucus.24, 25 However, prognosis 
and clinicopathological features of these induced lesions are comparable to AC.25 Therefore, all patients 
with a lesion with a mucinous component of 90% or more, but with a negative preoperative biopsy for 
MC were considered radiotherapy-induced MC and excluded from the analysis (n = 29).
3. Patients with locally advanced RC
The LARC study group consisted of 540 patients without metastatic disease who underwent 
preoperative chemoradiotherapy followed by TME for LARC between April 1998 and January 2013. 
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Table 1.  Patient and tumor characteristics according to histological subtype in patients from the TME trial and patients 
with locally advanced rectal cancer who received preoperative chemoradiotherapy.
TME trial Locally advanced
Characteristic MC (%)
n = 103 (8.2)
AC (%)
n = 1157 (91.8)
P value MC (%)
n = 58 (10.7)
AC (%)
n = 482 (89.3)
P value
Randomization TME trial 0.195 -
  Surgery alone 47 (7.2) 605 (92.8) - -
  Radiotherapy and surgery 56 (9.2) 552 (90.8) - -
Chemoradiotherapy regime - 0.326
  CAP - - 21 (36.2) 210 (43.6)
  CAP + OXA - - 15 (25.9) 140 (29.0)
  CAP + BEV - - 1 (1.7) 9 (1.9)
  Bolus 5FU-Mayo - - 17 (29.3) 85 (17.6)
  Unknown - - 4 (6.9) 38 (7.9)
Gender 0.686 0.605
  Male 64 (62.1) 742 (64.1) 38 (65.5) 229 (62.0)
  Female 39 (37.9) 415 (35.9) 20 (34.5) 183 (38.0)
Age 0.568 0.178
  < 45 5 (4.9) 52 (4.5) 2 (3.4) 22 (4.6)
  45-59 31 (30.1) 323 (27.9) 24 (41.4) 147 (30.5)
  60-75 52 (50.5) 546 (47.2) 31 (53.4) 275 (57.1)
  > 75 15 (14.6) 236 (20.6) 1 (1.7) 38 (7.9)
CRM 0.006 <0.001
  Negative (> 1mm) 75 (72.8) 966 (83.5) 38 (65.5) 435 (90.2)
  Positive (≤ 1mm) 28 (27.2) 191 (16.5) 20 (34.5) 47 (9.8)
Pathological N-stage 0.001 0.293
  Negative 48 (46.6) 728 (62.9) 36 (62.1) 332 (68.9)
  Positive 55 (53.4) 429 (37.1) 22 (37.9) 150 (31.1)
Type of resection 0.335 0.136
  Low anterior 60 (58.3) 757 (65.4) 21 (36.2) 237 (49.2)
  Abdominoperineal 38 (36.9) 349 (30.2) 33 (56.9) 217 (45.0)
  Hartmann 5 (4.9) 51 (4.4) 0 (0) 9 (1.9)
  Other 0 0 4 (6.9) 19 (3.9)
MC, mucinous adenocarcinoma; AC, non-mucinous adenocarcinoma; CRM, circumferential resection margin; CAP, 
capecitabine; OXA, oxaliplatin; BEV, bevacizumab; 5FU, 5-fluorouracil
This group was used to analyze benefit from preoperative chemoradiotherapy in LARC patients. 
Tumors were considered LARC if the MRF was endangered on imaging. Patients were treated in either 
Catharina Hospital Eindhoven (n = 486) or Radboud university medical center (n = 54), which are both 
tertiary referral centers and data was recorded prospectively. To rule out induction of the mucinous 
phenotype in irradiated patients, tumors with extensive mucus or designated as MC were assessed 
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by a pathologist (IN) and evaluated on pre-operative MRI (when available for review) by a radiologist 
(JF). Evaluation of MRI was also performed for patients with a pathological complete response, 
leaving no vital tumor cells. Based on signal intensity measurements on T2-weighted fast spin echo 
images, MC was identified.26, 27 In accordance with Dutch radiotherapy guidelines, radiotherapy was 
administered five days per week at a daily dose of 1.8-2 Gy, with a total dose of 45-50.4 Gy in 25-28 
fractions. Different concurrent regimens of systemic therapy were given during the study period. 
Tumors were operated with adherence to beyond TME principles, with the primary goal of obtaining 
a radical resection.28 Patients had regular follow-up after surgery. 
Statistical Analysis
The χ2 test was used to compare clinicopathological characteristics by histological subtype. In survival 
analyses OS was defined as the interval between the date of surgery (date of diagnosis for NCR 
data) until the date of death or until last follow-up. Patients who were alive at the end of follow-up 
were censored in survival analyses. OS curves were generated according to the Kaplan-Meier method 
and equality of distributions was compared with log-rank testing. Multivariate analysis of OS was 
performed using the Cox proportional hazard model. Patients from the NCR were grouped into 1-year 
cohorts to analyze time related changes in 5-year OS. All tests of significance were two-tailed and 
differences at P values of < 0.05 were considered significant. 
Results
Improved outcome of RC patients over time
To analyze 5-year OS over time, data from the NCR on patients who were diagnosed with RC between 
1989 and 2006 was used. Survival improved over time in both MC and AC patients (Figure 2). Five-
year OS in AC patients improved from 40.3% (95% CI 37.8-42.8) in 1989 to 54.1% (95% CI 52.1-56.0) 
in 2006 (p < 0.0001), compared with 32.0% (95% CI 24.7-39.3) and 53.1% (95% CI 46.4-59.8) in 
Figure 2.  Five-year overall survival rates with 95% confidence limits for mucinous (MC) and non-mucinous (AC) rectal 
cancer patients in a nationwide cohort from 1989 to 2006.
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MC patients (p < 0.0001). This was most prominent in stage II and III patients. Five-year OS for MC 
was significantly worse from 1989-1998, but was no longer different from AC from 1999 onwards, 
indicating that modern treatment of RC using enhanced imaging, TME surgery and neo-adjuvant 
therapies may have had a significant impact on prognosis of MC patients.
Contribution of short-term radiotherapy
The benefit of short-term radiotherapy for MC and AC patients was analyzed using data from the 
TME trial. There were 103 (8.2%) MC patients and 1157 (91.8%) AC patients in the TME trial (Table 
1). A positive CRM was more commonly found in MC patients than in AC patients (27.2% versus 
16.5%, p = 0.006). AC patients less frequently developed a local recurrence (LR) after preoperative 
radiotherapy. The 10-year cumulative incidence of LR was 13% in the TME alone group and 5.6% 
in the group that underwent radiotherapy (p < 0.0001). A similar, though insignificant trend, was 
seen for MC patients, with a 10-year LR rate of 22.9% versus 15.6% (p = 0.218). The hazard ratio 
(HR) of developing LR was higher in MC patients than in AC patients (HR 2.06, 95% CI 1.23-4.46), 
independent of therapy. In accordance with previously published data from the TME trial, there was 
no improvement in survival for AC patients following radiotherapy (10-year OS 53.3% versus 50.5% 
after radiotherapy, p = 0.679; Figure 3). MC patients who underwent preoperative radiotherapy did 
not show an improved survival either (10-year OS 44.7% versus 49.4% after radiotherapy, p = 0.475). 
Figure 3.  Overall survival and local recurrence in (A) rectal non-mucinous adenocarcinoma and (B) rectal mucinous 
adenocarcinoma patients who were treated with total mesorectal excision (TME) with or without preoperative short-
term radiotherapy (RT).
Contribution of chemoradiotherapy
A total of 58 (10.7%) MC patients and 482 (89.3%) AC patients with LARC were analyzed (Table 1). 
MC patients more commonly underwent a resection with a positive CRM (34.5% versus 9.8%, 
p < 0.0001) than AC patients. The higher rate of CRM positivity in MC patients was observed for ypT3 
and ypT4 tumors only. The median follow-up period was 45 months (range 0-158 months). Long-
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term chemoradiotherapy benefited MC and AC patients equally (Figure 4). At 5 years there was no 
difference in OS between MC and AC patients (64.3% versus 70.6%, p = 0.459). The rate of LR was low 
and was not different between MC and AC patients. 
Figure 4.  (A) Overall survival and (B) local recurrence in mucinous adenocarcinoma (MC) and non-mucinous 
adenocarcinoma (AC) LARC patients who were treated with preoperative chemoradiotherapy. 
The 5-year cumulative incidence rate of LR was 14.3% in MC patients and 9.5% in AC patients 
(p = 0.203). Tumor downstaging, as indicated by a lower pT than cT, was more common in AC patients 
than in MC patients (68.7% versus 55.2%, p = 0.039). Interestingly, pathological complete responses 
were not seen in MC patients, compared with 16.4% (n = 79) in AC (p < 0.0001).
Discussion
Consensus for treatment of RC patients is obtained in multidisciplinary team meetings, in which 
patient and tumor characteristics are taken into consideration. Herein, MC is commonly regarded as 
an unfavorable tumor subtype for preoperative therapies, with a poor prognosis. This study provided 
an analysis of the current treatment of rectal MC and showed that there is no longer a difference in 
overall survival between rectal MC and AC patients. 
The generally accepted thought of a poorer prognosis for rectal MC came about from research that 
was performed with (small) patient groups from timed cohorts, as was demonstrated in our meta-
analysis. Population-based data from the NCR was used to evaluate OS of RC patients from 1989 
to 2006. Five-year OS analysis showed an improvement for both rectal MC and AC patients over 
time. Improved survival of RC patients as a consequence of modern treatment has previously been 
demonstrated, but was never assessed in MC patients.29, 30 We found that survival of MC patients 
used to be worse than AC patients, but was comparable from 1999 onwards. The latter has not 
been described before and indicated that introduction of better preoperative imaging, TME surgery, 
and preoperative therapies may have led to equalization of survival in both subtypes.1, 31-34 Surgery 
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according to TME principles or in advanced cases beyond TME principles improves chances of 
obtaining a radical resection, which is of particular importance in MCs, which are generally larger and 
have a less impressive response to chemoradiotherapy than ACs.21
The multicenter randomized TME trial and MRC CR07 trial demonstrated improved local control 
after preoperative short-term radiotherapy for patients with operable RC.7, 8 In the current study we 
showed that both MC and AC patients who were treated with preoperative short-term radiotherapy 
had a lower rate of LR than patients who were treated with surgery alone. These findings support the 
use of preoperative short-term radiotherapy for both subtypes. 
In LARC patients the MRF is threatened and preoperative chemoradiotherapy is usually recommended. 
To study the benefit from chemoradiotherapy, a cohort of 540 patients with mucinous and non-
mucinous LARCs from two experienced hospitals was assessed. There was no difference in OS 
between MC and AC, indicating equal benefit of preoperative chemoradiotherapy for both subtypes. 
Nevertheless, pathologic complete responses did not occur in MC patients, there was a lower rate 
of T-stage downstaging and MC patients more often had a positive CRM, as has been observed 
before.18, 20-22, 35 However, in our study this did not result in a worse outcome for MC patients. We 
hypothesize that other factors, such as mucus and tumor cell density, determine the impact of a 
positive CRM, but this has not been studied for MC and is an important issue for future research.36 
It is unknown what mechanisms are responsible for the relative chemo and radio-resistance of MC. 
This is likely to be due to a combination of a different molecular signature and different physical 
properties of mucus containing tumors compared with AC. Mutated KRAS, which is more commonly 
found in MC, is one of the biomarkers that is strongly associated with a non-complete pathologic 
response to chemoradiotherapy.37 Furthermore, MC is associated with a higher rate of microsatellite 
instability (MSI).38 Tumors exhibiting MSI generally have a better prognosis than microsatellite stable 
tumors.39 Conflicting results have been published regarding the predictive impact of MSI on response 
to radiotherapy.39, 40 Unfortunately, KRAS and MSI status was not known for the patients in our study 
and these analyses could not be performed. 
A complete response to chemoradiotherapy impedes the pathologist from determining the 
histological classification of a tumor. Since MC can be adequately recognized on MRI scanning, our 
radiologist reviewed MRIs of patients with a pathological complete response in the LARC group in the 
present study to address this problem.26, 27 A number of tumors showed at pathological evaluation 
extensive mucus pools without vital tumor cells (pathological complete response).41, 42 These tumors 
did not display the MC phenotype on preoperative MRI and thus were recognized as AC, emphasizing 
the role and importance of imaging in tumor characterization during preoperative work-up.
Based on findings from the present study we conclude that modern treatment of RC has benefited 
MC patients. Enhancements in the fields of imaging and quality of surgery most likely improved 
outcome. As a higher rate of CRM positive resections was demonstrated in the MC groups, there still 
should be a raised awareness for incomplete removal of the tumor. MRI may aid in early identification 
of rectal MC and recognition of this tumor characteristic may alter the therapeutic path.26, 27 
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To our knowledge, the present study is the largest study analyzing preoperative therapies for MC in 
RC patients. Data from different cohorts enabled us to study the impact of MC in different clinical 
settings. Although this study analyzed different treatment modalities in the largest group of rectal MC 
patients to date, it should be acknowledged that it is possible that observed trends were statistically 
insignificant as a consequence of lack of power. The TME trial and LARC cohort were not powered for 
the aim of this study, indicating once more the limitations of MC concerning accrual in clinical trials. 
Results from this study should be interpreted with caution since the non-randomized nature of this 
study could be a confounding factor. Patient from the LARC cohort underwent surgery after various 
waiting intervals, which may have influenced the degree of tumor regression. In that perspective, 
it seems interesting to study the effect of a longer time interval to surgery, since delaying surgery 
following chemoradiotherapy seems to result in the highest chance of a pathological (complete) 
response.43 
In conclusion, our results indicate that there is no longer a difference in survival between MC and 
AC patients and that preoperative therapies should be recommended for both histological subtypes. 
However, the risk of a positive CRM was higher in MC patients. Therefore, more appreciation for MC 
in multidisciplinary team meetings is necessary and optimal preoperative staging remains a crucial 
factor in the clinical work-up of MC patients.
Modern treatment of mucinous rectal cancer
105
5
References
1. Martling, A.L. et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. 
Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 356, 93-6 (2000).
2. Braendengen, M. et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy 
in nonresectable rectal cancer. J Clin Oncol 26, 3687-94 (2008).
3. McCarthy, K., Pearson, K., Fulton, R. & Hewitt, J. Pre-operative chemoradiation for non-metastatic locally advanced 
rectal cancer. Cochrane Database Syst Rev 12, CD008368 (2012).
4. Wong, R.K., Tandan, V., De Silva, S. & Figueredo, A. Pre-operative radiotherapy and curative surgery for the 
management of localized rectal carcinoma. Cochrane Database Syst Rev, CD002102 (2007).
5. Ceelen, W., Fierens, K., Van Nieuwenhove, Y. & Pattyn, P. Preoperative chemoradiation versus radiation alone for 
stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer 124, 2966-72 (2009).
6. Peeters, K.C. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit 
in irradiated patients with resectable rectal carcinoma. Ann Surg 246, 693-701 (2007).
7. van Gijn, W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 
12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12, 575-82 (2011).
8. Sebag-Montefiore, D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients 
with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373, 811-20 (2009).
9. Hyngstrom, J.R. et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: 
analysis from the National Cancer Data Base. Ann Surg Oncol 19, 2814-21 (2012).
10. Hugen, N. et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann 
Oncol 24, 2819-24 (2013).
11. Hugen, N. et al. The molecular background of mucinous carcinoma beyond MUC2. J Path: Clin Res 1, 3-17 (2014).
12. Green, J.B. et al. Mucinous carcinoma--just another colon cancer? Dis Colon Rectum 36, 49-54 (1993).
13. Xie, L., Villeneuve, P.J. & Shaw, A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous 
adenocarcinoma: a population-based study in Canada. Int J Oncol 34, 1109-15 (2009).
14. Chen, J.S. et al. Clinical significance of signet ring cell rectal carcinoma. Int J Colorectal Dis 19, 102-7 (2004).
15. Du, W. et al. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from 
an Asian country. Dis Colon Rectum 47, 78-85 (2004).
16. Secco, G.B. et al. Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. 
Oncology 51, 30-4 (1994).
17. Parmar, M.K., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published 
literature for survival endpoints. Stat Med 17, 2815-34 (1998).
18. Shin, U.S. et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg 
Oncol 18, 2232-9 (2011).
19. Sengul, N. et al. Effects of radiotherapy on different histopathological types of rectal carcinoma. Colorectal Dis 8, 
283-8 (2006).
20. Grillo-Ruggieri, F. et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative 
chemoradiotherapy. Dis Colon Rectum 50, 1594-603 (2007).
21. Oberholzer, K. et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to 
neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 82, 842-8 (2012).
22. Yu, S.K., Chand, M., Tait, D.M. & Brown, G. Magnetic resonance imaging defined mucinous rectal carcinoma is an 
independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. Eur J 
Cancer (2014).
23. Kapiteijn, E. et al. Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment 
of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. 
Dutch ColoRectal Cancer Group. Eur J Surg 165, 410-20 (1999).
106
Chapter 5
24. Nagtegaal, I.D. et al. Short-term preoperative radiotherapy interferes with the determination of pathological 
parameters in rectal cancer. J Pathol 197, 20-7 (2002).
25. Nagtegaal, I. et al. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene 
expression profile but not in clinical behaviour. J Pathol 204, 183-92 (2004).
26. Hussain, S.M., Outwater, E.K. & Siegelman, E.S. Mucinous versus nonmucinous rectal carcinomas: differentiation 
with MR imaging. Radiology 213, 79-85 (1999).
27. Kim, M.J. et al. Accuracy in differentiation of mucinous and nonmucinous rectal carcinoma on MR imaging. J 
Comput Assist Tomogr 27, 48-55 (2003).
28. Beyond, T.M.E.C. Consensus statement on the multidisciplinary management of patients with recurrent and 
primary rectal cancer beyond total mesorectal excision planes. Br J Surg 100, E1-33 (2013).
29. Elferink, M.A. et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following 
changes in therapy, 1989-2006. Eur J Cancer 46, 1421-9 (2010).
30. den Dulk, M. et al. Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery 
and pre-operative radiotherapy. Eur J Cancer 44, 1710-6 (2008).
31. Beets-Tan, R.G. et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in 
rectal cancer surgery. Lancet 357, 497-504 (2001).
32. Taylor, F.G. et al. Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin 
Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. J Clin Oncol 
(2013).
33. Burton, S. et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive 
circumferential margins? Br J Cancer 94, 351-7 (2006).
34. Brown, G. et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal 
ultrasound or magnetic resonance imaging? Br J Cancer 91, 23-9 (2004).
35. Oberholzer, K. et al. Rectal cancer: assessment of response to neoadjuvant chemoradiation by dynamic contrast-
enhanced MRI. J Magn Reson Imaging 38, 119-26 (2013).
36. Trakarnsanga, A. et al. What is the significance of the circumferential margin in locally advanced rectal cancer after 
neoadjuvant chemoradiotherapy? Ann Surg Oncol 20, 1179-84 (2013).
37. Garcia-Aguilar, J. et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation 
therapy in rectal cancer. Ann Surg 254, 486-92; discussion 492-3 (2011).
38. Mekenkamp, L.J. et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 
48, 501-9 (2012).
39. Colombino, M. et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. 
Ann Oncol 13, 1447-53 (2002).
40. Negri, F.V. et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or 
radiochemotherapy. Br J Cancer 98, 143-7 (2008).
41. Shia, J. et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation 
and their association with long-term outcome. Am J Surg Pathol 28, 215-23 (2004).
42. Rullier, A. et al. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal 
carcinoma. Am J Surg Pathol 29, 602-6 (2005).
43. Sloothaak, D.A. et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. 
Br J Surg 100, 933-9 (2013).
Modern treatment of mucinous rectal cancer
107
5
Supplemental material
Supplementary Data S1.  Search strategy for meta-analysis.
To illustrate the prognostic impact of MC, a literature search was done in PubMed and EMBASE, 
last search performed on September 1, 2013, with a Boolean search term combination as shown 
below. Only cohort, case-control or cross-sectional studies in English or German, that used the WHO 
definition for MC, that compared survival between MC or AC in RC patients, included all stages of 
disease and contained data to calculate a hazard ratio (HR), were included in the meta-analysis 
(flow chart of study selection in Supplementary Figure S1). Reference lists of retrieved studies were 
searched for further relevant publications. The primary outcome was overall survival. HRs as reported 
in publications were used for analysis. If no HR was reported, it was calculated from the published 
data as described by Parmar et al. Heterogeneity was assessed by means of the I2 statistic.
The National Library of Medicine (MEDLINE/PubMed)
((((((“Colorectal Neoplasms”[Mesh])) OR (((cancer[tiab] OR carcinoma*[tiab] OR tumor[tiab] OR 
tumors[tiab] OR tumour*[tiab] OR neoplasm*[tiab] OR adenocarcinoma*[tiab])) AND (rectum[tiab] 
OR rectal[tiab] OR colorectal[tiab] OR colon[tiab] OR colonic[tiab])))) AND ((((“Adenocarcinoma, 
Mucinous”[Mesh])) OR (mucin*[tiab])) OR (colloid[tiab])))) AND (((((((((((“Survival”[Mesh])) OR 
(Survival[tiab])) OR (outcome[tiab]))) OR (death[tiab] OR deaths[tiab]))) OR (“Prognosis”[Mesh:noexp])) 
OR (Prognosis[tiab]))) OR (“Disease-Free Survival”[Mesh])) ((((((“Colorectal Neoplasms”[Mesh])) 
OR (((cancer[tiab] OR carcinoma*[tiab] OR tumor[tiab] OR tumors[tiab] OR tumour*[tiab] OR 
neoplasm*[tiab] OR adenocarcinoma*[tiab])) AND (rectum[tiab] OR rectal[tiab] OR colorectal[tiab] 
OR colon[tiab] OR colonic[tiab])))) AND ((((“Adenocarcinoma, Mucinous”[Mesh])) OR (mucin*[tiab])) 
OR (colloid[tiab])))) AND (((((((((((“Survival”[Mesh])) OR (Survival[tiab])) OR (outcome[tiab]))) OR 
(death[tiab] OR deaths[tiab]))) OR (“Prognosis”[Mesh:noexp])) OR (Prognosis[tiab]))) OR (“Disease-
Free Survival”[Mesh]))
The Intelligent Gateway to Biomedical & Pharmacological Information EMBASE
1.  ((cancer or carcinoma* or tumor or tumors or tumour* or neoplasm* or adenocarcinoma*) 
 and (rectum or rectal or colorectal)).ti,ab.
2.  rectum tumor/ or colorectal tumor/ or exp rectum cancer/
3.  colloid carcinoma/
4.  (mucin* or colloid).ti,ab.
5.  3 or 4
6.  exp disease course/
7.  (Survival or outcome or death or deaths or Prognosis).ti,ab.
8.  6 or 7
9.  colon tumor/ or exp colon cancer/
10.  1 or 2 or 9
11.  10 and 5
12.  8 and 11
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Supplementary Figure S1.  Flow chart of study selection for meta-analysis.
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Abstract
Clinical studies regarding colorectal cancer (CRC) have suggested differences in metastatic patterns 
between mucinous adenocarcinoma (MC), signet-ring cell carcinoma (SRCC) and the more common 
adenocarcinoma (AC). The current study systematically evaluates metastatic patterns of different 
histological subtypes in CRC patients and analyses metastatic disease upon primary tumor localization. 
A nationwide retrospective review of pathological records of 5817 patients diagnosed with CRC 
who underwent an autopsy between 1991 and 2010 was performed. Patients were selected from 
the Dutch pathology registry (PALGA). To substantiate clinical relevance, metastatic patterns were 
compared with the prospective randomized multicenter Total Mesorectal Excision (TME) trial, which 
investigated efficacy of preoperative radiotherapy in rectal cancer patients.
In the autopsy study, 1675 patients had metastatic disease. MC and SRCC patients more frequently had 
metastatic disease (33.9% and 61.2% versus 27.6%, p < 0.0001) and had metastases at multiple sites 
more often compared with AC patients (58.6% and 70.7% versus 49.9%, p = 0.001). AC predominantly 
metastasized to the liver and MC and SRCC more frequently had peritoneal metastases. Metastatic 
patterns were also related to the primary tumor site, with a high rate of abdominal metastases in 
colon cancer patients, whereas rectal cancer patients more often had metastases at extra-abdominal 
sites. Results from the TME trial confirmed findings in rectal cancer patients from the autopsy study.
There are profound differences in metastatic patterns between histological subtypes and the 
localization of the primary tumor in CRC. Findings from this study encourage to take these factors 
into account for follow-up strategies and future studies. 
Metastatic patterns in colorectal cancer 
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Introduction
Despite the intensive follow-up for colorectal cancer (CRC) patients, metastatic disease still accounts 
for a high number of cancer-related deaths. At the time of presentation approximately 20% of 
patients has metastatic disease and 30-40% of patients treated for potentially curable CRC relapses.1 
Large-scale autopsy studies have generated insight into metastatic patterns and demonstrated 
that different primary cancers metastasize to different sites with different frequencies.2 CRCs most 
commonly metastasize to the liver, lung and peritoneum, but various other metastatic sites such as 
bone, spleen, brain and distant lymph nodes have been described.2-4 Rare metastatic sites, such as 
pancreas and heart, are not well studied and generally only described in case reports.
Several clinical studies regarding CRC suggested that there are differences in metastatic patterns 
between histological subtypes. Mucinous adenocarcinoma (MC) represents 10-15% of CRC and is 
considered a distinct clinical entity, with a predominant right-sided location and a poor prognosis 
in metastatic disease.5-7 In follow-up of clinical trials, it was observed that MCs have a different 
distribution of metastatic disease, compared with the more common adenocarcinoma (AC).5 Signet-
ring cell carcinoma (SRCC) is a relatively rare histological subtype of adenocarcinoma, present in 1% 
of CRC patients and is associated with a poor overall survival.6, 8, 9 Population- and institution-based 
studies found extensive lymphatic and peritoneal spread in SRCC suggesting a different biology.8 
Post-mortem studies offer a possibility to register both the extent and location of metastatic disease 
in different subtypes. Findings during autopsy may be considered the ultimate endpoint of disease. 
Most autopsy studies, however, have focused on metastatic patterns in one or more types of cancer, 
but have failed to address differentiating aspects such as histology within specific tumor subtypes. 
This nationwide study evaluates the patterns of metastases in a large number of autopsies from 
patients with a history of CRC to generate insight into the relevance of histological subtype in the 
metastatic spread of CRC. To confirm the clinical relevance of our results, we also analyzed data from 
a prospective randomized multicenter trial.10
Patients and methods
A nationwide retrospective review of pathological and autopsy records of 5930 patients diagnosed 
with CRC and eventually autopsied between 1991 and 2010 was performed. Patients were selected 
from the Dutch pathology registry (PALGA).11 In the Netherlands post-mortem examination is 
performed at the request of the family or treating doctor and is carried out by a pathologist. All 
autopsies included in this study were performed in order to obtain information on the medical status 
of the deceased or to determine the exact cause of death. No forensic autopsies were included. 
Undifferentiated tumors and tumors that were classified as carcinoids, neuro-endocrine tumors or 
other than adenocarcinoma (n = 87) were excluded. Furthermore, patients were excluded from the 
study if the location of the metastases could not be retrieved from the records (n = 27). Patient 
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demographics (gender and age) were available for all cases, but information on cause of death or 
other clinical information was lacking in this database.
A total of 1679 patients with metastatic colorectal disease was identified. Tumor histology had been 
assessed by different pathologist in all cases. For this study, only MC, AC and SRCC were included. 
Local staging according to the TNM classification (5th edition of the American Joint Committee on 
Cancer) was reconstructed from the tumor extension described in the pathology or autopsy record. 
Metastases that were found within six months after surgery were considered synchronous. Tumors 
were classified as proximal if they were found in the cecum, ascending colon or transverse colon, and 
were classified as distal if they were found in the descending or sigmoid colon.
To confirm the clinical relevance of data from the autopsy study, we selected patients from the Total 
Mesorectal Excision (TME) trial. The design of the TME trial was reported previously.10 This randomized 
multicenter study in the Netherlands included 1530 patients with primary resectable rectal cancer. 
Even though metastatic disease was an ineligibility criterion, there were 88 patients with synchronous 
metastases. Patients underwent clinical examination every three months during the first year after 
surgery and annually thereafter for at least two more years. Examination during follow-up included liver 
imaging and endoscopy. When metastatic disease was detected, only the metastatic lesions present at 
that moment were registered. Metastases that developed subsequently were not registered.
Statistical Analysis
The χ2-square test was used to compare demographics and tumor characteristics between the 
groups. All tests of significance were two-tailed: differences at P values of < 0.05 were considered 
to be significant. Statistical analyses were performed with the statistical software package SPSS 20.0 
(SPSS, Inc. Chicago, IL, USA).
Results
A total of 5817 autopsies was included in this study. AC was found in 4941 (84.9%) cases, compared 
with 809 MC (13.9%) and 67 SRCC (1.2%). The median age of all patients at death was 76 years (range 
25-102). Metastatic disease was present in 1679 (28.9%) patients and was found in 27.6%, 33.9% 
and 61.2% of patients with AC, MC and SRCC, respectively (p < 0.0001). Clinicopathological data of 
metastatic CRC patients are presented in Table 1. The median time between surgery and autopsy was 
28 months (range 7-246) in stage I, II and III patients and 1 month (range 0-222) in stage IV patients. 
Patients who developed metastatic disease were diagnosed with an initial stage I tumor in 3.2% and 
1.1% of AC and MC cases. None of the SRCC patients had stage I disease. In more than half of all 
patients, metastatic disease was synchronous with the primary tumor.
Distribution of metastases according to histology
MC and SRCC patients more frequently had metastases at multiple sites (58.6% and 70.7%, versus 
49.9% in AC, p = 0.002). Liver metastases were most frequent in both AC and MC patients (73.0% 
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and 52.2%). In SRCC patients, more than half of all patients developed metastases on the peritoneal 
surface. Uncommon sites of metastatic diseases were brain, kidney, adrenal gland, ovary, heart, 
omentum, bone, pleura, pancreas and spleen. 
There were major differences in metastatic patterns between histological subtypes (Figure 1 and 
Supplementary Table S1). AC more frequently metastasized to the liver compared with MC and SRCC, 
73.0% versus 52.2% and 31.7% (p < 0.0001). MC and SRCC metastases were more frequently found 
on the peritoneal surface, 48.2% and 51.2% respectively, compared with 20.1% in AC (p < 0.0001). 
Lung metastases were found in one-third of all cases, which was not different between the groups. 
SRCC markedly metastasized to distant lymph nodes more frequently, 43.9% compared with 22.3% 
and 19.9% in MC and AC, respectively (p = 0.001). These metastases were usually found adjacent to 
an organ with metastatic disease. Rare metastatic locations, such as heart, bone and pancreas, were 
Table 1.  Clinicopathological features of patients with metastatic colorectal cancer diagnosed between 1991 and 2010.
Features AC MC SRCC P value
n = 1364 % n = 274 % n = 41 %
Sex 0.158
Female 539 39.5 124 45.3 19 46.3
Male 825 60.5 150 54.7 22 53.7
Age at diagnosis 0.376
Median (range) 71 (25-95) 72 (36-91) 73 (32-54)
< 45 27 2.0 7 2.6 2 4.9
45-59 271 19.9 43 15.7 7 17.1
60-74 627 46.0 135 49.3 15 36.6
≥ 75 439 32.2 89 32.5 17 41.5
Location of primary 0.001
Proximal colon 420 30.8 116 42.3 20 48.8
Distal colon 443 32.5 71 25.9 8 19.5
Rectum 373 27.3 61 22.3 7 17.1
Colon, unknown 128 9.4 26 9.5 6 14.6
Initial Stage 0.208
I 43 3.2 3 1.1 0 0
II 192 14.1 27 9.9 3 7.3
III 272 19.9 59 21.5 10 24.4
IV 769 56.4 168 61.3 26 63.4
Unknown 88 6.5 17 6.2 2 4.9
Number of metastases 0.002
1 682 50.1 113 41.4 12 29.3
> 1 680 49.9 160 58.6 29 70.7
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found up to three times more frequently in SRCC than in MC or AC. Metastases to the ovary and 
skin or subcutaneous tissue were more common in SRCC and MC. Two autopsies on female patients 
reported a metastasis to the breast, both patients were diagnosed with SRCC.
Distribution of metastases according to primary tumor site
Supplementary Table S2 and Figure 2 show metastatic patterns in relation to the primary tumor site. 
The frequency of liver metastases did not differ between colon and rectal cancer patients (69.6% 
versus 67.4%). Colon cancer patients presented more frequently with intra-abdominal metastases, 
such as peritoneal metastases (28.8% versus 16.1%, p < 0.0001), omental metastases (9.1% versus 
2.9%, p < 0.0001) and ovarian metastases (3.2% versus 1.1%, p = 0.019). Rectal cancer patients, 
however, presented more frequently with extra-abdominal metastatic sites such as lung (42.0% 
versus 30.7%, p < 0.0001) and brain (5.0% versus 2.6%, p = 0.014). These findings were observed for 
both AC and MC patients, even though not all sites reached statistical significance. In SRCC patients, 
however, no differences in patterns between colon and rectum could be identified (data not shown). 
Combination of metastases
Many patients developed metastatic disease at more than one site. Figure 3 summarizes the most 
frequent combinations. AC patients had the highest percentage of liver metastases, and suffered 
frequently from liver metastases as the only metastatic site. The occurrence of metastases exclusively 
to the liver was less common in MC and SRCC patients. Especially in SRCC patients, liver metastases 
Figure 1.  Distribution of metastases according to histology.
AC, adenocarcinoma; MC, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma; LN, lymph node
**, p ≤ 0.01;   ***, p ≤ 0.001,;  ****, p ≤ 0.0001.
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Figure 2.  Distribution of metastases according to tumor site.
LN, lymph node;   *, p ≤ 0.05;   ****; p ≤ 0.0001.
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Figure 3.  Relative frequencies of combinations with (A) liver metastases (p < 0.0001), (B) lung metastases (p = 0.75) and 
(C) peritoneal metastases (p < 0.0001) in adenocarcinoma (AC), mucinous adenocarcinoma (MC) and signet-ring cell 
carcinoma (SRCC).
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were almost always observed in combination with other metastases. There were no differences in 
the frequencies of lung metastases, nor in the combinations of lung metastases with metastatic 
disease at other sites. Even though MC and SRCC patients suffered from peritoneal metastases more 
frequently, the proportion of peritoneal metastases only versus combinations with other metastases 
was equally distributed within all three groups.
Clinical relevance: TME trial
There were 403 (31.1%) AC patients and 50 (32.7%) MC patients in the TME trial who developed 
metastatic disease (p = 0.398) during follow-up (median follow-up 11.6 years). There was only one 
SRCC patient in the study, who developed metastases in distant lymph nodes (both axillar and cervical) 
and on the peritoneal surface during follow-up. There were no differences in metastatic patterns 
between patients who were treated with or without preoperative radiotherapy (data not shown). In 
Supplementary Table S3 and Figure 4 the distribution of metastases in rectal cancer patients from 
the TME trial and autopsy study is summarized. In the TME trial, liver metastases occurred more 
frequently in AC patients (59.6% versus 36.0%, p = 0.002), whereas peritoneal metastases were more 
common in MC patients (14.0% versus 4.5%, p = 0.005). This was comparable with the findings from 
the autopsy study. Frequencies of metastases at other sites were not significantly different in the 
TME trial.
Figure 4.  Distribution of metastases in rectal cancer patients from the TME trial and autopsy study.
AC, adenocarcinoma; MC, mucinous adenocarcinoma; LN, lymph node; *, p ≤ 0.05; **, p ≤ 0.01; ****, p ≤ 0.0001.
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Discussion
This study is the first large-scale modern autopsy study for metastatic patterns in well-known subtypes 
of CRC. We show major differences in frequencies and combinations of metastatic sites between 
histological subtypes. These differences may have significant implications for clinical treatment, 
follow-up strategies and future clinical trials.
Compared with AC, the presence of metastatic disease in more than one location was more 
frequent in MC. Since curative surgery is an option mainly limited to liver metastases, this may be an 
explanation for the poor performance of MC patients in trials for metastatic disease.5, 12 In MC patients 
we found a high rate of peritoneal metastases. Several clinical studies already suggested differences 
in metastatic patterns between histological subtypes.5, 12, 13 These studies also described a high 
number of peritoneal metastases in MC, with percentages varying from 22% to 45%. 12, 13 Peritoneal 
metastases are associated with a poor prognosis and survival is even worse if metastases in other 
organs are present.14 Moreover, palliative chemotherapy in patients with peritoneal metastases is 
not very successful.15 The high number of peritoneal metastases in MC is therefore another possible 
explanation for the poor survival in MC patients in advanced disease. 
SRCC patients also presented more frequently with more than one metastatic site and an increased 
risk of peritoneal metastases. Interestingly, we found a high rate of distant lymph node metastases in 
SRCC. This enhanced lymphatic spread of SRCC has been noticed previously in small clinical studies.8 
SRCC patients showed a divergent pattern of metastases, with involvement of rare metastatic sites, 
such as heart, bone, pancreas and skin. Therefore, attention should be paid to uncommon findings on 
imaging in SRCC patients during clinical follow-up, since these may reflect metastatic disease.
Underlying mechanisms for differences in metastatic patterns between histological subtypes are 
not clear. Several studies have described molecular and biological differences between AC, MC and 
SRCC, contributing to a more aggressive biological behavior.16 A theory behind the high number of 
peritoneal metastases in MC is that production of mucus under pressure allows cancers to gain access 
to the peritoneal cavity, through separation of tissue planes in the bowel wall and mucus producing 
tumors may spread throughout the peritoneal cavity more easily in the form of gelatinous ascites.17, 
18 Moreover, fluid produced by MC tumors enhances uptake into regional lymph nodes, facilitating 
lymphatic spread throughout the body.17 
In this study, we also analyzed the differences in metastatic patterns between colon and rectal cancer. 
We show that both colon and rectal cancer predominantly metastasize to the liver. Moreover, colon 
cancer patients presented with abdominal metastases more often, whereas rectal cancer patients 
presented more frequently with extra-abdominal metastatic sites such as lung and brain. This was 
seen in both MC and AC patients, but not in SRCC patients. In the trial population, we confirmed the 
differences between rectal MC and AC regarding liver and peritoneal metastases, thus emphasizing 
the clinical relevance of our study data. The higher rate of metastatic lesions that was found in the 
autopsy study can be explained by the obvious reasons that only the first metastatic lesions were 
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registered in the TME trial and autopsy yields better detection of metastases. Studies that analyzed 
patterns of tumor recurrence and metastatic disease also found an increased risk of lung metastases 
in rectal cancer and found prognosis of lung metastases to be poor.19-21 The higher rate of distant 
metastases in rectal cancer can be explained by the venous drainage of the rectum bypassing the 
liver straight into the inferior vena cava. 
Knowledge of differences in metastatic patterns is important and may induce changes in clinical 
practice. A high rate of peritoneal carcinomatosis was found in MC and it has been advocated that all 
MC patients should undergo resection accompanied by perioperative intraperitoneal chemotherapy 
to improve survival.17 The high number of peritoneal metastases in MC and SRCC should raise concern 
in case of tumor spillage and should possibly even result in adjuvant therapeutic measures. Insight 
into metastatic patterns may also impact the design of follow-up. Since liver and lung metastases are 
most-common, regular imaging of chest and liver should be maintained. However, in case of unusual 
or indefinable lesions, other imaging techniques such as PET-CT should be employed at an earlier 
stage, especially in MC and SRCC patients. Early detection of peritoneal metastases should be priority 
in these patient groups.   
To our best knowledge this is the largest autopsy study focusing solely on metastatic disease from CRC. 
Furthermore, it is the first study that shows differences in metastatic pathways between histological 
subtypes in a large nationwide population. However, there are limitations due to the retrospective 
nature of this study. First of all, it is important to notice that an autopsy study unequivocally leads 
to a biased population, in which patients are included who have died postoperatively, had an 
unexpected clinical course, or died of other causes than CRC. Nevertheless, autopsy studies offer 
a unique opportunity to study the distribution of metastases and arguably can be seen as the 
gold standard in the study of cancer metastases. Secondly, it has not been possible to review the 
individual pathological diagnosis. Even though definitions of MC and SRCC have been standardized, 
variations in interpretation may have resulted in misclassification. However, the distribution of 
histological subtypes is similar to numbers reported in the literature.6, 7 We also confirmed the clinical 
relevance of our findings with follow-up data of a phase III clinical trial. Even though the TME trial is 
a prospective trial, the numbers of metastatic lesions were lower, due to a more limited examination 
and registration compared with the autopsy study. This substantiates the importance of findings from 
autopsy studies. However, it may still be possible that there is an underestimation of the number of 
metastatic lesions in this autopsy study. Although we included only whole-body autopsies, metastatic 
lesions situated outside of the routinely examined regions may have been missed. Moreover, brain 
autopsy was not allowed for each patient. These limitations may have led to an underestimation of 
especially brain and bone metastases, but this bias potentially applies to all subgroups. 
This study shows that histological subtype and primary tumor localization are important predictors 
of metastatic spread. MC and SRCC metastasize to different sites, in different combinations and are 
more likely to have a higher number of metastases. Furthermore, we show that colon and rectal 
cancers have different metastatic patterns as well. Based on profound differences in metastatic 
patterns between histological subtypes and localization of the primary tumor, we encourage to take 
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these factors into account during preoperative examination for metastases and during follow-up. Our 
results also indicate that these factors should be considered a stratification factor in future research 
initiatives focusing on advanced disease. 
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Supplemental material
Supplementary Table S1.  Distribution of metastases according to histology. 
Metastatic site AC MC SRCC P value
n = 1364 % n = 274 % n = 41 %
Liver 996 73.0 143 52.2 13 31.7 < 0.0001
Lung 460 33.7 92 33.6 13 31.7 0.964
Peritoneum 275 20.2 132 48.2 21 51.2 < 0.0001
Distant lymph nodes 273 20.0 61 22.3 18 43.9 0.001
Bone 76 5.6 20 7.3 7 17.1 0.007
Other sites 402 29.5 110 40.1 21 51.2 < 0.0001
Brain 45 3.3 9 3.3 0 0 0.496
Kidney 39 2.9 9 3.3 1 2.4 0.916
Adrenal gland 94 6.9 21 7.7 4 9.8 0.718
Ovary 28 2.1 14 5.1 3 7.3 0.003
Heart 18 1.3 12 4.4 3 7.3 < 0.0001
Omentum 84 6.2 38 13.9 4 9.8 < 0.0001
Pleura 60 4.4 21 7.7 4 9.8 0.030
Pancreas 22 1.6 8 2.9 3 7.3 0.016
Spleen 28 2.1 5 1.8 3 7.3 0.067
Skin/subcutaneous tissue 49 3.6 19 6.9 4 9.8 0.010
Mesentery 28 2.1 8 2.9 4 9.8 0.005
Other 82 6.0 25 9.1 7 17.1 0.005
AC, adenocarcinoma; MC, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma
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Supplementary Table S2.  Distribution of metastases according to tumor location.
Metastatic site Colon Rectum P value
n = 1238 % n = 441 %
Liver 856 69.1 296 67.1 0.432
Lung 380 30.7 185 42.0 < 0.0001
Peritoneum 357 28.8 71 16.1 < 0.0001
Distant lymph nodes 248 20.0 104 23.6 0.116
Bone 73 5.9 30 6.8 0.496
Other sites 414 33.4 119 27.0 0.012
Brain 32 2.6 22 5.0 0.014
Kidney 34 2.7 15 3.4 0.483
Adrenal gland 81 6.5 38 8.6 0.145
Ovary 40 3.2 5 1.1 0.019
Heart 26 2.1 7 1.6 0.505
Omentum 113 9.1 13 2.9 < 0.0001
Pleura 63 5.1 22 5.0 0.934
Pancreas 27 2.2 6 1.4 0.287
Spleen 29 2.3 7 1.6 0.347
Skin/subcutaneous tissue 60 4.8 12 2.7 0.059
Mesentery 38 3.1 2 0.5 0.002
Other 86 6.9 28 6.3 0.668
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Chapter 7 
REDUCED RATE OF COPY NUMBER ABERRATIONS IN MUCINOUS 
COLORECTAL CARCINOMA 
N. Hugen, F. Simmer, L.J.M. Mekenkamp, M. Koopman, E. van den Broek, J.H.W. de Wilt, C.J.A. Punt, 
B. Ylstra, G.A. Meijer and I.D. Nagtegaal
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Abstract
Mucinous carcinoma (MC) is found in 10-15% of colorectal cancer (CRC) patients. It differs from the 
common adenocarcinoma (AC) in histopathological appearance and clinical behavior.
Genome-wide DNA copy number and survival data from MC and AC primary CRC samples from 
patients from two phase III trials (CAIRO and CAIRO2) was compared. Chromosomal copy number 
data from The Cancer Genome Atlas (TCGA) was used for validation. Altogether, 470 ACs were 
compared to 57 MCs.
MC showed a reduced amount of copy number aberrations (CNAs) compared with AC for the CAIRO/
CAIRO2 cohort, with a median amount of CNAs that was 1.5-fold lower (p = 0.002). Data from TCGA 
also showed a reduced amount of CNAs for MC. MC samples in both cohorts displayed less gain at 
chromosome 20q and less loss of chromosome 18p. A high rate of chromosomal instability was a 
strong negative prognostic marker for survival in MC patients from the CAIRO cohorts (hazard ratio 
15.60, 95% CI 3.24-75.05).
Results from this study indicate that the distinct MC phenotype is accompanied by a different genetic 
basis when compared with AC and show a strong association between the rate of chromosomal 
instability and survival in MC patients. 
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Introduction
Colorectal cancer (CRC) is categorized by histological subtype according to the WHO classification. 
The majority of patients (~ 85%) is diagnosed with adenocarcinoma not otherwise specified 
(AC). Mucinous adenocarcinoma (MC) is detected in 10-15% of patients and is characterized 
by abundant extracellular mucus lakes that comprise more than half of the tumor volume.1 MC 
differs from AC in both clinical and pathological presentation.2, 3 MC is more frequently found 
in the proximal colon and at a higher stage at presentation than AC.2, 3 Also, the response to 
therapies varies between MC and AC, as patients with MC show a poorer response to palliative 
chemotherapy compared with AC, resulting in a worse survival.4-7 These findings suggest a 
distinct genetic background of MC.
There are two major pathways through which genomic instability can occur in CRC, namely 
chromosomal instability (CIN) and microsatellite instability (MSI). CIN is found in the majority 
(~ 85%) of CRCs and is a type of genetic instability in which chromosomal aberrations accumulate, 
leading to an altered expression of tumor suppressor genes and oncogenes.8 MSI accounts for 
the remaining 15% of CRCs and is caused by a defective DNA mismatch repair mechanism that 
leads to a clonal change in the number of microsatellites.9 Tumors with MSI are more commonly 
found in MC patients compared with AC patients, and exhibit less copy number aberrations 
(CNAs).5, 10
Although MSI is more common in MC than in AC, the vast majority of MCs supposedly still 
develops through the CIN pathway. Unfortunately, most large-scale genomic studies of CRC did 
not address differences between histological subtypes and focused mainly on AC. Specific DNA 
CNAs that cause gene dosage effects in oncogenes and tumor suppressor genes, typically occur 
during adenoma to carcinoma progression, and thus are an integral part of the pathogenesis 
of CRC.11 Therefore, analysis of DNA CNAs between MC and AC in a sufficiently large collection 
of samples may generate more insight into an early and possibly diverging event in cancer 
development.
In this study we use DNA copy number data from primary tumor samples of patients with MC or AC 
who participated in two phase III clinical trials. These data were used to test whether the distinct 
MC and AC phenotypes relate to differences in genomic profiles. Molecular characterization of MC 
may improve our understanding of the reduced response rate to systemic therapies and therefore 
contributes to the development of targeted treatment modalities for MC. 
Patients and methods
Patients and materials
For this study we used clinical and genome data of patients from two randomized controlled trials 
and validated our findings with data from The Cancer Genome Atlas (TCGA).
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CAIRO and CAIRO2 cohorts
We used high resolution array comparative genomic hybridization (aCGH) data that were generated 
from DNA isolated from formalin-fixed and paraffin-embedded (FFPE) primary tumors, which was 
hybridized against paired germ line DNA samples. The processes of sample selection, DNA isolation and 
aCGH data have been described previously.12 Samples were derived from patients who participated 
in the CAIRO study (CKTO 2002-07, ClinTrials.gov; NCT00312000)13 or CAIRO2 study (CKTO 2005-02, 
ClinTrials.gov; NCT00208546)14 of the Dutch Colorectal Cancer Group (DCCG). These phase III trials 
had different systemic regimens as first-line treatment for CRC patients with metastatic disease. In the 
CAIRO study, patients were randomly assigned to either sequential or combination treatment with 
capecitabine and irinotecan, followed by oxaliplatin. In the CAIRO2 study patients were randomized 
between treatment with capecitabine, oxaliplatin and bevacizumab, with or without the addition of 
cetuximab. All patients had given written informed consent prior to study entry, which also included 
translational research on tumor tissue. aCGH was performed on a subset of the patients from these 
trials.12 In the CAIRO2 study the aCGH was only performed on material from the control arm since 
the addition of cetuximab in the experimental arm yielded a worse outcome. Furthermore, only 
tumors with paired germ-line tissue, and with areas of high tumor cell percentage available (> 70%) 
had been included. A total of 349 high quality DNA copy number profiles were generated. Tumors 
were classified according to the guidelines of the World Health Organization. If more than 50% of the 
tumor consisted of extracellular mucus it was classified as MC.1 AC was defined as a tumor without 
extracellular mucus. Only tumors that were categorized as MC or AC were included in our analyses. 
Tumors with MSI usually exhibit limited CNAs, and therefore form a separate entity among CRCs. 
These patients (n = 31) were excluded from the present study. In the current study DNA copy number 
profiles of 17 MC and 135 AC patients from the CAIRO study and 12 MC and 100 AC patients from the 
CAIRO2 study were compared.
The Cancer Genome Atlas cohort
To validate findings from the CAIRO cohorts, copy number information for MC and AC samples from 
the TCGA data portal was analyzed. On 27 January 2014 all available colon adenocarcinoma level 3 
copy number data were downloaded from the TCGA Data Portal using the Data Matrix (https://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm). TCGA copy number data had been generated with 
Affymetrix SNP 6.0 arrays (Santa Clara, USA). Only data obtained from primary tumors was used. The 
histopathological designation as provided by TCGA was used, and only tumors that were categorized 
as MC or AC were selected. Furthermore, MSI tumors were excluded from the analyses. In total, DNA 
copy number profiles of 28 MC and 235 AC patients were compared. 
Clinicopathological data
For each patient, the following clinicopathological characteristics were available: age, gender, site of 
primary tumor, number of metastatic sites involved, invasion depth, lymph node status, MSI status 
and histological subtype. Tumors from the TCGA cohort were classified as proximal if they were found 
in the cecum, ascending colon or transverse colon, up to the splenic flexure, and were classified as 
distal if they were found in the descending colon or sigmoid colon. MSI status was determined by 
immunohistochemistry with antibodies against MLH1, MSH2, MSH6 and PMS2. MSI analysis was 
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performed on indication by PCR followed by GeneScan analysis for MSI markers (BAT25, BAT26, 
BAT40, D2S123, D5S346, D17S250).15, 16 Differences in baseline characteristics between groups were 
determined using Fisher’s exact testing. Statistical analyses were two-sided and P values< 0.05 were 
considered significant.
Processing of aCGH and SNP array data
Array CGH was performed using customized Agilent oligonucleotide arrays. Methods of DNA 
extraction, labeling, hybridization and scanning were previously described17 and the exact array 
design can be found online in the Gene Expression Omnibus (GEO) (GPL8687 http://www.
ncbi.nlm.nih.gov/geo). The probes were mapped to human reference sequence GRCh37/hg19 
(February 2009). The statistical programming language R was used for data processing. The 
quality of the aCGH DNA copy number profiles was assessed by calculating the median absolute 
deviation (MAD) from the log2ratios of signal intensities from tumor and paired germ line DNA. 
A MAD value of 0.4 and smaller was used as a quality criterion, which all DNA copy number 
profiles passed. A wave-smoothing algorithm was applied on the profiles and the profiles were 
median normalized and corrected for tumor cell percentage using the R package ‘CGHcall’.18 For 
segmentation the R package ‘DNAcopy’ was used.19 Next, mode normalization was performed. 
Subsequently, the DNA copy number (deletion, loss, neutral, gain, or amplification) was 
determined for each segment using the R package ‘CGHcall’.12 This data was used to generate 
genome-wide frequency plots and box plots with the number of aberrations. For further 
analyses the dimensions of the aCGH data set were reduced using the R package ‘CGHregions’ 
(averror = 0.01).20 This step reduced the calls into subregions. Each subregion consisted of a 
series of neighboring clones on the chromosome whose aCGH-signature was shared by all 
clones. With this step 2010 subregions were obtained with a median size of 0.5Mb (interdecile 
range = 110kb - 2Mb). 
The TCGA level 3 SNP6 data consisted of copy number values (log2ratios) generated with 
‘nocnv’ segmentation. For the genome wide frequency plots, information was extracted from 
the downloaded files with LINUX shell and BEDTools.21 By extracting the genomic positions of all 
segment ends, a file with unique genomic positions was made. This gave 52654 genomic positions 
distributed over all chromosomes. Next, for each TCGA sample the log2 ratio at these positions 
was collected. In R these copy number values were converted into calls. The threshold was set as 
previously described.22 Values lower than -0.23 were assigned copy number loss, and values higher 
than 0.2 were assigned gain, all other values were assigned neutral. These values correspond to 
30% of the tumor cells with that CNA. This data was used to generate the frequency plots using 
functions of the R package ‘CGHbase’.
Analysis of the level of chromosomal instability
For each sample we counted the number of probes called as loss, neutral or gain and subsequently 
calculated the percentage of probes with an aberrant call. The distribution of this level of chromosomal 
instability was plotted in box-plots. To assess whether the distribution of MC and AC samples was 
different, the Wilcoxon rank sum test was used (also known as Mann-Whitney test).
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Identification of regions with differential copy number
DNA copy number information of the 2010 subregions was analyzed in a supervised way. MCs 
from both CAIRO studies were compared with ACs from the same studies. Per sample group, 
the frequencies of losses, neutrals and gains were determined for each region. To calculate the 
statistical significance of DNA copy number differences between MC and AC the Wilcoxon rank sum 
test was used, and a correction for multiple testing was performed with the Benjamini-Hochberg 
Figure 1.  Comparison of the overall frequencies of DNA copy number aberrations (CNAs) between mucinous carcinoma 
(MC) and adenocarcinoma (AC). Genome-wide frequency plots of DNA CNAs detected in the CAIRO/CAIRO2 (A) and TCGA 
(B) cohorts. The x-axis displays clones on the array ordered by chromosomal map positions of the clones. The y-axis displays 
the percentage of tumors with gains (above zero) or losses (below zero). Boundaries of chromosomes are indicated by 
dotted lines.
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procedure. An adjusted P value < 0.01 was considered statistically significant. The TCGA data 
were used for validation of the differential subregions identified with the CAIRO/CAIRO2 samples. 
Frequency plots were generated for subregions that showed differences in copy number and a 
Wilcoxon rank sum test was performed on the calls to determine significant DNA copy number 
differences between MC and AC, followed by correction for multiple testing with the Benjamini-
Hochberg procedure.
Figure 2.  Levels of chromosomal instability. For each sample the percentage of probes with an aberrant call was 
calculated. The box plots show per cohort the distribution of the percentage of probes with an aberrant call for the 
adenocarcinoma (AC) and mucinous adenocarcinoma (MC) samples. In both cohorts a lower median chromosomal 
instability for MC is observed.
Survival analysis
To determine the impact of CIN on survival in MC and AC patients, groups were divided into CIN high 
and CIN low. The threshold was set at the median level of CIN of all samples of the CAIRO cohorts 
which was 29.66%. Patients who demonstrated a CIN rate below the median were considered CIN low 
and consequently, patients who demonstrated a CIN rate that was above the median were considered 
CIN high. Overall survival (OS) was defined as the interval between the date of randomization until 
the date of death of any cause or until last follow-up. Patients who were alive at the end of follow-up 
were censored in the survival analyses. OS curves were estimated using the Kaplan-Meier method 
and compared with the log-rank test. Multivariable analysis of OS was performed using the Cox 
proportional hazard model. Statistical analyses were performed with the statistical software package 
SPSS 20.0 (SPSS Inc, Chicago, Illinois, USA). 
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Results
Clinicopathological data of the CAIRO/CAIRO2 and TCGA cohort
The baseline characteristics on MC and AC patients from the CAIRO/CAIRO2 cohort are presented in 
Supplementary Table S1. MC patients were more commonly over 60 years of age than AC patients 
(86.3% versus 62.5%, p = 0.04). There were no other significant differences in clinicopathological 
characteristics between MC and AC patients. Data on survival between AC and MC in advanced-stage 
disease were published previously on these series.5 Clinicopathological data on colon cancer patients 
from the TCGA cohort is presented in Supplementary Table S2. In MC patients from the TCGA cohort, 
tumors were more commonly located in the proximal colon than in AC patients (78.6% versus 49.4%, 
p = 0.004). The distribution of tumors was not different in the CAIRO/CAIRO2 cohort. There were no 
further substantial differences in baseline characteristics.
Figure 3.  Distribution of differentiated regions. Genome plot depicting a linear view of the chromosomes and distribution 
of the regions with a significant differential DNA copy number frequency between mucinous adenocarcinoma (MC) and 
adenocarcinoma (AC) patients in the CAIRO/CAIRO2 cohort. The 234 regions are localized on 11 chromosomes.
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Different copy number profiles between MC and AC
The frequency of CNAs in MC and AC patients from the CAIRO/CAIRO2 and TCGA cohorts are depicted 
in Figure 1. These genome-wide profiles of CNAs of MC and AC patients appeared rather similar in both 
cohorts, but overall MCs displayed a lower level of chromosomal instability (Figure 2, left). In the MCs 
from the CAIRO/CAIRO2 cohort a median of 21% of the genome showed either deletions, losses, gains 
or amplifications, compared with 31% for the ACs (p = 0.002). For the TCGA cohort this was 19% for 
MC versus 29% for AC, respectively (p = 0.0002). In the CAIRO/CAIRO2 cohort there were particularly 
differences in the overall frequencies of the gains between AC and MC (Supplementary Figure S1). 
Next, analyses were performed to further identify chromosomal subregions with significant 
differential copy number. We identified 234 significantly differential subregions in the CAIRO/CAIRO2 
cohort (p = 0.01; Figure 3). These subregions were located on chromosomes 5, 6, 7, 8, 10, 11, 13, 16, 
17, 18 and 20. 
Validation in TCGA data
To confirm the findings from the CAIRO/CAIRO2 cohort, data from TCGA were analyzed. The TCGA 
data not only represents another patient cohort, but also a different method to determine DNA 
CNAs, since single channel SNP arrays were used, rather than CGH arrays. In addition, no paired 
normal DNA was used and DNA was isolated from fresh frozen material. MC samples displayed a 
reduced rate of CNAs than AC samples (Figure 2, right). Furthermore, MC samples in this cohort 
showed a significantly differential copy number for chromosome 18 and 20 (Figure 4), but not 
for the other chromosomes with significant differential subregions for the CAIRO/CAIRO2 cohort 
(chromosomes 5, 6, 7, 8, 10, 11, 13, 16 and 17). This included 13q gain, which showed a highly 
significant difference between AC and MC in the CAIRO/CAIRO2 cohort, while in the TCGA cohort this 
could not be confirmed (Supplementary Figure S2).
Different copy numbers at chromosome 18 and 20
MC patients displayed significantly less losses at chromosome 18 compared with AC patients in both 
cohorts. In the TCGA cohort, this comprised nearly the entire chromosome, but for the CAIRO/CAIRO2 
cohort, this was mainly restricted to regions of the p-arm (Figure 4). The significant loci on 18p for the 
CAIRO/CAIRO2 cohort were merged into one region of main interest of 14Mb, which involved almost 
the entire p-arm (18p11.32-18p11.21). For this region of interest, 34% of MC patients showed a loss 
in the CAIRO/CAIRO2 cohort, compared with 69% of AC patients. In the TCGA data these percentages 
were 14% and 64% respectively. At the q-arm of chromosome 20 both the CAIRO/CAIRO2 and TCGA 
cohorts showed less gains in MC patients compared with AC patients (Figure 4). This region of interest at 
chromosome 20 was 33Mb and comprised essentially the entire q-arm (20q11.21-20q13.33). A gain at 
this region was found in 52% MC patients in the CAIRO/CAIRO2 cohort, while AC patients showed 93% 
gain or amplification. The percentages of these gains were 46% and 84%, respectively for the TCGA data.
Survival is related to CIN status in MC patients
The relation between survival and either a high or low rate of CIN was explored. There were 112 AC 
and 20 MC patients in the CIN low group versus 123 AC and 9 MC patients in the CIN high group. 
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Figure 4.  Frequency plots of DNA copy number aberrations (CNAs) in chromosome 18 and chromosome 20. Detailed 
view of chromosomes with the differential regions of the CAIRO/CAIRO2 cohort that are validated in the TCGA data set. 
The y-axis displays the percentage of tumors with gain (above zero) or loss (below zero). The chromosomes represent 
ideograms with chromosomal bands. The corrected P values obtained with statistical significance testing and correction 
for multiple testing are depicted in boxes below the plots. Black represents adjusted p < 0.01 and indicated a significant 
difference in DNA copy number between adenocarcinoma (AC) and mucinous adenocarcinoma (MC); white represents 
adjusted p > 0.01 and no indication of a significant difference. The significant loci obtained from the CAIRO/CAIRO2 
cohort on 18p and 20q can be merged into two regions of main interest: chr18:122131-13971462 and chr20:29833609-
62880524. For the region of interest on p18 34% of MC patients showed a loss in the CAIRO/CAIRO2 cohort, compared 
with a loss in 69% in AC patients. For the region of interest on q20 52% of MC patients in the CAIRO/CAIRO2 cohort 
showed a gain, while AC patients showed 93% gain or amplification.
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OS rates in MC patients were dependent on the rate of CIN. MC CIN high patient had a statistically 
significant poorer OS compared with MC CIN low patients. MC CIN high patients had a median OS of 
6.6 months (95% CI 4.8-8.4) versus 19.4 months (95% CI 11.7-27.0) for MC CIN low patients (Figure 
5a). An OS difference according to CIN status was not observed in AC patients, with a median OS 
of 19.7 months (95% CI 17.8-21.7) for AC CIN high patients compared with 21.2 months (95% CI 
16.3-26.1) in AC CIN low patients (Figure 5b). Interestingly, MC CIN low patients had an OS that was 
comparable to that of AC patients. Also, in the multivariable Cox regression analysis a high rate of CIN 
was a strong negative prognostic marker for OS in MC patients from the CAIRO cohorts with a hazard 
ratio of 15.60 (95% CI 3.24-75.05; Supplementary Table S3).
Discussion
MC is considered a unique subtype of CRC based on its histopathological appearance and clinical 
behavior. This study investigated whether the distinct visual microscopic pathological characteristics 
of MC are associated with different genetic aberrations when compared with AC in MSS primary 
tumors. 
In CRC, CIN and MSI are two well-defined genomic pathways that are involved in carcinogenesis. 
MSI is found in approximately 15% of CRCs, but is more commonly found in MCs than in ACs.5, 9, 
10, 23 Although MSI and CIN are not mutually exclusive, CNAs are far less common in MSI than MSS 
tumors.24, 25 In the present series of MSS CRCs an overall lower level of genetic instability was observed 
in MC compared with AC. As to specific DNA CNAs, the frequency of gain of chromosome 20q and 
the frequency of loss of chromosome 18p was significantly lower in MC. Chromosomal gains of 20q 
and losses of 18p are among the most-common molecular aberrations in CIN induced CRCs and since 
their occurrence is associated with progression from adenoma to carcinoma they are considered 
early genetic events.11, 26 It should therefore be noted that these regions are consequently most prone 
Figure 5.  Survival according to rate of chromosomal instability (CIN). Overall survival in (A) mucinous adenocarcinoma 
(MC) patients and (B) adenocarcinoma (AC) patients from the CAIRO/CAIRO2 cohort, distributed according to a high or 
a low rate of CIN.
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to reach statistical significance if there are overall differences in genetic instability as we observed for 
AC versus MC. Notwithstanding, these regions could be less contributory in MC development.
Amplification of 20q is an early molecular event and considered one of the key events that may 
induce the malignant process.11, 27, 28 Gain of a chromosomal region at 20q is present in over 60% 
of CRCs.25, 28, 29 There are several common regions of overlap of the highest level of gains at the 
20q arm, which makes it plausible that multiple genes are involved in CRC development. The exact 
mechanism through which this occurs has not yet been elucidated, but an increasing number of 
genes that would be responsible for this 20q amplicon-driven progression has been identified.27, 30, 31 
Gain of 20q has also been associated with a poor prognosis in CRC patients.32 Previously, we found 
that prognosis of MC patients in advanced-stage disease was worse compared with AC patients, due 
to a decreased response to palliative chemotherapy.5 Our group identified chromosomal regions 
that were associated with a decreased responsiveness to the addition of irinotecan in advanced 
colorectal cancer.12 However, these specific regions did not differ between MC and AC patients in 
the current study. The poor response to chemotherapy may be related to the deviant pattern along 
which metastatic disease spreads in MC patients. Compared with AC, MC is less likely to present 
with liver metastases only, whereas intra-abdominal metastases are observed in more than half of 
all cases with advanced disease.33 One study that analyzed CNAs between patients with different 
metastatic patterns showed that gain of the 20q chromosomal arm was associated with liver-specific 
metastases, suggesting a role in the process of liver metastasis in CRC.34 Patients who did not develop 
metastatic disease and patients with peritoneal metastases showed a gain of 20q less frequently.34, 
35 These findings fit very well with the aberrant metastatic pattern that has been observed in MC 
patients.
Losses of chromosome 18q and 18p are seen in two third of CRC patients.36 Especially loss of 18q is a 
well-known aberration that has been associated with adenoma to carcinoma progression. However, 
loss of 18p has also been found to be an early genetic change in primary CRC.26, 37 It is unknown what 
genes on 18p can be held accountable for the malignant progression. Gain of chromosome 13q is 
found in approximately half of CRCs.29, 36, 38 and is associated with adenoma to carcinoma progression 
as well.37 Interestingly, in the present study we found less gain for virtually the entire 13q-arm in the 
CAIRO/CAIRO2 cohort, but this could not be confirmed with data from the TCGA cohort. 
We found that a high level of CIN was associated with a poor outcome in MC patients, but not in AC 
patients. Previously, CIN has been associated with a poor prognosis, mostly in stage II and III CRC.39 
Apparently, this also accounts for MC stage IV patients. It has been suggested that abnormalities of the 
spindle checkpoint drive CIN.40 Overexpression of AURKA (located on Chr 20q13, encoding the kinase 
Aurora-A) or loss of CHEK2 (located on Chr 22q12, encoding the DNA damage checkpoint kinase 
Chk2) increase microtubule assembly, promoting CIN.41 The mitotic checkpoint may thus provide a 
novel therapeutic target to improve overall survival and/or to modify response to chemotherapy.42 
It is increasingly acknowledged that CRC is a heterogeneous disease and there is ample evidence 
that tumors differ on a molecular level. Previously, two studies that used allelotyping PCR for a few 
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loci showed that lower allelic imbalance is associated with MC.43, 44 In the current study, based on 
data from two independent cohorts we conclude that the distinct phenotype of MC is accompanied 
by a different genome-wide genetic profile when compared with AC, marked by a reduced rate of 
DNA CNAs overall, as well as less frequent gain of 20q and less frequent loss of 18p. Therefore, it 
may be possible that CIN plays a less prominent role in MC development. The differences in CNAs 
were found in a metastatic cohort (CAIRO/CAIRO2 cohort) as well as in a cohort with more early 
stage tumors (TCGA cohort), supporting the view that there is a genetic distinction between MC 
and AC that transcends the stage of presentation. Evidently, the consequences of chromosomal 
aberrations on gene expression levels eventually determine the functional phenotype. This study 
did not provide an insight into the specific pathway along which MCs developed, but was able to 
demonstrate that MC differed from AC on a molecular level. Since the DNA copy number effect was 
seen for large chromosomal regions and throughout the genome, the effects are probably due to 
genomic imbalance and alterations at multiple genes rather than specific genes. Further studies that 
can assess molecular differences between MC and AC with a higher resolution (e.g. next-generation 
sequencing) are therefore needed. Previously, it has been reported that mutation rates in the 
therapeutically important RAS/RAF/MAPK and PI3K/AKT pathways are significantly higher in MC than 
in AC.5, 45-47 Moreover, MC is more frequently associated with MSI and the CpG island methylator 
(CIMP) phenotype.45, 46, 48 Although these features are not exclusive for MC patients, they do suggest 
that MC may develop through an alternative genetic instability pathway than CIN, which may explain 
the distinct tumor behavior and response to therapies. Due to low number it was not possible to 
compare differences in copy number changes between MSI MC and MSS MC patients in this study. It 
will be important to further investigate the molecular background of MC to increase knowledge on 
tumor behavior and to explore opportunities for targeting therapies. These data will enable clinicians 
to improve prediction of the course of disease and response to systemic treatment. 
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Supplemental material
Supplementary Table S1.  Clinicopathological characteristics of metastatic colorectal cancer patients who were included 
in the CAIRO/CAIRO2 cohort.
Features AC MC P value
n = 235 % n = 29 %
Sex 0.4
  Female 93 39.6 9 69.0
  Male 142 60.4 20 31.0
Age at diagnosis 0.04
  Median (range) 64 (36-81) 67 (50-79)
  < 45 9 3.8 0 0
  45-59 79 33.6 4 13.8
  60-74 126 53.6 19 65.5
  ≥ 75 21 8.9 6 20.7
Location of primary 0.3
  Colon 120 51.1 15 51.7
  Rectum 71 30.2 6 20.7
  Rectosigmoid 33 14.0 8 27.6
  Multiple locations 1 0.4 0 0
  Unknown 10 4.3 0 0
Invasion depth 0.9
  T1-2 18 7.7 1 3.4
  T3 170 72.3 23 79.3
  T4 42 17.9 5 17.2
  Unknown 5 2.1 0 0
Lymph node status 0.6
  N0 65 27.7 9 31.0
  N1 74 31.5 12 41.4
  N2 82 34.9 7 24.1
  Unknown 14 6.0 1 3.4
Number of metastases 0.4
  1 123 52.3 12 41.4
  > 1 111 47.2 17 58.6
  Unknown 1 0.4 0 0
Fisher’s exact test was applied.
AC, adenocarcinoma; MC, mucinous adenocarcinoma
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Supplementary Table S2.  Clinicopathological characteristics of patients from the TCGA cohort.
Features AC MC P value
n = 235 % n = 28 %
Sex 0.4
  Female 96 40.9 14 50.0
  Male 139 59.1 14 50.0
Age at diagnosis 0.8
  Median (range) 68 (31-90) 68 (45-90)
  < 45 10 4.3 0 0.0
  45-59 53 22.6 7 25.0
  60-74 107 45.5 12 42.9
  ≥ 75 65 27.7 9 32.1
Location of primary 0.004
  Proximal colon 116 49.4 22 78.6
  Distal colon 119 50.6 6 21.4
Invasion depth 0.6
  T in situ 1 0.4 0 0.0
  T1 7 3.0 0 0.0
  T2 43 18.3 3 10.7
  T3 162 68.9 21 75.0
  T4 22 9.4 4 14.3
Lymph node status 0.4
  N0 131 55.7 13 46.4
  N1 58 24.7 6 21.4
  N2 45 19.1 9 32.1
  Unknown 1 0.4 0 0.0
Distant metastasis 1.0
  M0 176 74.9 21 75.0
  M1 36 15.3 4 14.3
  Unknown 23 9.8 3 10.7
Fisher’s exact test was applied.
AC, adenocarcinoma; MC mucinous adenocarcinoma; Proximal colon, ascending colon from 
cecum up to the splenic flexure; Distal colon, descending colon, sigmoid and rectosigmoid 
junction
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Supplementary Table S3.  Multivariate analysis with 95% confidence interval (CI) on overall survival in mucinous 
adenocarcinoma patients from the CAIRO/CAIRO2 cohort.
Features Hazard ratio 95% CI
Sex
  Male 1
  Female 0.67 0.18-2.51
Age group
  45-59 1
  60-74 0.26 0.05-1.47
  ≥ 75 0.47 0.06-3.52
Tumor location
  Colon 1
  Rectum 1.46 0.29-7.44
  Rectosigmoid 0.99 0.18-5.25
Invasion depth
  T1-2 6.04 0.33-109.54
  T3 1
  T4 2.47 0.50-12.18
Lymph node status
  N0 1
  N1 1.31 0.32-5.29
  N2 1.31 0.30-5.68
  Unknown 1.95 0.10-38.04
Number of metastases
  1 1
  > 1 2.14 0.56-8.13
CAIRO study
  CAIRO 1
  CAIRO2 0.79 0.27-2.28
CIN status
  CIN low 1
  CIN high 15.60 3.24-75.05
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Supplementary Figure S1.  Levels of chromosomal instability. The box plots show the number of calls per cohort that 
have been categorized as loss or deletion, neutral, or gain or amplification for the adenocarcinoma (AC) and mucinous 
adenocarcinoma (MC) samples. In the CAIRO/CAIRO2 cohort there were particularly differences in the overall frequencies 
of gains between AC and MC. In the TCGA cohort the overall frequencies of both gains and losses were lower in MC 
compared with AC. 
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Supplementary Figure S2.  Frequency plots of DNA copy number aberrations (CNAs) in chromosome 13 determined 
in mucinous adenocarcinoma (MC) and adenocarcinoma (AC) patients from the CAIRO/CAIRO2 and TCGA cohorts. 
Probes on the array are ordered along the x-axis by their genomic position and the y-axis represents the frequency as 
the percentage of tumors with the respective gains (above zero) or losses (below zero). The chromosomes represent 
ideograms with chromosomal bands. The corrected P values obtained with statistical significance testing and correction 
for multiple testing are depicted in boxes below the plots. Black represents adjusted p < 0.01 and indicated a significant 
difference in DNA copy number between AC and MC; white represents adjusted p > 0.01 and no indication of a significant 
difference.
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Abstract
The majority of colorectal cancers (CRCs) are classified as adenocarcinoma not otherwise specified 
(AC). Mucinous carcinoma (MC) is a distinct form of CRC and is found in 10-15% of patients with CRC. 
MC differs from AC in terms of both clinical and histopathological characteristics and has long been 
associated with an inferior response to treatment compared with AC. The debate concerning the 
prognostic implications of MC in patients with CRC is ongoing and MC is still considered an unfavorable 
and unfamiliar subtype of the disease. Nevertheless, in the past few years epidemiological and clinical 
studies have shed a new light on the treatment and management of patients with MC. Use of a 
multidisciplinary approach, including input from surgeons, pathologists, oncologists and radiologists 
is beginning to lead to more tailored approaches to patient management, on an individualized basis. 
In this review, the authors provide insight into advances that have been made in care the of patients 
with MC. The prognostic implications for patients with colon or rectal MC are described separately; 
moreover, the predictive implications of MC regarding responses to commonly used therapies for 
CRC, such as chemotherapy, radiotherapy and chemoradiotherapy, and the potential for, and severity 
of metastasis are also described. 
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Introduction
Colorectal cancer (CRC) is a major health burden: an estimated 1.2 million people develop CRC 
worldwide every year and it is the fourth most-frequent cause of cancer-related mortality.1, 2 CRCs are 
clinically divided into those of the colon and of the rectum, and these subgroups require distinctly 
different treatment regimens. CRCs can also be classified on the basis of findings from histological 
assessment of the tumor specimen. Adenocarcinoma not otherwise specified (AC) is the most-
common form of CRC (observed in ~ 85% of patients with CRC), whereas 10-15% of patients with 
CRCs have mucinous adenocarcinoma (MC), which is characterized by abundant mucus secretion 
comprising at least 50% of the tumor volume.3 MC is more commonly found in patients with colon 
cancer than in those with rectal cancer (15% versus 9% of patients, respectively).4 The prognostic 
and predictive implications of MC, as well as the clinical implications for treatment and follow-up of 
patients with this form of CRC are currently subject to debate. Researchers are currently attempting 
to identify prognostic and predictive factors that might improve the individualized management of 
patients with MC. The prospect of personalized medicine, which enables targeting of specific tumor 
phenotypes in patients with CRC on the basis of tumor histology, has attracted both substantial 
and increasing interest from the oncology community. Histological classification of the tumor 
subtype is part of routine histopathological assessment and results of these analyses are used by 
clinicians to guide decision-making regarding multimodality treatment of patients with CRC. The 
infrequent occurrence of MC relative to AC renders results from randomized controlled trials using 
unselected populations of patients with CRC inappropriate, and limits the availability of convincing 
evidence regarding the prognostic or predictive relevance of this subtype. Thus, factors involved in 
development of MC are not well understood and results from small studies have been generalized to 
the entire population of these patients. Developments in this area in the past 10 years, however, have 
shed a new light on the MC subtype of CRC. This review aims to provide insight into the advances that 
have been made in care of patients with MC. Important details include the prognostic and predictive 
implications of MC regarding responses to commonly used therapies for CRC, and how responses to 
treatment differ from those of patients with AC. Other important issues are also discussed, including 
the potential to tailor management strategies to best suit the needs of individual patients, the value 
of early recognition of the MC subtype using MRI and the implications of the aberrant metastatic 
pattern of MC observed in most patients. 
Pathology of mucinous adenocarcinoma
MC is distinguished as a subtype of CRC that is more frequently found in female patients and is 
predominantly, but not exclusively, located in the proximal colon.5-7 The aetiology of MC is not well 
understood. Observations from clinical studies have shown that MC is less common in patients in 
Asian countries, and higher rates of MC have been reported in Europe, North- America and Australia. 
These geographical variations in prevalence suggest that several factors, including lifestyle and 
dietary variations might have a role in the development of MC.8 Furthermore, MC is more commonly 
diagnosed in patients with inflammatory bowel disease (IBD), such as Crohn’s disease or ulcerative 
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colitis, and patients with a history of pelvic or abdominal radiotherapy are also more likely to be 
diagnosed with MC.8 The chronic inflammation observed in patients with both IBD and radiation 
enteritis is possibly responsible for the higher rates of MC observed in these patients, although exact 
mechanisms of development are unclear.8
Despite the limited understanding of MC development, MC is recognized to constitute a distinct 
pathological entity within the spectrum of CRCs. By definition, MC is a subtype of CRC in which more 
than 50% of the tumor consists of extracellular mucus. The designation of a tumor as mucinous is, 
therefore, arbitrary and is often dependent on the individual pathologist’s subjective assessment and 
level of experience. Histological tumor grading of patients with MC is also challenging. According to 
the WHO criteria,3 tumor grade should be assigned based on the extent of glandular formation. By 
convention MC is considered poorly differentiated (grade 3).3 Nevertheless, grade assignment is largely 
subjective, with no or few defined criteria, and this prognostic factor is considered inappropriate for 
classification of patients with MC.9 MC is thus considered to be a poorly differentiated tumor type, 
although no clinical or molecular arguements exist that might substantiate this dogma. The extent 
to which histopathological characteristics, such as growth pattern, tumor border aspect, location 
of mucus and tumor cell:mucus ratio, influence outcomes is currently unknown. Furthermore, the 
presence of a signet-ring cell component in patients with MC has been associated with poor outcome, 
but the exact clinical importance of this factor needs to be further investigated.10 Standardized 
histological assessment of a large series of patients with MCs might enable greater insight into the 
defining characteristics of MC. In addition, research on molecular variations might help to identify 
groups of patients that have more benign or malignant tumor behavior in terms of survival and/or 
response to therapies.
Compared with AC, MC is more commonly diagnosed at an advanced stage of disease.4, 6 A few possible 
explanations for this phenomenon exist. Firstly, MC has a tendency to be located in the proximal colon 
and MCs are of a less firm consistency than ACs, causing detectable symptoms to arise only when the 
disease reaches a more advanced stage.5, 6 In addition, MC has a different molecular signature to AC, 
which might cause faster disease progression.11 The exact molecular aberrations that are responsible 
for this pattern of disease progression, and the sequence of any alterations, are currently unknown. 
Various molecular aberrations have been described, although a common mucinous pathway has not 
yet been identified. For example, compared with AC, MCs more often have microsatellite instability 
(MSI), which is also observed in patients with Lynch syndrome, suggesting that MC might arise from 
an alternative oncogenic pathway.12 Whenever MCs are microsatellite stable, however, they are 
characterized by a markedly reduced rate of copy-number aberrations when compared with AC.13 
BRAF mutations are also commonly found in patients with MC and are associated with an infiltrative 
pattern of tumor growth.12, 14 The MUC2 gene, which encodes mucin-2 (MUC2), a protein that coats 
the epithelia of the intestines, airways and other mucous-membrane-containing organs is frequently 
overexpressed in patients with MC, although this molecular feature is not exclusive to this form 
of disease.15 By contrast, expression of MUC2 is generally decreased in patients with other forms 
of CRC.16 Overexpression of MUC2 might protect against antitumor immune effectors by forming 
a mucus layer, thus promoting tumor development.17 Interestingly, a study in which investigators 
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classified cellular phenotypes and compared responses to therapy among patients with different 
MC phenotypes showed that patients with high MUC2 expression had a better prognosis than those 
with other molecular subtypes.18 This finding suggests that mucus-producing tumors are not per se 
associated with a worse outcome. An increased rate of mutations is observed in the RAF/RAF/MAPK 
(BRAF and KRAS) and PI3K/AKT (PIK3CA) pathways in patients with MC.12 
Table 1.  Outcomes of mucinous adenocarcinoma (MC) versus adenocarcinoma (AC), according to primary tumor location.
Study Colon cancer Rectal cancer
Hazard ratio (95% CI) Hazard ratio (95% CI)
Hyngstrom et al. (2012)6 1.03 (1.00-1.06)* 1.22 (1.16-1.29)*
Hugen et al. (2013)5 0.98 (0.93-1.04)# 1.22 (1.11-1.34)#
* Indicates relative survival; # Indicates overall survival; CI, confidence interval
Prognosis of mucinous carcinoma
Early stage colonic mucinous carcinoma
In a study published in 2012, the authors reviewed the prognostic significance of MC, compared 
with AC in patients with CRC.19 A total of 34 publications reporting the outcomes of patients with MC 
and patients with AC were evaluated and survival was compared using a meta-analysis. An overall 
hazard ratio (HR) of 1.05 (95% confidence interval [CI] 1.02-1.08) in patients with MC versus those 
with AC was calculated after correction for tumor stage at presentation. The treatment approaches 
for patients with colon cancer versus those with rectal cancer differ substantially and patient survival 
is also related to the location and stage of the primary tumor, meaning that patients with CRC are 
by no means a homogeneous population. Thus, two independent population-based studies were 
conducted to analyze the effects of MC versus AC in patients with either colon or rectal cancer, using 
multivariable analyses to minimize the influence of confounding factors.5, 6 Findings of both studies 
demonstrated that the MC histological phenotype, compared with AC histology, was not a negative 
prognostic factor in patients with colon cancer (Table 1).5, 6 In fact, in another independent study in 
a cohort of patients with non-metastatic colon cancer, the investigators demonstrated better overall 
survival in patients with MC compared with those of patients with AC (HR 0.33, 95% CI 0.14-0.79) 
and fewer systemic recurrences.20 The results of this study, which were published in 2014, suggest 
that advances in patient care apparently resulted in improved outcomes for patients with colonic MC 
compared with those of patients with colonic AC.
Early stage rectal mucinous carcinoma
In contrast to colonic MC, rectal MC was associated with a poor prognosis, relative to rectal AC, in both 
aforementioned population-based studies (Table 1).5, 6 This difference in survival was most prominent 
in patients with stage III rectal cancer. However, the approaches to diagnosis and treatment of rectal 
cancer have both changed substantially over the past 30 years and the survival of patients with rectal 
cancer has, as a result of these changes, improved over time.21 Modern treatment of rectal cancer has 
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also benefited patients with rectal MC, resulting in equal overall survival outcomes of patients with 
MC and AC, which were reported in January 2015. This analysis of 5-year overall survival data from 
patients in the Netherlands Cancer Registry between 1989-2007 demonstrated that overall survival 
was initially worse for patients with MC, but was not significantly worse, statistically, than that of 
patients with AC from 1999 onwards.22 This improvement in outcomes coincides with the introduction 
of both total mesorectal excision (TME) and neo-adjuvant radiotherapy and chemoradiotherapy for 
the treatment of CRC in the Netherlands. Tumor size in patients with rectal cancer is a limiting factor 
for complete surgical removal. Patients with MC generally have tumors of a higher T-stage than those 
with ACs, and large rectal tumors are less likely to be removed radically. For patients with MCs this 
leads to a higher incidence of positive circumferential resection margins (CRM), which is considered 
a strong indicator of a negative prognosis (HR 1.7, 95% CI 1.3-2.3).23, 24 The introduction of adequate 
rectal cancer imaging and TME surgery has lowered the number of CRM positive resections and 
thereby improved the outcomes of patients with MC relative to those of patients with AC. Over the 
past 15 years, surgeons have become more experienced with TME surgery and because the quality 
of surgery is an important factor that influences the frequency of local recurrences, the improved 
prognosis of patients with MC is most likely a result of this development.25
Advanced disease
When MC is diagnosed in the metastatic setting, the prognosis of the patients is generally worse than that 
of patients diagnosed with metastatic AC. Several studies, including two randomized trials investigating 
patients with metastatic CRC (mCRC), have demonstrated that the MC disease subtype, versus other 
types of CRC, is a poor prognostic factor: median overall survival rates varied between 8.0-14.0 months 
for patients with metastatic MC, compared with 17.9-23.4 months for those with metastatic AC (Figure 
1).26-28 The controversies reported in the literature regarding the prognostic relevance of MC versus AC 
in patients with CRC are probably caused by the use of cohorts from different points in time, merging of 
data from patients with colon cancer and rectal cancer and inclusion of patients with advanced disease. 
Predictive relevance of mucinous carcinoma
Advanced-stage colonic MC
Findings from clinical studies of systemic treatment of metastatic forms of MC provide the best available 
evidence on the predictive relevance of this disease versus AC regarding benefit from therapies. 
Treatment with chemotherapy can, in some patients, add to disease morbidity and, in patients who have 
severe toxicity, can even result in premature death. Thus, adverse effects and outcomes of chemotherapy 
should be carefully weighed against any expected benefits. As mentioned previously, several study 
reports indicated a poor outcome in patients with MC who were treated with palliative systemic therapy 
for advanced-stage disease.26-28 This poor outcome was independent of BRAF mutational status, which 
is a strong negative prognostic indicator in patients with mCRC and is commonly found in patients with 
MC (Figure 1).26, 29 Moreover, the MC phenotype is an adverse prognostic factor in patients with CRC who 
underwent resection of liver metastases.30, 31 In these studies, patients with mucinous metastases had 
a poorer response to preoperative chemotherapy as well as inferior disease-free and overall survival. 
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Adjuvant treatment of colonic MC 
Adjuvant chemotherapy is recommended for patients with high-risk or node positive colon cancer. 
Histological subtype is generally not taken into consideration in the decision-making process 
concerning use of adjuvant chemotherapy. In two studies, investigators analyzed the effects of 
adjuvant chemotherapy in patients with stage III disease, using multivariable analysis to correct 
for confounding factors; no difference in overall survival was found in patients with MC compared 
with patients with AC in either study (Figure 1).5, 32 The extent of heterogeneity in treatment 
responses among patients with MC, however, suggests that patients with CRC should not be 
considered one entity. Firstly, MSI is common in patients with MC, and this tumor characteristic 
has been associated with a better prognosis than having a microsatellite stable (MSS) tumor, 
but has also been related to less benefit from 5-fluorouracil (5-FU) chemotherapy.33 Within the 
subgroup of patients with MC, one hypothesis is that the presence of MSI might determine 
whether a patient has a good or bad response to chemotherapy.34, 35 Secondly, patients with MC 
more frequently have high levels of DNA topoisomerase 1 (TOP1) expression than those with 
AC; high TOP1 expression is also correlated with a poor response to 5-FU treatment in patients 
with mCRC.36 A search for markers that predict treatment responsiveness should, therefore, be 
Figure 1.  Forrest plot depicting outcomes from studies of palliative and adjuvant chemotherapy for patients with 
mucinous adenocarcinoma (MC) versus those with adenocarcinoma (AC). Differences between categorical outcomes 
were calculated by the author based on primary data reported in the relevant manuscript using the hazard ratio and 
corresponding 95% confidence interval (CI). 
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performed and subgroup analyses could be used to distinguish between patients who might, or 
not benefit from 5-FU treatment.
These theories, however, do not explain the differences in responses to chemotherapy in the 
adjuvant and/or palliative setting. The mechanisms behind these differences in response to 
chemotherapy are unclear, but the pathway that leads to development of advanced-stage disease 
in patients with MC might account for differences in outcomes in the palliative setting.26-28, 37-40 
Patients with MC more frequently have metastases at more than one site, and the distribution 
and the combination of metastases is often different to that of patients with AC. Patients with 
AC predominantly have metastases in the liver, whereas those with MC more frequently have 
extrahepatic metastases, such as distant lymph nodes metastases or metastases on the peritoneal 
surface.27, 28, 38-42 The presence of extrahepatic metastases, especially within the peritoneum, is 
associated with a very poor prognosis.43, 44 Also, chances of successful delivery of chemotherapy 
might be altered in patients with CRC of the MC subtype. In these patients mucus, which surrounds 
the tumor cells, might function as a physical barrier to the delivery of chemotherapy. A difference 
in pharmacokinetics between the solid metastases observed in patients with advanced-stage 
disease, which are protected by a layer of extracellular mucus, and micrometastases without such 
a barrier, which are the key target of adjuvant therapy, might explain the differences in response. 
Furthermore, a poorly developed microvasculature owing to the large mucus volume surrounding 
the tumor might reduce delivery of chemotherapeutics in patients with larger solid metastases.45 
Also, compressing forces (solid stress) exerted by the bulky mucinous tumor on the penetrating 
vascular system might reduce the extent of drug delivery to the tumor (Figure 2).46 In conclusion, 
MCs are not per se resistant to chemotherapeutic treatment compared with AC, but responses 
of patients with MC might vary owing to variations in stage of disease and molecular tumor 
characteristics.
(Neo)adjuvant treatment of rectal MC
The use of adjuvant chemotherapy in patients with rectal cancer is highly controversial and is not 
universally recommended. In one study, investigators analyzed the effects of adjuvant chemotherapy 
in patients with MC of the rectum following TME surgery.47 Improved overall survival was detected 
in patients with MC who received adjuvant chemotherapy, compared with those who did not (5-
year overall survival 66.1% versus 32.5%, p < 0.0001). This finding was irrespective of preoperative 
therapies, but the results might have been biased by selective patient inclusion.
Preoperative treatment strategies used to treat patients with rectal cancer vary between nations. 
In Europe, results of the Dutch TME and MRC CR07 trials resulted in the recommendation of short-
term radiotherapy (5x5 Gy) for treatment of patients with early stage (T3) and/or node positive 
tumors to reduce the risk of local recurrence.48, 49 Downstaging of the tumor using long-course 
chemoradiotherapy (CRT) is recommended for patients with a T4 or T3 tumor with threatened CRM 
(locally advanced rectal tumors). In North-America, short-term radiotherapy is not commonly used, 
and preoperative therapy mainly consists of CRT for locally advanced rectal tumors (Figure 3). The poor 
prognosis of patients with rectal MC gave rise to the idea that responses to preoperative therapies 
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Figure 2.  Differences between mucinous carcinoma (MC) and adenocarcinoma (AC) not otherwise specified (NOS). MCs 
have tumor characteristics that might explain the resistance to systemic therapy, especially in the setting of advanced 
disease, including microsatellite instability, less favorable intrinsic tumor characteristics and the formation on multiple 
metastases when compared with AC. The effects of differences in tumor micro-environment (mucus layer, vasculature, 
architecture) are currently hypothetical.
Figure 3.  Schematic axial view of rectal tumors. The mesorectal fascia forms the outer lining of the mesorectum, which 
surrounds the rectal canal. A total mesorectal excision is the current surgical standard of care and involves resection of the 
tumor together with the fatty tissue surrounding the tumor. The circumferential resection margin is defined as the shortest 
distance from an affected region to the mesorectal fascia and is an important prognostic marker. Primary resection of a 
locally advanced rectal tumor has a high risk of incomplete resection (resulting in tumor positive circumferential resection 
margins). Thus, these tumors are generally treated with preoperative chemoradiotherapy in order to reduce tumor size.
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for rectal cancer were impaired in patients with MC. Results from the TME trial demonstrated that 
patients with MC or AC both benefited from short-term preoperative radiotherapy, leading to a 
decrease in local recurrences.22 Patients with MC more often had a CRM that was tumor positive, but 
the overall prognosis was comparable with that of patients with AC.22
Tumor downstaging is an important objective of CRT in patients with locally advanced rectal cancer. 
An inferior rate of tumor downsizing has been observed in patients with MC compared with 
those with AC following CRT (Figure 4).24, 50-53 Measuring tumor response to CRT on MRI remains 
challenging in patients with MC, as differentiation between tumors and inactive mucus lakes is 
often difficult.54 Patients with rectal MC have a higher risk of having positive CRM irrespective of 
use of preoperative therapy than patients with AC. A pathological complete response (pCR), which 
means that no vital tumor cells are found after preoperative treatment, is seldom observed in 
patients with MC.22, 24, 50, 53, 55, 56 This finding is suggestive of differences in susceptibility or inherent 
resistance to preoperative CRT in patients with MC and raises questions regarding the benefit of 
this treatment in these patients. This poor tumor response to CRT is not well understood, but 
it has been hypothesized that a reduced vascular density, with a decreased blood supply and 
corresponding hypoxic state, might reduce the effectiveness of CRT.57 Patients with MCs are also 
more likely to have a KRAS mutation than those with AC, which is considered a biomarker of an 
incomplete response to therapy in patients with rectal cancer. Patients with KRAS mutant rectal 
cancers are less likely to develop a pCR to 5-FU based CRT than those with wild-type KRAS rectal 
cancers.58 The higher rate of CRM positivity in patients with MC, however, does not unequivocally 
lead to a worse overall survival than that of patients with AC. This finding suggests that having 
positive CRM has different implications in patients with MC.22 These patients have tumors with 
a lower cellular density than those with ACs and mucus is usually found in the periphery of the 
tumor, which might lead to more tumor residues being present in patients with positive CRM. 
Previous studies have already demonstrated, however, that improved local control is not equivalent 
to prolonged survival and that development of distant metastases mainly determines survival.59 
Further studies on the effects of CRT on tumor cell characteristics should be performed to analyze 
whether invasiveness is altered after CRT. Also, a more targeted approach towards treatment of 
patients with MC, possibly with increased use of preoperative CRT, or longer waiting intervals 
between neo-adjuvant treatment and surgery, with the aim of improving tumor downsizing, should 
be investigated.
Besides the establishment of preoperative therapies for treatment of patients with rectal cancer, both 
the introduction of TME surgery and better imaging techniques has contributed to an improvement 
in overall survival in patients with rectal cancer over the past decades.60 Introduction of TME surgery 
to routine clinical practice has resulted in a decrease in CRM positive resections and is, therefore, an 
appropriate procedure for obtaining better resections in patients with MC, who generally have larger 
tumors.24, 39 Technological advances in imaging have improved preoperative staging and selection of 
the most-appropriate preoperative therapies. Improved early recognition of MCs offers clinicians an 
opportunity to attempt personalized treatments with greater awareness of the risks of incomplete 
removal of the tumor.
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Figure 4.  Forrest plot depicting outcomes from studies on the frequency of downstaging in response to chemoradiotherapy 
in patients with mucinous carcinoma (MC) versus adenocarcinoma (AC). *Indicates author’s own risk ratio and 95% 
confidence interval (CI) calculations based upon primary data reported in the relevant manuscript. 
Figure 5.  Identification of mucinous adenocarcinoma (MC). (A) Sagittal and (B) axial T2-weighted MRI scan of a patient 
with MC, which can be easily recognized owing to the distinctive mucinous high signal intensity on high-resolution MRI 
images. (C,D) Haematoxylin and eosin stained tumor (magnification 1x). This figure emphasizes the need for careful 
mapping of tumor biopsy samples to preoperative imaging findings, in order to enable personalized medicine, based on 
initial biopsy. Arrows indicate the presence of mucinous regions of the tumor. 
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Imaging 
Radiologists can recognize a tumor as a MC during preoperative work-up, owing to the distinctive 
high signal intensity of these tumors on high-resolution T2-weighted MRI scans, which is caused by 
the presence of mucus (Figure 5).24, 61, 62 This finding implies that, before obtaining histopathological 
confirmation of MC (after resection of the tumor), information concerning tumor type is available 
and could potentially influence the choice of therapy. Analysis of biopsy samples from a suspect 
lesion usually provides the multidisciplinary team with information regarding the tumor subtype 
and, thus, enables a limited set of tests for tumor typing to be performed. However, in patients 
with MC the chance of obtaining a false-negative histological diagnosis based on findings of biopsy 
analysis (such as an MC tumor being identified as AC) is five times as high when compared with MRI 
assessment.51 Mucus commonly coats the tumor at the extraluminal side, however, tissue in a biopsy 
is usually taken from the more superficial aspect of the tumor and might not contain a representative 
amount of mucus. 
Therefore, preoperative MRI is a more accurate method for detection of MC than biopsy sampling.51 
Moreover, preoperative therapies, such as radiotherapy and CRT might alter tumor characteristics, 
thus hampering accurate histological assessments.63, 64 For example, increased mucus production and 
mucus pools are observed in patients with tumors treated with short-term radiotherapy and these 
tumors might display a colloid response following CRT.64, 65 Indeed, radiation seems to drive mucinous 
differentiation; therefore, these phenomena should be regarded as a treatment response and should 
not be mistaken for tumors of the mucinous phenotype.66 This radiation-induced response is of 
particular importance for future research initiatives, otherwise all tumors which appear mucinous 
might be considered to be MC. Imaging is not only a very useful addition to biopsy sample analysis 
in the preoperative setting, but might also be used to determine whether a tumor with a mucinous 
phenotype was induced or not. Thus, radiologists must document tumor phenotype at baseline and 
pathologists must be aware of the imaging findings when reviewing the histology of these patients.
Future directions
The histological subtype of CRC is an easily accessible factor that, in the near future, is likely to be 
important in tailoring treatment to the characteristics of the individual patient. Discussions aimed 
at raising awareness of MC, and how it differs from AC, in multidisciplinary team meetings might 
help to prevent incorrect clinical decision-making in managing patients with CRC of this subtype. 
Despite the clear definition of MC, a common terminology whereby all pathologists can describe 
MCs is currently lacking. More insight into histopathological characteristics of MCs, such as tumor 
differentiation, growth pattern, tumor border aspect, location of mucus and tumor cell:mucus ratio is 
required. From a research perspective, further investigations of the molecular background of MCs, in 
order to increase understanding of tumor behavior and resistance to therapies should be considered 
a priority. In vivo and in vitro studies that assess the role of the mucus layer in chemotherapy delivery 
might also improve insight into chemoresistance. Investigations in this area might assist in the 
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development of a chemotherapy delivery system that overcomes the possible penetration difficulties 
associated with MC. The engineering of a coated nanoparticle drug-delivery vehicle that can cross the 
mucus barrier, therefore, offers great promise for improving the effectiveness of chemotherapeutic 
treatment in patients with advanced-stage disease.67 Agents that target the mucus layer itself, 
although not currently readily available, might also provide an additional therapeutic option that 
should be explored in an attempt to improve the effectiveness of systemic therapies.17 Furthermore, 
studies designed to assess differences between MC and AC at a high-resolution molecular level, using 
technologies such as next-generation sequencing, are needed. These data will enable clinicians to 
improve prediction of the course of disease and responses to systemic treatment, thereby aiding in 
selection of patients for additional treatment. 
Figure 6.  Potential contributions from different medical specialties. A multimodality approach has become the standard 
of care for management of patients with colorectal cancer and multidisciplinary team meetings should aim to raise 
awareness of the importance of histological subtypes where patients are managed using such an approach. 
AC, adenocarcinoma; MC, mucinous adenocarcinoma; CRM, circumferential resection margin.
Conclusions
A multimodality approach to management of patients with CRC has become the standard of care, 
and exchange of information between different disciplines has influenced patient management 
(Figure 6). Cancer therapy is increasingly being tailored to the individual patient, depending upon 
both patient and tumor characteristics. Tumor histology is one of the most easily accessible clinical 
features, although this information is not yet widely used in clinical practice. This lack of utilization 
most probably reflects conflicting results reported in the literature and uncertainty regarding exact 
clinical implications. Consensus on how to classify MCs accurately is also needed.
MCs can be diagnosed preoperatively and high-resolution MRI, being more accurate than analysis 
of initial biopsy samples, has an important role in this regard. Documenting MC using findings of 
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both imaging and analysis of pathological specimens is important and has direct clinical implications. 
Established mechanisms exist that might explain the relative resistance to chemotherapy and 
radiotherapy of patients with MC compared with those with AC. This resistance to treatment is 
probably caused by a combination of a different molecular signature and the markedly different 
physical properties of mucus containing tumors compared with ACs, which gives rise to unique 
patterns of spread, and substantially different patterns of vascularity and tumor cellularity. Despite 
a relatively poor prognosis, advances have been made in survival rates by careful en bloc removal of 
such tumors through improved standards of TME surgery. This removal strategy avoids intra-operative 
spillage and rupture of gelatinous MCs into the abdominal cavity. Awareness of the diagnosis of this 
subgroup, which has a poor prognosis, is important for surgical planning and follow-up surveillance 
of these patients. Future improvements in adjuvant and neo-adjuvant therapy might be achievable 
by using different approaches that take into account both the unique physical properties as well as 
molecular profiles of these tumors. Advances in tumor characterization will also have an important 
role in future, and will possibly enable further tailoring of treatment.
Review criteria
A search for relevant articles was performed using the PubMed database on February 1, 2015, 
using the following Boolean search term combination: (((((“Colorectal Neoplasms”[Mesh])) OR 
(((cancer[tiab] OR carcinoma*[tiab] OR tumour[tiab] OR tumours[tiab] OR tumour*[tiab] OR 
adenocarcinoma*[tiab])) AND (rectum[tiab] OR rectal[tiab] OR colorectal[tiab] OR colon[tiab]))) 
AND ((((“Adenocarcinoma, Mucinous”[Mesh])) OR (mucinous[tiab])) OR (colloid[tiab])))). A modified 
search was performed in the EMBASE database. Reference lists of selected articles were assessed 
for additional studies. Only studies that used the WHO definition of MC were selected.3 Inclusion or 
exclusion of a study was based on quality and relevance of the article.
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Future perspectives
In colorectal cancer (CRC) patient care personalized medicine is a promising concept. It is moving us 
to more precise medicine, which is rationally customized for the individual patient. Current treatment 
concepts, therefore no longer solely focus on stage of disease and the patient’s general health status, 
but also take specific tumor characteristics into account.
Recent studies, among those within this thesis, have demanded more appreciation for the 
histological subtype of CRC in multidisciplinary team meetings. However, the distinction between 
merely mucinous adenocarcinoma (MC), signet-ring cell carcinoma (SRCC), and adenocarcinoma not 
otherwise specified (AC) may no longer be sufficient. There is an urge for better prediction of prognosis 
and therapeutic planning for the individual patient, based on individual tumor characteristics. 
In this regard, very little is known about the impact of tumor features that are specifically seen in 
MC and SRCC. MC exhibits distinct molecular and epigenetic characteristics that can be associated 
with outcome and response to therapies. These characteristics may be relevant for development of 
future targeted therapies. Identification of tumor characteristics that are specific for MC or SRCC 
patients may improve prediction of prognosis and can be used to determine efficacy of (neo)adjuvant 
treatment regimens in these patients. Research initiatives that aim to improve knowledge in this 
regard will be performed in the near future and form an important extension of the studies from this 
thesis.
A common histopathological language
Although MC has a clear-cut definition, a common language to describe MCs is lacking. It appears 
that MC cannot be considered a single entity when visualized under the microscope. There is a 
variety of presentations regarding the growth pattern, wall composition and contents of the lumina 
of mucinous lakes in MC (Figure 1). MCs can present with either circumscribed or a diffuse infiltrative 
growth pattern. The wall composition varies from accelular, single layer or multi layer of cells to 
irregular. The contents of the mucinous lakes also shows diversity, ranging from single cells, clumps 
of cells to signet-ring cells. The frequency of these features has not been well described, nor has 
the prognostic impact been evaluated. Nonetheless, these features could present valuable tools in 
further classification of MCs. A future goal is to develop a system for MC that enables grading and 
classification of these tumors, which can be linked to outcome. Large-scale histological assessment 
of MC will generate more insight into the various pathological forms in which it can be found. In 
addition, the occurrence of other well-known histological and immunohistochemical features that 
are relevant for prognosis and selection of adjuvant treatment options, can be analyzed including 
lymphatic invasion, extramural vascular invasion, perineural growth, loss of mismatch repair proteins 
and mutations in BRAF and KRAS. 
Analyzing aberrations of a higher resolution
Besides the interest in a more accurate histological assessment of MCs and SRCCs there is a growing 
trend towards molecular characterization of tumors. Our analysis on copy number data as presented 
in Chapter 7 in this thesis already showed that MC was associated with less chromosomal instability 
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than AC. Analyzing DNA aberrations of a much higher resolution using next-generation sequencing 
will be the next step forward in determining the frequency of mutations in MC compared with AC. 
Using a panel of several hundred cancer related genes will enable us to determine the frequency of 
mutations in these genes in MC compared with AC. These findings may be linked to outcome and 
response to therapies. 
Figure 1. Histopathological features in mucinous carcinoma. Modified and reproduced with permission.1
Optimizing current treatment strategies
Prior to the broad implementation of targeting therapies, it remains necessary to optimize current 
treatment modalities. Findings from our studies have shown that MCs show a less impressive tumor 
down staging to neo-adjuvant chemoradiotherapy when compared with AC. It is common practice to 
evaluate the effect of neo-adjuvant chemoradiotherapy using repeat MRI prior to surgery. Especially 
in locally advanced rectal tumors the restaging MRI is used to evaluate the rate of downsizing and 
the involvement of the mesorectal fascia in the tumor process. Moreover, it aids in preoperative 
planning to determine the extent of surgery that is needed for cure. Since regression and downsizing 
of mucinous lakes in rectal MC patients is not expected, the restaging accuracy of repeat MRI is 
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not clear for MC patients. It is an important future goal to validate the use of restaging MRI in MC 
patients. 
Timing of surgery after neo-adjuvant chemoradiotherapy for rectal cancer is another controversy.2 
Surgery is generally performed six to eight weeks following completion of neo-adjuvant 
chemoradiotherapy. During the waiting interval the tumor regresses, which improves chances of a 
radical resection of the tumor. Recent studies have suggested a time-related response of the tumor 
to chemoradiotherapy and a prolonged waiting interval may increase chances of a radical resection.2-4 
It would be interesting to determine the optimal waiting time to surgery for rectal MCs. 
Figure 2.  Survival for adenocarcinoma (AC), mucinous adenocarcinoma (MC) and signet-ring cell carcinoma (SRCC) 
patients from the autopsy study who developed metastatic disease during follow-up.
The finding that the metastatic pattern of CRC is strongly influenced by the histological subtype may 
alter the attitude of multidisciplinary teams towards MC and SRCC patients during follow-up. We 
have shown major differences in metastatic patterns with a high rate of peritoneal metastases for MC 
patients, and especially for SRCC patients. Peritoneal metastases are considered a poor prognostic 
factor. Survival data that was extracted from the autopsy study in Chapter 6 shows that SRCC patients 
with metachronous metastases are associated with a very poor survival (Figure 2) compared with MC 
and AC patients. Although complete cytoreductive surgery followed by hyperthemic intraperitoneal 
chemotherapy (HIPEC) has shown promising results for patients with peritoneal metastases from 
colorectal origin, survival for SRCC patients remains poor.5 It has even been suggested that a surgeon 
should refrain from HIPEC in SRCC patients in the presence of relative other contraindications. 
Therefore, histological subtype should be taken into consideration during multidisciplinary team 
meetings in which follow-up strategies are discussed. From a research perspective, understanding the 
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resistance to systemic therapies is another main challenge. Studies that further define the role of the 
mucus layer in delivery of chemotherapy may improve insight into chemoresistance. Development of 
a chemotherapy delivery system that overcomes the possible penetration difficulties associated with 
MC, especially in patients with advanced-stage disease, should therefore be explored. On the other 
hand, it is not inconceivable that a more aggressive approach to prevent peritoneal metastases in 
high-risk patients such as SRCC patients will be introduced. Results of the recently started COLOPEC 
trial, in which patients with a cT4 stage colon cancer are treated with resection of the primary tumor 
and HIPEC will provide further insight in this matter.
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Mucinous colorectal carcinoma
The rapid development of individualized therapy for cancer patients has led to an increased 
interest of the oncology community in tumor subtypes. Improved identification of subtypes may 
lead to a better prediction of outcome and response to targeted therapies. In this perspective, the 
impact of the mucinous subtype in colorectal cancer (CRC) has been a matter of debate. Mucinous 
adenocarcinoma (MC) is a CRC subtype in which extracellular mucus contributes at least 50% of 
the tumor volume. However, neglecting this subtype in randomized clinical trials and inaccurate 
CRC registries have posed problems in determining clinical impact. Moreover, despite the deviant 
phenotypic presentation, tumor development and the molecular background of MC are poorly 
understood. For the signet-ring cell carcinoma (SRCC), another distinct CRC subtype, a poor prognostic 
impact has been established previously. However, insight into potential adjuvant treatment options is 
lacking, as well as understanding of tumor biology. 
In Chapter 1 we reviewed factors that are involved in MC development in an effort to elucidate 
different etiological aspects of MC. We demonstrate that there are worldwide differences in the 
prevalence of MC as low rates have been found in studies from Asian countries and higher rates have 
been reported in the Western world. Moreover, we show that MC is more commonly diagnosed in 
patients suffering from inflammatory bowel diseases such as Crohn’s disease or ulcerative colitis. 
Based on merged data from the literature we noticed that MC is found in approximately 23% of 
Crohn’s disease patients and in 21% of patients with ulcerative colitis that are diagnosed with 
CRC. MC is also more common in Lynch syndrome patients, with approximately 22-40% of Lynch 
syndrome-associated CRCs being MC. Finally, an increased rate of MC is observed in patients who 
develop CRC following radiotherapy. Our literature search revealed 180 cases of radiation-associated 
CRCs, of which 38% was MC. In rectal cancer patients even 52% of radiation-associated tumors were 
MC. These findings are suggestive of a different oncogenic development for MC in which there may 
be a predominant role for inflammation and may generate more insight into the etiological pathways 
leading to the development of MC.
In Chapter 2 we describe a review of the literature on the molecular background of MC. The 
distinct clinical presentation and pathological appearance of MC suggest a deviant development 
and molecular background for this subtype. MC is characterized by a high rate of MUC2 expression, 
which accounts for the mucinous phenotype. In the review we merged data from a large number of 
studies and demonstrate that mutations in the therapeutically important RAS/RAF/MAPK and PI3K/
AKT pathways are significantly higher in MC compared with non-mucinous adenocarcinoma (AC). 
Furthermore, MC shows higher rates of microsatellite instability (MSI) and MC is more frequently 
of the CpG island methylator phenotype (CIMP). Although the majority of MCs arises in the large 
intestine, this subtype also develops in other organs, such as the stomach, pancreas, biliary tract, 
ovary, breast and lung. We compared findings from the colorectal MC with molecular characteristics 
of MCs from other organs. In these organs, MCs show alterations in the RAS/RAF/MAPK and PI3K/
AKT pathways as well, but a common “mucinous pathway” cannot be identified. Interestingly, the 
genetic instability pathway of MSI, which is a predominant characteristic of mucinous CRC, cannot be 
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linked to MC in all other organs. Further identification of molecular aberrations may improve therapy 
development, but could also explain resistance of tumors to such therapies.
In Chapter 3 we used population-based data from the Eindhoven Cancer Registry on 27,251 
unselected CRC patients who were diagnosed between 1990 and 2010 to study the prognostic impact 
of MC in CRC. Colorectal MC has been associated with an impaired prognosis compared with AC. It 
has been demonstrated that response to palliative chemotherapy is poor in metastatic disease, but 
benefit of adjuvant chemotherapeutic treatment had never been assessed in large patient groups. 
In this study, MC was found in 12% (n = 3052) of CRCs and MC had a distinct distribution of tumor 
location compared with AC. Only 24% of MCs was located in the rectum and 54% in the proximal 
colon, compared with 38% of ACs in the rectum and 31% in the proximal colon. Also, AC was more 
often classified as stage I disease than MC (20.5% versus 10.9%). Survival analysis demonstrated that 
MC was a poor prognostic factor for rectal cancer patients (hazard ratio 1.22, 95% confidence interval 
[CI] 1.11-1.34). However, there was no difference in overall survival between MC and AC when the 
tumor was located in the colon. Additionally, we studied the benefit of adjuvant chemotherapy for 
stage III colon cancer patients following radical resection between MC and AC patients. Multivariate 
regression analysis showed a similar survival after adjuvant chemotherapy for stage III MC and AC 
patients, supporting current adjuvant treatment recommendations for both subtypes.
The relatively rare signet-ring cell carcinoma (SRCC) is a poorly studied subtype of CRC, but has been 
associated with a poor survival compared with MC and AC. In Chapter 4 we performed a nationwide 
study on 196,757 CRC patients who were diagnosed between 1989 and 2010 and were registered 
in the Netherlands Cancer Registry (NCR). SRCC was found in 1.0% of CRC patients and SRCC was 
more commonly found at stage III or IV, compared with AC (75% versus 44%). SRCC was also more 
frequently found in the proximal colon than AC (58% versus 32%). We assessed prognostic impact of 
SRCC according to the primary site of the tumor and found that SRCC was a poor prognostic factor 
at both colonic and rectal localization. Five-year relative survival estimates demonstrated a poorer 
survival in both colon and rectal cancer patients in stage II, III and IV. Due to the aggressive behavior 
of SRCC we aimed to gain insight into potential adjuvant treatment options in an effort to enhance 
survival in these patients. Therefore, we analyzed benefit from adjuvant chemotherapy for stage 
III colon cancer patients for SRCC and AC. Although stage III colonic SRCC patients had a poorer 
relative survival compared with AC after receiving adjuvant chemotherapy, there was no significant 
interaction between SRCC and adjuvant chemotherapy (relative excess risk 1.10, 95% CI 0.81-1.51). 
This suggested a comparable benefit from adjuvant chemotherapy in AC and SRCC; therefore adjuvant 
treatment recommendations should be adhered to, regardless of histological subtype.
Treatment of rectal cancer patients has changed rapidly over the past 20 years. Introduction of TME 
surgery in combination with preoperative radiotherapy with or without the addition of chemotherapy 
has improved local control rates and overall survival. Nevertheless, MC is generally regarded an 
unfavorable prognostic subtype with a decreased response to preoperative therapies. In Chapter 5 
we studied the benefit from modern rectal cancer treatment for MC. In this study we analyzed the 
prognostic impact of rectal MC over time, using data from the Netherlands Cancer Registry. We found 
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a worse 5-year overall survival for rectal MC patients compared with rectal AC patients from 1989-
1998 (32% versus 40%), but demonstrated that survival was no longer different from 1999 onwards 
(54% versus 53%). Furthermore, we analyzed the benefit of preoperative therapies for rectal cancer 
patients, using two other cohorts. To study the benefit of preoperative short-term radiotherapy, 
we used patients from the prospective randomized multicenter TME trial (n = 1530), who were 
randomly assigned to either short-term radiotherapy followed by TME surgery or to TME surgery 
alone. A higher rate of resections with a tumor positive circumferential resection margin (CRM) was 
found in MC patients, but there was no difference in overall survival between both subtypes (10-year 
overall survival 49% versus 51%). Both MC and AC patients developed less local recurrences if they 
were treated with preoperative short-term radiotherapy. Efficacy of long-term chemoradiotherapy 
was analyzed in a cohort with patients who underwent preoperative chemoradiotherapy for locally 
advanced rectal cancer (LARC). It was found that MC patients demonstrated less tumor downsizing 
and no pathological complete responses occurred in MC patients. Moreover, MC patients more 
often had a positive CRM, but this did not result in a poorer survival. In conclusion, in the era of 
modern rectal cancer treatment, survival between MC and AC is no longer different. Most probably 
enhancements in the fields of imaging and quality of surgery have improved outcome. Given the 
higher rate of positive CRM in MC, achieving a radical resection should remain the main focus 
during treatment of rectal MC patients and warrants more attention for MC during preoperative 
multidisciplinary team meetings.
In Chapter 6 we systematically evaluated metastatic patterns of different histological subtypes in 
CRC patients and analyzed metastatic disease upon primary tumor localization. We conducted a 
nationwide retrospective review of pathological records of 5817 patients who were diagnosed with 
CRC and who finally underwent an autopsy between 1991 and 2010. Patients were selected from the 
Dutch pathology registry (PALGA). A total of 1675 patients had metastatic disease and this was more 
often found in MC and SRCC patients, than in AC patients (34% and 61% versus 28%). Moreover, 
MC and SRCC patients had metastases at multiple site more often compared with AC patients (59% 
and 71% versus 50%). Liver metastases were most frequent in both AC and MC patients (73% and 
52%). More than half of all SRCC patients developed metastases on the peritoneal surface. Major 
differences between metastatic patterns were also found between subtypes. AC more frequently 
metastasized to the liver compared with MC and SRCC. The latter two were more frequently found 
on the peritoneal surface compared with AC. There was no difference in lung metastases between 
the subtypes. Metastatic patterns were also related to the primary tumor site, with a high rate of 
abdominal metastases in colon cancer patients, whereas rectal cancer patients more often had 
metastases at extra-abdominal sites. To substantiate the clinical relevance of our autopsy study, we 
compared metastatic patterns with data from the TME trial. These results confirmed our findings in 
rectal cancer patients from the autopsy study. Results from this study demonstrated that there are 
profound differences in metastatic patterns between histological subtypes and the localization of the 
primary tumor in CRC. This may account for differences in response to chemotherapy for metastatic 
disease. Findings from this study encourage to take these factors into account during preoperative 
examination and follow-up. Moreover, they indicate that these factors should be considered 
stratification factors in future research initiatives focusing on advanced disease. 
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Although the differences in tumor behavior and response to therapies are indicative of a distinct 
molecular background of MC, most large-scale genetic studies on CRC did not address differences 
between histological subtypes. In Chapter 7 we conducted an in-depth analysis of the genetic 
background of MC using high quality array comparative hybridization data from microsatellite stable 
patients who participated in the CAIRO and CAIRO2 studies. For validation purposes we used publicly 
available data from The Cancer Genome Atlas (TCGA). We compared copy number profiles of 527 
patients among which were 57 MC patients. Genome-wide we found that MC showed a reduced 
amount of copy number aberrations (1.5 fold lower) compared with ACs. Especially less gain of 
chromosome 20q and loss of chromosome 18p was observed. Moreover, a high rate of chromosomal 
instability was a strong negative prognostic marker for survival in MC patients from the CAIRO cohorts 
(hazard ratio 15.60, 95% CI 3.24-75.05). These results indicated that the distinct clinicopathological 
entity of MC is also accompanied by a different genetic basis.
Progressive insight into MC and the clinical relevance of this subtype are reflected in Chapter 8, in 
which we have put the findings from this thesis in a broader (clinical) context. The multidisciplinary 
team approach has become standard of care for colorectal cancer patients and demands appreciation 
of histological subtypes from each involved medical specialty. The review describes how individual 
management could be tailored and summarizes the pitfalls when managing individuals with MC. 
Future improvements in adjuvant and neo-adjuvant therapy might be achievable by using different 
approaches that take factors into account such as tumor location, tumor stage and the unique 
physical properties as well as molecular profiles of these tumors. Advances in tumor characterization 
will have an important role in future, and may possibly enable further targeting of treatment.
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Mucineus colorectaal carcinoom
Darmkanker is een van de meest voorkomende vormen van kanker en is verantwoordelijk voor een 
groot deel van de kanker gerelateerde sterfte wereldwijd. In Nederland worden jaarlijks meer dan 
15.000 patiënten met darmkanker gediagnosticeerd en ontwikkelt ongeveer 5% van alle mensen een 
colorectaal carcinoom (CRC) gedurende zijn of haar leven. Omdat niet iedere soort kanker dezelfde is, is 
vanuit de medisch oncologische wereld een toenemende interesse in op maat gesneden therapie voor 
de individuele patiënt. Hierbij wordt rekening gehouden met patiëntfactoren, zoals leeftijd en geslacht, 
maar ook met kankerspecifieke factoren, zoals het stadium van de tumor en het histologische subtype. 
Onderzoek heeft aangetoond dat deze factoren in meer of mindere mate kunnen bijdragen aan het 
voorspellen van de overlevingskans en het effect dat te verwachten is op therapie. De voorspellende 
waarde van het histologische subtype hierin is echter controversieel. Het meest voorkomende subtype 
CRC is het reguliere adenocarcinoom (AC), dat in 85% van de gevallen voorkomt. In ongeveer 15% van 
de gevallen wordt een mucineus adenocarcinoom gediagnosticeerd (MC) en in 1% van de patiënten 
is er sprake van een zegelringcelcarcinoom (ZRCC). Het MC kenmerkt zich door een tumor die voor 
meer dan 50% uit slijm bestaat. Dit slijm  bevindt zich buiten de tumorcellen. Bij ZRCC is er ook sprake 
van uitgebreide slijmvorming, maar dit bevindt zich in de tumorcel. Doordat MC en ZRCC minder vaak 
voorkomen dan AC, zijn deze subtypen beperkt bestudeerd. Er is weinig kennis over de ontwikkeling 
van deze subtypen en hun moleculaire achtergrond. Bovendien is de behandeling van CRC gebaseerd 
op uitkomsten van grote klinische studies die zich voornamelijk richtten op AC. In dit proefschrift wordt 
het MC nader gekarakteriseerd op basis van klinische, epidemiologische en moleculaire bevindingen.
Hoofdstuk 1 gaat in op de etiologische achtergrond van MC en geeft een overzicht van de literatuur. Er 
is een wereldwijd verschil in de prevalentie van MC, waarbij MC minder vaak voorkomt in Azië dan in 
de Westerse wereld. MC blijkt vaker voor te komen bij patiënten die darmkanker ontwikkelen op basis 
van inflammatoire darmziekten zoals Morbus Crohn en colitis ulcerosa. Data uit verschillende studies 
laten zien dat ongeveer 23% van de Morbus Crohn patiënten en 21% van de colitis ulcerosa patiënten 
die darmkanker ontwikkelen een tumor van het mucineuze type hebben. MC wordt bovendien vaker 
gevonden in patiënten met het erfelijke Lynch syndroom. In 22-40% van de patiënten met een Lynch 
syndroom geassocieerde tumor blijkt het om een MC te gaan. Behandeling met radiotherapie lijkt 
ook van invloed te zijn op de ontwikkeling van het mucineuze subtype. In de literatuur werden 180 
gevallen gevonden van darmkanker na bestraling, waarvan het in 38% een MC betrof. Dit percentage 
lag zelfs nog hoger bij de rectumcarcinomen die na radiotherapie ontstonden (52%). Het herkennen 
van omstandigheden waaronder MC zich ontwikkelt, zoals ontsteking, biedt meer inzicht in het 
ontstaan van MC en in factoren die een rol kunnen spelen bij de ontwikkeling hiervan.
Het bepalen van moleculaire kenmerken van tumoren is een recente ontwikkeling binnen de oncologie 
die leidt tot een verbetering van diagnostiek en therapie. Moleculaire verschillen tussen tumoren 
kunnen leiden tot een variatie in tumorgedrag en kunnen de werkzaamheid van een behandeling 
verminderen. Een inleiding in de moleculaire achtergrond van MC wordt gegeven aan de hand van een 
overzicht van de literatuur in Hoofdstuk 2. De afwijkende klinische en pathologische presentatie van 
MC doet vermoeden dat er ook op moleculair niveau verschillen zijn tussen MC en AC. Overexpressie 
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van MUC2 is een kenmerkende moleculaire eigenschap van MC en verklaart het slijmvormende aspect 
van deze tumoren. Ten aanzien van MC is er verder echter beperkt inzicht in de mutatiefrequentie 
van therapeutisch relevante moleculaire kenmerken zoals de RAS/RAF/MAPK en PI3K/AKT cascades. 
Door het combineren van gegevens uit diverse studies die zich richtten op deze cascades blijkt dat 
BRAF, KRAS en PIK3CA mutaties vaker voorkomen in MC dan in AC. Bovendien komt bij MC vaker 
microsatellietinstabiliteit en het CpG island methylator fenotype (CIMP) voor. Ook buiten de darm 
worden tumoren van het mucineuze subtype gevonden, zoals in de maag, pancreas, galwegen, ovarium, 
borst en long. De betrokkenheid van mutaties in de RAS/RAF/MAPK en PI3K/AKT cascades in deze 
tumoren wordt verder uiteengezet in dit hoofdstuk en een vergelijking met het colorectale MC wordt 
gemaakt. Hoewel de informatie in de literatuur beperkt is, zijn ook voor de andere mucineuze tumoren 
afwijkingen beschreven in de RAS/RAF/MAPK en PI3K/AKT cascades. Er kan echter geen eenduidige 
“mucineuze cascade” worden gevonden die in MCs van alle organen aanwezig is. 
Het MC wordt beschouwd als een prognostisch ongunstige tumor, maar wordt op eenzelfde manier 
behandeld als het AC. In Hoofdstuk 3 beschrijven we de prognostische waarde van MC aan de hand van 
gegevens van het Integraal Kankercentrum Zuid. Voor deze studie werden 27.251 patiënten geselecteerd 
die tussen 1990 en 2010 waren gediagnosticeerd met CRC. In 12% (n = 3052) van de patiënten was er sprake 
van een MC. Er waren verschillen tussen MC en AC patiënten op een aantal punten. MC werd vaker in het 
proximale deel van het colon gevonden en minder vaak in het rectum dan AC. Daarnaast werd MC vaker 
in een hoger stadium gediagnosticeerd dan AC. Bij overlevingsanalyses bleek dat de overleving van MC 
afhankelijk was van de locatie van de tumor. Zo werd er geen verschil in overleving gevonden tussen MC en 
AC wanneer het een coloncarcinoom betrof, terwijl de overleving van MC patiënten slechter was wanneer 
ze waren gediagnosticeerd met een rectumcarcinoom (hazard ratio 1,22; 95% betrouwbaarheidsinterval 
1,11-1,34). Verder werd in deze studie de overleving na adjuvante chemotherapie onderzocht voor 
coloncarcinoom patiënten die een resectie van de primaire tumor hadden ondergaan. De uitkomsten 
van een multivariate analyse bij stadium III coloncarcinoom patiënten lieten zien dat er geen verschil in 
overleving was tussen MC en AC patiënten die aanvullend met chemotherapie waren behandeld. Op basis 
van de resultaten van deze studie kan behandeling met adjuvante chemotherapie worden aanbevolen 
voor zowel MC als AC stadium III coloncarcinoom patiënten.
Het ZRCC wordt over het algemeen gezien als een agressief subtype met een slechte prognose. Het is 
een zeldzame tumorsoort en er is niet veel bekend over de effectiviteit van adjuvante behandelingen 
voor patiënten met een ZRCC. In Hoofdstuk 4 beschrijven we de resultaten van een landelijke studie 
met gegevens van 196.757 CRC patiënten die werden gediagnosticeerd tussen 1989 en 2010. In deze 
studie had 1% van de patiënten een ZRCC. In vergelijking met AC werd ZRCC vaker geclassificeerd 
als een stadium III of IV tumor. Ook was er tussen de tumortypen een verschil in verdeling over het 
colorectum. Bij ZRCC patiënten bevond 58% van tumoren zich in het proximale colon, terwijl dit 
slechts het geval was bij 32% van de AC patiënten. Ongeacht of de tumor zich in het colon of rectum 
bevond, hadden ZRCC patiënten een slechtere overleving dan AC patiënten. Vanwege de sombere 
prognose van het ZRCC is het belangrijk om inzicht te krijgen in de effectiviteit van aanvullende 
behandelingen, om de prognose van deze patiënten te kunnen verbeteren. Ondanks de slechtere 
overleving van ZRCC patiënten werd er geen verschil gevonden in overlevingswinst tussen AC en 
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ZRCC na adjuvante chemotherapie voor stadium III coloncarcinoom. Deze uitkomst geeft aan dat er 
een vergelijkbaar voordeel is van adjuvante chemotherapie voor ZRCC en AC patiënten en patiënten 
met een ZRCC geen aanvullende behandeling mag worden onthouden op basis van het subtype.
De behandeling van rectumcarcinoom patiënten is de afgelopen twintig jaar sterk verbeterd. Zowel 
de introductie van TME chirurgie, waarbij de tumor in het rectum wordt verwijderd samen met het 
omliggende vetweefsel, de nauwkeurige beeldvorming met MRI, als de behandeling met neoadjuvante 
therapieën hebben geleid tot een verbetering van locale controle en een betere overleving. In Nederland 
worden rectumcarcinoom patiënten, afhankelijk van het stadium van de tumor, voorafgaand aan de 
operatie behandeld met radiotherapie of chemoradiotherapie. Zoals beschreven in hoofdstuk 3 wordt het 
rectale MC gezien als een prognostisch ongunstige tumor. In Hoofdstuk 5 beoordelen we de effectiviteit 
van de moderne behandeling van het mucineuze rectumcarcinoom. De prognose van het rectale MC werd 
in verschillende tijdsperioden geanalyseerd. Overeenkomstig de literatuur bleek op basis van data van 
het Integraal Kankercentrum Nederland dat de 5-jaarsoverleving in de periode van 1989 tot 1998 van MC 
patiënten slechter was dan van AC patiënten (32% versus 40%). Echter was deze overleving niet langer 
verschillend vanaf 1999 (54% versus 53%), wat verklaard kan worden door verbetering van de behandeling 
van rectumcarcinoom patiënten op diverse gebieden, zoals betere chirurgie en betere beeldvorming. De 
effectiviteit van kortdurende neoadjuvante radiotherapie voor rectumcarcinoom werd onderzocht aan de 
hand van data uit de TME trial. Patiënten in deze multicenter trial ondergingen TME chirurgie en werden 
gerandomiseerd tussen het wel of niet ontvangen van kortdurende neoadjuvante radiotherapie. Patiënten 
met een MC hadden vaker een positieve circumferentiële resectiemarge (CRM) dan AC patiënten. Hierdoor 
ontwikkelden MC patiënten vaker een lokaal recidief. Er was echter in beide groepen sprake van een afname 
van de lokaal recidiefkans na preoperatieve radiotherapie en er was geen verschil in overleving tussen MC 
en AC patiënten. Het effect van neoadjuvante chemoradiotherapie werd onderzocht met behulp van een 
cohort van 540 patiënten met een lokaal uitgebreid rectumcarcinoom (locally advanced rectumcarcinoom). 
Vergeleken met AC patiënten reageerden MC patiënten minder sterk op de chemoradiotherapie. De 
volumereductie van de tumor was minder en een pathologisch complete respons, waarbij geen vitale 
tumorcellen meer worden aangetroffen in het resectiepreparaat kwam niet voor bij MC. Bovendien 
hadden MC patiënten vaker een incomplete resectie. Omdat dit niet leidde tot een slechtere overleving, is 
het mogelijk dat een positieve CRM na chemoradiotherapie bij MC patiënten een andere betekenis heeft 
dan bij AC patiënten. Concluderend heeft de moderne behandeling van het rectumcarcinoom, waarin de 
beeldvorming en kwaliteit van chirurgie zijn verbeterd, geleid tot een sterke verbetering van de prognose 
van het rectale MC. Voor zowel MC als AC zijn preoperatieve therapieën effectief. Echter dient gezien het 
vaker voorkomen van een incomplete resectie bij MC patiënten er onverminderd aandacht te zijn voor de 
preoperatieve beoordeling van het rectumcarcinoom en de herkenning van een MC.
Obductiestudies worden nog zelden verricht, hoewel ze een belangrijke bron van informatie over het 
eindstadium van ziekte kunnen vormen en hierdoor bij uitstek geschikt zijn voor het bestuderen van 
metastasering van tumoren. Hoofdstuk 6 beschrijft de uitkomsten van een obductiestudie waarin de 
metastaseringspatronen van verschillende histologische subtypen systematisch zijn geanalyseerd. In deze 
studie werden na een landelijke zoekvraag in de PALGA registratie de pathologieverslagen beoordeeld 
van 5.817 CRC patiënten die tussen 1991 en 2010 werden geobduceerd. Er waren 1.675 patiënten met 
gemetastaseerde ziekte. Metastasen kwam vaker voor bij MC of ZRCC patiënten dan bij AC patiënten 
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(34% en 61% versus 28%). Bovendien was er bij MC en ZRCC vaker sprake van multipele metastasen 
dan bij AC (59% en 71% versus 50%). De meest voorkomende locatie voor metastasering van MC en 
AC was de lever (52% en 73%), maar MC metastaseerde ook vaak naar het peritoneum. Bij het ZRCC 
was het peritoneum zelfs de meest voorkomende locatie van metastasering. Naast het histologisch 
subtype bleek ook de primaire locatie van de tumor van belang voor het metastaseringspatroon. Het 
coloncarcinoom had in vergelijking met het rectumcarcinoom vaker intra-abdominale metastasen, zoals 
het peritoneum. Het rectumcarcinoom daarentegen metastaseerde vaker naar extra-abdominale locaties, 
zoals de longen en hersenen. Ter validatie werden gegevens over metastasering gebruikt uit de TME trial. 
Hiermee werd de klinische relevantie van de obductiestudie bevestigd. De bevindingen uit deze studie 
laten zien dat zowel het histologische subtype als de tumorlocatie dienen te worden meegenomen in de 
preoperatieve screening voor gemetastaseerde ziekte en ondersteunen het invoeren van deze factoren als 
stratificatiefactoren voor toekomstige onderzoeken die zich richten op gemetastaseerd CRC. 
Omdat het MC verschilt van het AC in zowel uiterlijke verschijning als in klinisch gedrag is het aannemelijk 
dat er ook in het genetische profiel variaties zijn tussen beide typen. In Hoofdstuk 7 analyseren we de 
genetische achtergrond van het MC aan de hand van array comparative genomic hybridization (aCGH). 
De datasets met gegevens over het aantal kopieën van een bepaald chromosomaal gebied (copy number 
profielen) waren afkomstig van twee klinische trials (CAIRO en CAIRO2) die verschillende systeemtherapieën 
voor patiënten met gemetastaseerd CRC onderzochten. Daarnaast werd gebruikgemaakt van de data 
van The Cancer Genome Atlas (TCGA) voor validatie. Data van 527 patiënten (470 AC en 57 MC) werd 
geanalyseerd. Er werden profielen gemaakt, op basis waarvan het genoom van AC en MC tumoren 
werd vergeleken. Het was opvallend dat MC minder chromosomale instabiliteit liet zien dan AC. Dit was 
significant voor chromosoom 20q (minder toename) en chromosoom 18p (minder verlies). Tevens werd 
in deze studie de overleving voor MC patiënten geanalyseerd op basis van de chromosomale instabiliteit. 
Hierbij bleek dat MC patiënten die meer chromosomale instabiliteit lieten zien een slechtere prognose 
hadden dan patiënten met een minder instabiel profiel (hazard ratio 15.60, 95% betrouwbaarheidsinterval 
3.24-75.05). Voor de laatste groep was de overleving vergelijkbaar met die van AC patiënten. De resultaten 
van deze studie laten zien dat MC niet alleen een tumor subtype is dat een afwijkende klinische presentatie 
heeft, maar dat ook de genetische basis van deze tumoren anders is dan van AC. Voor de ontwikkeling van 
toekomstige “targeted” therapieën is dat een bevinding die van belang zou kunnen zijn.
Ten aanzien van het mucineuze subtype is er sprake van een voortschrijdend inzicht in de moleculaire 
achtergrond en de klinische relevantie. Enkele studies uit dit proefschrift hebben hieraan bijgedragen. 
In Hoofdstuk 8 wordt dit in de context van de huidige literatuur besproken. Doordat de zorg voor 
CRC patiënten een multidisciplinair karakter heeft, is het voor alle disciplines die betrokken zijn bij 
deze keten essentieel om de relevantie van het histologische subtype op waarde te kunnen schatten 
voor prognostische en therapeutische doeleinden. In de review wordt ingegaan op de verschillen 
tussen MC en AC vanuit een klinisch perspectief en worden handvatten geboden voor een op maat 
gesneden therapie. Verdere verbetering van adjuvante en neoadjuvante therapie zou verkregen 
kunnen worden door zowel de unieke fysieke eigenschappen als het moleculaire profiel te betrekken 
in de keuze voor therapie. Grootschalige analyses die gericht zijn op tumorkarakterisering kunnen op 
deze manier bijdragen aan een potentieel vergrote doelmatigheid van therapie. 
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